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Abbreviations 
ABCA4     ATP-binding cassette, subfamily A, member 4 
ACE          angiotensin 1 converting enzyme 
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 
aHUS atypical haemolytic uremic syndrome 
AMD        age-related macular degeneration 
APOE        apolipoprotein E   
AREDS Age-Related Eye Disease Study 
ARMS2    age-related maculopathy susceptibility 2  
AUC area under the receiver operating characteristic curve 
B3GALTL beta 1, 3 glycosyltransferase 
BrM         Bruch’s membrane 
C1-9 complement component 1-9 
C1QBP complement component 1, q subcomponent binding protein 
CD           cuticular drusen 
CD-CV common disease-common variant 
CD-RV common disease-rare variant 
CETP cholesterol ester transfer protein 
CFB complement factor B 
CFH         complement factor H 
CFHR complement factor H related protein 
CFI complement factor I 
CHARGE Cohorts for Heart and Ageing Research in Genomic Epidemiology 
CI             confidence interval 
CIRCL Cologne Image Reading Center and Laboratory 
cM centimorgan 
CNV copy-number variant 
COG7 component of oligomeric golgi complex 7 
COL8A1 collagen, type 8, alpha 1 
COL10A1 collagen, type 10, alpha 1 
COL15A1 collagen, type 15, alpha 1 
CR1 complement receptor type 1 
CST3         cystatin C 
CX3CR1    chemokine (C-X3-C) motif receptor 1 
dbSNP single nucleotide polymorphism database 
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DDR1 discoidin domain receptor tyrosine kinase 1 
DHRD doyne honeycomb retinal dystrophy 
DZ            dizygotic 
ECM extracellular matrix 
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 
ELOVL4    elongation of very long fatty acids-like 4 
ETDRS Early Treatment Diabetic Retinopathy Study  
EUGENDA European Genetic Database 
EVS Exome Variant Server 
FA            fluorescence angiography 
FADS fatty acid desaturase 
FBLN1-6 fibulin 1-6 
FBN2 fibrillin 2 
FGL1 fibrinogen-like 1 
FILIP1L filamin A interacting protein 1-like 
FRK fyn-related Src family tyrosine kinase 
GA geographic atrophy 
GCL         ganglion cell layer 
GWAS    genome-wide association study 
HapMap haplotype map 
HELLP hemolysis, elevated liver enzymes, and low platelets syndrome 
HGVS Human Genome Variation Society 
HLA          human leukocyte antigen  
HMCN1   hemicentin 1 
HTRA1    htrA serine peptidase 1 
IER3 immediate early response 3 
IGFBP7 insulin-like growth factor binding protein 7 
IL17RC interleukin 17 receptor C 
INDEL insertion/deletion 
INL          inner nuclear layer 
IPL           inner plexiform layer 
iPOP integrated personal omics profile  
ITGA1 integrin, alpha 1 
kb kilobase 
LIPC lipase, hepatic 
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log Logarithm 
LPL lipoprotein lipase 
LRP6         low density lipoprotein receptor-related protein 6 
MAF minor allele frequency 
MALDI-TOF matrix-assisted laser desorption/time of flight 
MASP mannan-binding lectin serine protease 1 
Mb Megabase 
MBL mannan-binding lectin 
MCP  membrane cofactor protein 
MG1 macroglobulin domain 1 
MIM Mendelian Inheritance in Man 
MIPs molecular inversion probes 
MMP9       matrix metallopeptidase 9 
MPGN II membranoproliferative glomerulonephritis type II 
mtDNA mitochondrial DNA 
MZ           monozygotic  
NFL          nerve fiber layer 
NGS next generation sequencing 
NV           neovascular 
ONL        outer nuclear layer 
OPL         outer plexiform layer 
OR            odds ratio 
PCR polymerase chain reaction 
PLEKHA1 pleckstrin homology domain containing, family A (phosphoinositide binding 
specific) member 1 
POLR2B polymerase (RNA) II (DNA directed) polypeptide B 
PolyPhen 2 polymorphism phenotyping version 2 
PON1        paraoxonase 1 
PR            photoreceptor 
PTPN22 protein tyrosine phosphatase, non-receptor type 22 
RA rheumatoid arthritis 
RAD51B RAD51 paralog B 
REST RE1-silencing transcription factor 
RPE         retinal pigment epithelium 
RS Rotterdam Study 
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SD standard deviation 
SIFT sorting tolerant from intolerant 
SKAT sequence kernel association test  
SKAT-O SKAT-optimal 
SLC16A8 solute carrier family 16, member 8 
SNP          single nucleotide polymorphism 
SOD2        superoxide dismutase 2 
SYN3 synapsin 3 
T1D type 1 diabetes 
TFPI tissue factor pathway inhibitor 
TGFBR1 transforming growth factor, beta receptor 1 
TIMP3 TIMP metallopeptidase inhibitor 3 
TLR4         toll-like receptor 4 
TNFRSF10A tumor necrosis factor receptor superfamily, member 10a 
UBE3D ubiquitin protein ligase E3D 
VEGFA        vascular endothelial growth factor A 
VLDLR     very low density lipoprotein receptor 
VWF von Willebrand factor 
WES whole exome sequencing 
WGS whole genome sequencing 
1 
 
 
  
2 
 
7 
 
1. Anatomy of the Eye 
The eye is a complex organ and was described as an ‘organ of extreme perfection’ by Charles 
Darwin [1]. Approximately 90% of the genes in the human genome are expressed in one of the 
eye’s tissues at some point in life, exemplifying its complexity [2]. The eye is responsible for visual 
perception, and alterations in the functions of the eye result in visual impairment, greatly reducing 
quality of life. 
 
             Figure 1. Anatomy of the human eye (modified from Cooke Bailey et al.2013 [3]) 
 
The interior of the human eye is composed of three fluid-filled chambers (figure 1). The anterior 
and posterior chambers are filled with aqueous humour, which provides nourishment to avascular 
tissues, including the cornea and the lens. The vitreous chamber is the largest fluid-filled space, 
which contains vitreous humour and is considered as an extremely tenuous connective tissue. The 
cornea, lens and vitreous body are responsible for light transmission and focus [4]. The eye contains 
three layers. The outer layer is formed by the cornea and sclera. The transparent cornea is a major 
refracting component that facilitates light rays to refract and project on to the retina. The sclera is an 
opaque white protective outer coat that protects the intraocular contents. The middle layer is 
composed of three interconnected structures, including the iris, ciliary body, and choroid. The iris is 
a circular pigmented contractile membrane that regulates the amount of light entering the pupil. The 
ciliary body is present at the juncture of the iris and choroid, where it controls the shape of the lens 
and produces the aqueous humour. The choroid is a vascular layer between the sclera and the retina, 
which provides nourishment to the retina. The choroid, the retinal pigment epithelium (RPE), and 
the retina form the innermost layer of the eye. 
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1.1 The Retina 
The retina is a light-sensitive neural tissue that transforms light signals into neural signals (Figure 
2A). The retina is composed of multiple layers, which include the nerve fibre layer, ganglion cell 
layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, 
photoreceptor layer, RPE, and Bruch’s membrane (Figure 2B). Five distinct types of neurons and 
supporting cells are embedded in the neural layers of the retina. The photoreceptor, horizontal, 
bipolar, amacrine, and ganglion cells are involved in capturing and processing the light signals. The 
Müller glia cells function as organizational backbones to the retina. 
 
Figure 2. (A) Colour fundus photograph of a normal retina. M, macula; F, fovea; 
OD, optic disc. (B) Micrograph of a normal retina. NFL, nerve fiber layer; GCL, 
ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer 
plexiform layer; ONL, outer nuclear layer; PR, photoreceptor layer; RPE, retinal 
pigment epithelium; BrM, Bruch’s membrane (Figure B. Adapted from Handa et al. 
2012 [5]). 
 
The retina contains two types of photoreceptor cells, which include the cones and the rods. The 
average human retina consists of approximately 4.6 million cones and 92 million rods [6]. Both cell 
types contain distinct opsin pigments that facilitate the phototransduction process. Rods consist of 
rhodopsin pigments that are extremely sensitive to light and enable vision in dim light conditions, 
which is called scotopic vision. Cones consist of photopsin pigments that perceive colours in bright 
light conditions, which is called photopic vision [7]. 
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1.2 The Macula 
The macula is the cone-enriched central region of the retina of approximately 6 mm in diameter, 
responsible for high visual acuity and colour vision (Figure 2A). It appears as a yellow spot on the 
fundus due to the presence of xanthophyll, lutein, and zeaxanthin pigments that protect the macula 
by filtering out short-wave-length light [8]. Based on differential photoreceptor content, the macula 
is subdivided into the fovea and the parafovea. The fovea is a small pit at the centre of the macula, 
which is densely packed with only cones and is encircled by the rod-dominated parafovea [6].  
 
2. Age-related Macular Degeneration (AMD)  
AMD (OMIM 603075) is a progressive retinal disorder causing blindness in elderly people aged 
over 50 years [9]. The disease primarily affects the macula, causing progressive deterioration of 
visual acuity [10]. AMD was estimated to cause visual impairment in more than 33 million people 
worldwide in 2010, and the number has been estimated to increase to 196 million by 2020 and 288 
million by 2040, given the ageing population [11,12]. An early clinical sign of AMD is the 
appearance of drusen, which are yellow extracellular deposits of protein and lipid material, between 
the basal lamina of the RPE and the inner collagenous layer of Bruch’s membrane. Drusen are 
classified as small (<63µm in diameter), medium (63-124µm), and large (>125µm) based on their 
size. In addition, drusen are classified based on the appearance of their margins: hard drusen have 
discrete margins whereas soft drusen have indistinct margins [13]. 
 
2.1 Clinical Classification 
AMD presents with a broad spectrum of clinical appearances and pathologies, primarily classified 
into early, intermediate, and advanced AMD. Early AMD is characterized by the presence of a few 
medium-sized (63-124µm) drusen, but without pigmentary abnormalities. Intermediate AMD is 
characterized by the presence of large drusen (>125µm) or pigmentary changes associated with 
medium drusen. Advanced AMD is further classified into geographic atrophy (GA) or neovascular 
AMD (NV-AMD). GA is characterized by RPE atrophy and photoreceptor degeneration. NV-AMD 
is characterized by the presence of choroidal neovascularization, leading to growth of abnormal, 
fragile blood vessels, resulting in haemorrhage or scar formation [14]. 
 
2.2 Cuticular Drusen (CD) 
CD (OMIM 126700) is a clinical subtype of AMD, and clinical presentation of CD is characterized 
as a symmetrically distributed pattern between both eyes of at least 50 scattered, uniformly-sized, 
small (25-75µm) hyperfluorescent drusen on FA in each eye, of which at least 20 drusen are located 
outside the Wisconsin age-related maculopathy grading template [15,16]. CD phenotype commonly 
appears in early adulthood, and it is also called ‘basal laminar drusen’ or ‘early adult-onset, grouped 
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drusen.’ A large number of CD typically appear as ‘stars-in-the-sky’ on FA (Figure 3). CD has a 
strong genetic predisposition, which is evident by its higher prevalence in families and early age at 
onset [17,18]. It has been estimated that approximately 10% of AMD cases display the CD 
phenotype [19]. 
 
              Figure 3. CD patient showing hyperfluorescent drusen on fluorescence angiography (FA) 
 
2.3 Drusen Composition 
The molecular composition of drusen is known to contain lipids, carbohydrates, zinc, and several 
complement system proteins (complement components and complement regulators) [16,20]. The 
substructure and composition of CD are similar to or indistinguishable from drusen that are present 
in AMD, suggesting a common drusen biogenesis phenomenon in both CD and AMD phenotypes 
[21]. However, some peculiarities distinguish CD from drusen in AMD, such as the number, earlier 
age at onset, and drusen pattern [16]. Additionally, CD display differential fluorescence 
characteristics. CD appear as hyperfluorescent because they fluoresce typically during the early 
arteriovenous phase, whereas drusen in AMD fluoresce during a later phase of the fluorescence in 
angiograms [22]. Because of the fluorescence properties of CD and drusen in AMD, it has been 
speculated that CD may consist of hydrophilic polar phospholipids and fluoresce early, whereas 
drusen in AMD may consist of hydrophobic neutral lipids and fluoresce minimally in the late phase 
of the angiograms. However, the lipid compositional differences could not be determined because of 
the use of xylene in immunohistochemistry studies [16,23].  
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3. Genetic Basis of AMD 
AMD is a complex disease caused by both genetic and environmental factors. Several 
environmental factors have been identified, of which ageing itself and cigarette smoking are 
consistently associated with AMD [24]. The genetic basis for AMD is well established in spite of 
the late disease onset and phenotypic variability. The genetic basis of AMD was first described 
through familial aggregation and twin studies, and later by the linkage-segregation, candidate-gene, 
and genome-wide association studies (GWASs), as will be detailed below. 
 
3.1 Familial Aggregation Studies 
Familial aggregation studies are conducted to determine the familial component in the disease onset. 
These studies compare the disease prevalence in relatives of cases with relatives of controls. In 
AMD, a North American-based familial aggregation study compared the AMD prevalence in first-
degree relatives of 119 AMD cases with first-degree relatives of 72 controls. The study showed a 
significantly higher prevalence of AMD in first-degree relatives of cases (23.7%) in comparison to 
first-degree relatives of controls (11.6%) (OR = 2.4; 95% CI = 1.2 - 4.7; P = 0.013) [25]. Another 
familial aggregation study based in Rotterdam was conducted in first-degree relatives of 87 
advanced AMD cases and 135 controls. The life-time risk estimate of advanced AMD was 
significantly higher in relatives of cases (50%) than in relatives of controls (12%) (OR = 4.2; 95% 
CI = 2.6 - 6.8; P = 0.001) [26]. These studies have demonstrated that AMD aggregates in families, 
which may be due to shared genetic or environmental factors. 
 
3.2 Twin Studies 
Twin studies are conducted to determine the heritability component of the disease. These studies 
compare the disease concordance in monozygotic (MZ) and in dizygotic (DZ) twins and estimate 
the relative contribution of genetic and environmental factors in the disease onset. In AMD, a twin 
study was conducted in 226 MZ and 280 DZ twins and showed that MZ twins (0.37) had a higher 
level of disease concordance than DZ twins (0.19) [27]. Another study measured AMD heritability 
in 210 MZ, 181 DZ, and 58 singletons [28]. This study also showed a higher level of disease 
concordance in MZ twins. The heritability was estimated to be as high as 0.46 to 0.71 for AMD, 
which suggests that genetic factors can explain 46-71% of the total risk of the disease [28]. Twin 
studies have thus demonstrated that genetic factors play a major role in the pathophysiology of 
AMD. 
 
3.3 Linkage Analyses 
Linkage analyses are performed to determine the mode of transmission of the disease. These 
analyses rely on Mendel’s laws to identify the disease susceptibility loci. Linkage analyses typically 
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require large families to facilitate the identification of significant linkage intervals, which contain 
the disease susceptibility genes. The first linkage analysis was conducted in a large family with 
AMD. The study demonstrated that the disease segregated in an autosomal-dominant fashion and 
discovered a disease susceptibility locus on chromosome 1q25-31 [29]. However, large families are 
not adequately available for study of late-onset diseases. Therefore, subsequent linkage analyses 
were conducted in a larger number of smaller AMD families with multiple affected siblings and 
other close relatives, which identified susceptibility loci on almost all of the chromosomes [30-36]. 
However, the most replicated linkage regions were identified on chromosomes 1q25-31 and 10q26. 
Later studies identified the CFH and ARMS2/HTRA1 genes on chromosomes 1q25-31 and 10q26, 
respectively. Therefore, linkage studies successfully identified the most significant contributors of 
AMD susceptibility [37]. 
 
3.4 Association Analyses 
Association analyses are conducted to determine the association of specific variants in certain genes 
with the diseases. This method assumes that the associated variants may be causal or are in linkage 
disequilibrium, the non-random association of alleles at different loci, with causal variants. Before 
genome-wide techniques became available, association studies were limited to the study of 
candidate genes [38,39]. In AMD, the candidate genes were selected either from linkage regions 
because of their functional relevance or because they had previously been identified in monogenic 
forms of macular degeneration. Overall, candidate-gene-based association studies resulted in a large 
number of variants associated with AMD, but without replication in other independent cohorts, their 
relevance to AMD pathogenicity remains unclear. However, these analyses consistently identified 
the association of the CFH gene with AMD [40,41]. Candidate genes that showed a positive 
association with AMD at least once include the FBLN5, CST3, CX3CR1, TLR4, VEGF, LRP6, 
MMP9, and HLA genes [42-48]. Candidate genes that showed both positive and negative 
associations with AMD include the APOE, ABCA4, HMCN1, PON1, ELOVL4, VLDLR, ACE, and 
SOD2 genes [49]. In AMD, candidate-gene based association studies achieved a limited success 
because the analyses were limited to specific regions, genes, and variants. 
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3.5 Genome Wide Association Studies (GWAS) 
3.5.1 GWAS and the CFH Gene Association 
A GWAS is a non-hypothesis driven method that measures the association of single-nucleotide 
polymorphisms (SNPs) across the genome to a specific clinical condition or a trait. This method 
relies on the common disease-common variant (CDCV) hypothesis, which assumes that genetic 
influences on common diseases are attributable to common variants [50]. Over the past years, it has 
been the most commonly used method and was developed with an advancement of high-throughput 
technology and annotation of common variants in the human genome [51,52]. 
              
                Figure 4. Manhattan plot showing the –log10 (P) values of SNPs (adapted from 
Klein et al. 2005 [53]) 
In 2005, the first GWAS was conducted in AMD and successfully identified strong associations 
between AMD and SNPs in and around the CFH gene [53]. The study included 96 AMD cases and 
50 controls, which were genotyped using a microarray containing 116,204 SNPs. Two intronic CFH 
SNPs (rs380390 and rs10272438) were significantly associated with AMD (P = 0.0043 and P = 
0.0080, respectively) after Bonferroni correction (P < 0.05/103,611 = 4.8×10-7) (Figure 4). 
Resequencing studies identified the coding variant, p.Tyr402His, in the CFH gene [41,54]. Among 
other non-synonymous variants, the p.Tyr402His variant showed a significant association to AMD 
and also showed a linkage disequilibrium with high-risk alleles [53]. Additionally, several other 
studies replicated the association of the CFH gene to AMD [40,41,54]. 
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3.5.2 The Complement Pathway Gene Associations to AMD 
 
                     Figure 5. The three different complement activation pathways (adapted from 
Degn et al. 2011 [55] 
The protein encoded by the CFH gene is a major regulator of the complement pathway, which plays 
a vital role in clearance of pathogens and immune complexes. The complement pathway is part of 
both innate and adaptive immunity and consist of over 30 plasma and cell surface proteins [56,57]. 
There are three different complement activation pathways (Figure 5). The alternative pathway is 
activated continuously at low level (‘tickover’) by spontaneous hydrolysis of the complement 
component 3 (C3). The lectin pathway is activated when mannan-binding lectin recognizes 
molecular patterns on pathogen surfaces. The classical pathway is activated by binding of C1q to the 
antigen-antibody complex [20]. The three activation pathways converge at C3 to generate C3 
convertase enzyme, which cleaves C3 into C3a and C3b. C3a acts as an anaphylatoxin, and C3b acts 
as opsonin and is involved in further complement activation steps in a cascade manner to form a 
cytolytic membrane attack complex on the surface of target pathogens. CFH is a central 
complement regulator protein that inhibits complement activation by the alternative pathway [58]. 
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Table 1. A list of the susceptibility loci that were identified in AMD by GWASs 
(modified from Weber et al. 2014 [59]) 
SNP/ Nearest Biological process OR 95% CI 
risk allele  gene       
rs10737680/A CFH Complement activation 2.43 2.39-2.47 
rs13081855/T COL8A1 Extracellular matrix organization 1.23 1.17-1.29 
rs6795735/T ADAMTS9 Extracellular matrix organization 1.10 1.07-1.14 
rs4698775/G CFI Complement activation 1.14 1.10-1.17 
rs429608/G C2/CFB Complement activation 1.74 1.68-1.79 
rs943080/T VEGFA Angiogenesis 1.15 1.12-1.18 
rs3812111/T COL10A1 Extracellular matrix organization 1.10 1.07-1.14 
rs3130783/A DDR1 Extracellular matrix organization 1.16 1.11-1.20 
  IER3 Regulation of inflammatory processes/apoptosis     
rs13278062/T TNFRSF10A Activation of NF-κB kinases/apoptosis 1.15 1.12-1.19 
rs334353/T TGFBR1 Extracellular matrix 
organization/angiogenesis 1.13 1.10-1.17 
rs10490924/T HTRA1 Extracellular matrix organization 2.76 2.72-2.80 
 
ARMS2 Unknown 
  
rs9542236/C B3GALTL Protein glycosylation 1.10 1.07-1.14 
rs8017304/A RAD51B DNA repair/apoptosis 1.11 1.08-1.14 
rs920915/C LIPC Cholesterol/LDL/HDL metabolism 1.13 1.09-1.17 
rs1864163/G CETP Cholesterol/LDL/HDL metabolism 1.22 1.17-1.27 
rs2230199/C C3 Complement activation 1.42 1.37-1.47 
rs4420638/A APOE Cholesterol/LDL/HDL metabolism 1.30 1.24-1.36 
rs5749482/G TIMP3 Extracellular matrix 1.31 1.26-1.36 
  SYN3 Neurotransmitter secretion     
rs8135665/T SLC16A8 Membrane transport 1.15 1.11-1.19 
 
The strong association between AMD and genetic variants in the CFH gene encouraged candidate-
gene-based association studies with other components of the complement pathway. Interestingly, 
these studies successfully found associations with a number of complement pathway genes. A gene-
based association study was conducted for the complement factor B (CFB) and the complement 
component 2 (C2) genes in about 900 AMD cases and 400 controls. The study discovered variants 
that conferred reduced risk of AMD, including the p.Leu9His (rs4151667) variant in CFB and the 
p.Glu318Asp (rs9332739) variant in the C2 gene [60]. Furthermore, an association of the 
complement component 3 (C3) and the complement component 5 (C5) genes was analysed in 847 
AMD cases and 701 controls. The study showed an association with the p.Arg80Gly (rs2230199) 
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variant in the C3 gene with AMD, whereas no evidence of association was found with variants in 
the C5 gene [61]. The association of the complement factor I (CFI) gene was analysed in 1,228 
AMD cases and 825 controls. The study identified two variants (rs10033900 and rs13117504) that 
showed genome-wide significant association only if they were in a combined haplotype [62]. In 
addition, the CFH-related (CFHR) genes were analysed for association in 780 AMD cases and 265 
controls. The analysis showed that deletion of the CFHR1 and CFHR3 genes was associated with 
reduced risk of AMD [63]. Thus far, the candidate-gene-based association studies successfully 
identified several risk and protective variants in the complement pathway genes. 
 
3.5.3 The PLEKHA1/ARMS2/HTRA1 Gene Associations 
A second major association signal was identified in a region that comprises the PLEKHA1, the 
ARMS2, and the HTRA1 genes [64,65]. All three genes are in a high linkage disequilibrium with 
each other; therefore, it became a challenge to disentangle the causative gene in this region. In an 
attempt to pinpoint the causative gene, a fine-mapping study was conducted in the region using 45 
tag SNPs. A non-synonymous variant (p.Ala69Ser/rs10490924) in the ARMS2 gene accounted for 
the bulk of association in this region. The same study also provided functional evidence that the 
ARMS2 protein localized to the mitochondrial outer membrane. Therefore, the p.Ala69Ser variant 
is likely to alter the mitochondrial function in AMD [66]. Another study, on the contrary, suggested 
that ARMS2 is an extracellular matrix (ECM) protein which interacts with fibulin-6, and mutations 
in the fibulin-6 gene are known to be associated with AMD [67]. This evidence suggests that the 
function and localization of ARMS2 is controversial. Additionally, one other study reported that a 
deletion-insertion polymorphism in the ARMS2 gene showed a significant association with AMD 
[68]. The genetic and functional studies supported the notion that ARMS2 is a likely candidate in 
this region. 
 
3.5.4 Other Susceptibility Loci Associations 
Subsequent GWASs were conducted in a large number of AMD cases and controls to facilitate the 
discovery of weaker genetic associations, and they also utilized a higher density of SNPs for better 
coverage in the genome. For example, Chen et al. conducted a genome-wide scan in 2,157 AMD 
cases and 1,150 controls. The top association signals were further validated in 8,570 AMD cases 
and 6,334 controls. The study discovered novel susceptibility loci for AMD near the TIMP3 
(rs9621532), the LIPC (rs493258), and the CETP (rs3764261) genes [69,70]. The association with 
the LIPC gene was further confirmed by a concurrent study by Neale et al. The study was conducted 
in 979 advanced AMD cases and 1,709 controls. The top association signals were validated in 5,789 
AMD cases and 4,234 controls. The study demonstrated a significant association between AMD and 
a variant in the LIPC gene (rs10468017) [71]. Another study was conducted in 1,536 exudative 
AMD cases and 18,894 controls and identified two novel loci at the TNFRSF10A/LOC389641 
(rs13278062) and the REST/C4orf14/ POLR2B/IGFBP7 (rs1713985)genes in the Japanese 
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population [72]. In summary, four large GWASs in AMD successfully detected ten susceptibility 
loci [53, 69, 71, 72]. 
 
3.5.5 Meta-Analyses 
In addition, meta-analysis studies were conducted to improve the power to detect even weaker 
genetic associations in AMD. Meta-analysis is a method that allows combining GWAS data from 
multiple studies by considering the heterogeneity of data across multiple studies [73]. In AMD, the 
first meta-analysis was conducted in 8,234 cases and 56,308 controls [74]. The study identified two 
novel loci near the FRK/COL10A1 (rs1999930) and the VEGFA (rs4711751) genes. The study also 
detected ten previously reported susceptibility loci, including the ARMS2/HTRA1 (rs10490924), the 
CFH (rs1061170, and rs1410996), the CFB (rs641153), the C2 (rs9332739), the C3 (rs2230199), 
the CFI (rs10033900), the LIPC (rs10468017), the TIMP3 (rs9621532), and the CETP (rs3764261) 
genes [74]. In 2010, the AMD gene consortium was formed to accelerate the discovery of 
susceptibility variants for AMD. The consortium was established with eighteen research groups 
across the world. It was supported by the National Eye Institute, the National Institute of Health. 
The consortium conducted a meta-analysis study in >17,100 advanced AMD cases and >60,000 
controls of European and Asian ancestry. The study identified seven novel loci near the 
COL8A1/FILIP1L (rs13081855), the IER3/DDR1 (rs3130783), the SLC16A8 (rs8135665), the 
TGFBR1 (rs334353), the RAD51B (rs8017304), the ADAMTS9 (rs6795735), and the B3GALTL 
(rs9542236) genes. The study also reported twelve previously reported loci (Table 1) [75]. 
The GWASs and the meta-analyses identified several risk and protective variants for AMD. These 
studies facilitated the discovery of various pathways involved in the pathogenesis of AMD, 
including the complement, the coagulation, the lipid metabolism, the atherosclerotic signalling, the 
collagen and extracellular matrix remodelling, the apoptosis, and the angiogenesis pathways. 
Overall, these studies identified nineteen major susceptibility loci in AMD, accounting for 15-65% 
of the heritability. The remaining proportion of the phenotypic variation, the so-called ‘missing 
heritability’, is yet to be discovered in AMD. 
 
3.6 Missing Heritability 
Heritability is defined as the proportion of total phenotypic variation in a population which is 
attributable to additive genetic factors [76]. Studying such heritable factors helps to understand the 
genetic architecture of complex diseases and ultimately to improve personalized medicine. The 
allelic architecture may vary across multiple traits in frequency, type, and effect size of 
susceptibility variants. Therefore, the missing heritability may take different forms for different 
traits [77]. Thus far, GWASs have been conducted mostly on common variants and discovered more 
than 8,500 risk-associated SNPs for a variety of complex traits. However, the effect size is weak 
(OR <1.5) for most of the associated SNPs, which collectively account for only 5-20% of the 
heritability for most complex traits [78,79]. In AMD, the risk-associated SNPs account for 15-65% 
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of the heritability [75] (Figure 5). A great proportion of the heritability, therefore, is not explained 
by common SNPs and is referred to as the ‘missing heritability’ [80]. 
 
                     Figure 5. Effect sizes of common and rare variants are depicted. Common 
variants account for 15-65% of heritability in AMD [81]. 
 
So far, GWASs have focussed mostly on the role of common variants accounting for the phenotypic 
variation in complex traits. These studies have not considered other plausible factors that may 
account for the remaining heritability. These factors may add another level of complexity in 
understanding complex traits, which include copy-number variants (CNVs), mitochondrial DNA 
(mtDNA) variants, epigenetics, gene-gene and gene-environment interactions, unidentified common 
variants, and highly penetrant rare variants. 
 
3.7 Role of Rare Variants 
Rare variants, defined as polymorphic alleles with a minor allele frequency (MAF) of <1% in the 
population, can exert strong effect sizes and can contribute to missing heritability [81]. The role of 
genetic variation (common or rare alleles) in complex traits has long been debated in genetic 
research. Some researchers suggest that common diseases are due to common variants, and, 
therefore, they support the common disease-common variant (CDCV) hypothesis [82]. Others 
suggest that rare variants are major contributors to common diseases, supporting the common 
disease-rare variant (CDRV) hypothesis [82,83]. The 1000 Genomes Project demonstrated that the 
majority of genetic variation in the human genome is rare and population-specific [84]. In addition, 
a population genetics theory suggested that many rare missense variants are deleterious for protein 
function in humans [85]. It is vital, therefore, to understand the role of rare variants, which can have 
different population characteristics [86]. 
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                         Table 2. A list of rare sequence variants identified in AMD 
Gene Change in 
  
dbSNP ID Odds 
ratio P-value Biological process 
  
Nucleotide Protein 
  
 
  
& Reference 
CFH c.3628C>T p.Arg1210Cys rs121913059 18.8 7.0×10-6 Complement system [87] 
CFI c.355G>A p.Gly119Arg rs141853578 22.2 3.79×10-6 Complement system [88] 
C3 c.463A>C p.Lys155Gln rs147859257 3.65 8.8×10-16 Complement system [89] 
C9 c.499C>T p.Pro167Ser rs34882957 2.2 6.5×10-7 Complement system [90] 
 
Emerging evidence suggests that rare variants can contribute to the pathophysiology of AMD and 
also to the missing heritability in this disease. In AMD, a simulation study evaluated five risk-
associated common variants in 322 densely affected AMD families. The study suggested that 
common variants were insufficient to account for disease burden [92]. In addition, a meta-analysis 
study suggested that each of the nineteen risk-associated loci may harbour several independent 
variants that are associated with AMD susceptibility [75]. The role of rare variants in AMD is 
further supported by the identification of rare missense mutations in the fibulin-5 (FBLN5), the 
hemicentin-1 (HMCN1), and the fibrillin-2 (FBN2) genes in AMD cases and families [42,91,93]. 
Recently, several studies have identified rare variants in the complement pathway genes, including 
the CFH, the CFI, the C3, and the complement component 9 (C9) genes [81,87-90] (Table 2). Rare 
variants have also been evident in other complex traits, such as variation in plasma levels of high 
density lipoprotein cholesterol, type II diabetes, and hypertension [94-96]. 
Taken together, the evidence suggests that rare variants may be plausible culprits underlying 
complex diseases and may also account for part of the missing heritability. The identification of rare 
variants at the association signals identified by GWASs can hint at the disease pathogenesis 
mechanisms of complex diseases. Previously, GWASs were unable to capture the rare variants 
because of their low frequencies and high heterogeneity. However, recent developments in 
sequencing technologies may offer great resources to study rare variants. 
 
3.8 Methods to Identify Rare Variants 
3.8.1 Candidate Gene Approach 
The candidate gene approach is a hypothesis-driven approach that can evaluate the role of specific 
genes in disease susceptibility of complex diseases. Candidate genes are typically selected from 
genes at association signals identified by GWAS, from linkage intervals, from genes of functional 
relevance, or from genes identified in familiar forms. The candidate gene approach witnessed a 
limited success in AMD during the pre-GWAS era, as described before [49]. In the post-GWAS era, 
however, the approach has successfully identified several rare variants in complex traits. In AMD, 
rare variants were identified in several complement pathway genes that are located at or near the 
GWAS loci [75,90] (Tables 1 and 2). 
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The candidate-gene-based approach requires screening of large numbers of samples to identify rare 
variants in complex diseases. An economical approach that can be used, combines sequencing and 
genotyping methods to identify rare variants. Initially, this approach involves sequencing of 
candidate genes in a subset of cases. Subsequently, the identified variants can be genotyped in a 
larger number of cases and controls to determine their association with disease. Sanger sequencing 
can be applied in this approach as sequencing is required in a limited number of subjects. Sanger 
sequencing has been the most commonly used DNA sequencing method, which relies on dideoxy 
chain-termination chemistry. The method was first developed by Frederick Sanger in 1977 [97]. The 
method has remained the most accurate DNA sequencing technique to date. However, Sanger 
sequencing is a laborious, low-throughput, and costly method, which are considered to be major 
drawbacks. It may not be the most appropriate technique, therefore, to sequence large numbers of 
samples in complex diseases. These limitations resulted in the development of next-generation 
sequencing (NGS) technologies. 
 
3.8.2 Next-Generation Sequencing and Whole Exome Sequencing 
In 2005, the first NGS technologies were introduced that offered high-throughput and cost-effective 
DNA sequencing [98,99]. The NGS technologies can sequence a large number of samples in 
parallel, called massive-parallel DNA sequencing. Therefore, NGS technologies can be used to 
identify rare variants in large number of samples in complex diseases. NGS technologies have 
predominantly been used for sequencing the entire genome (whole genome sequencing, WGS) or 
specific regions (targeted capture) of the genome. However, WGS is considerably more expensive 
than targeted capture, which can be used to sequence specific regions or all protein-coding regions 
in the genome with high coverage. 
Whole exome sequencing (WES) is a cost-effective approach that selectively sequences all protein-
coding regions (exome) of the genome. Collectively, protein-coding regions are approximately 30 
megabases in size, spread across 180,000 exons that constitute 1% of the human genome [100]. 
Protein-coding regions were estimated to harbour 85% of disease-causing mutations [101]. In 
addition, coding variants offer a straightforward functional annotation. Therefore, WES is an 
efficient strategy to study rare variants in the protein-coding regions in complex diseases. 
Three experimental designs can be applied to identify rare variants in complex diseases by WES. 
Firstly, a family-based design can be used, which involves sequencing of affected family members. 
This approach detects rare causal variants by analysing variants shared among affected family 
members. Hence, it can be helpful to include the most distantly related family members to facilitate 
the identification of rare causal variants because they share fewer variants [102]. Family-based 
designs can also be used to detect de novo mutations [103]. Next, the extreme-trait design can be 
used, which involves sequencing of individuals who are at the extreme end of a trait distribution. 
This approach is useful in identifying modest to high effect size variants [102]. Finally, the discrete-
trait design can be used, which involves sequencing of individuals who show an ‘unusual’ 
presentation of a trait, even after accounting for known risk factors [103].  
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4. Goal of this Thesis 
Previous genetic studies suggested that common variants may account for only 15-65% of the 
heritability in AMD [75]. It has been hypothesized that the remaining genetic fraction influencing 
the risk of developing AMD may be explained by rare, highly penetrant variants [81]. The present 
thesis aimed to identify rare variants in patients with AMD. The analyses were conducted both by 
sequencing and by genotyping methods to identify rare variants at or near the previously discovered 
AMD susceptibility loci. In addition, WES was conducted to identify rare variants in sporadic and 
familial AMD cases. 
Chapter 2 reports the finding of rare variants in the CFH gene in patients with the cuticular drusen 
subtype of AMD. It also discusses whether the p.Arg1210Cys variant in the CFH gene is restricted 
to a subset of AMD cases or is associated with AMD in general. 
Chapter 3 describes the analysis of rare variants in the C3 gene in patients with AMD. The study 
analyses for a genetic overlap at the C3 locus in patients with AMD and atypical haemolytic uremic 
syndrome, a rare kidney disorder. 
Chapter 4 uses a whole genome sequencing approach to identify rare sequence variants in patients 
with AMD. A conditional logistic regression analysis is performed to identify additional rare 
sequence variants at previously reported AMD loci. 
Chapter 5 uses a whole exome sequencing approach to identify rare sequence variants in families 
and sporadic cases with CD subtype of AMD. 
Chapter 6 provides a general discussion of all studies that were conducted on rare variants in 
AMD. It describes the role of the complement system, lipid metabolism, and ECM genes in AMD 
pathology, and allelic overlap between AMD and other phenotypes. It describes the role of rare 
variants in predictive testing and personalized medicine. Finally, it also provides novel approaches 
to solving the missing heritability in AMD. 
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ABSTRACT 
Purpose: Age-related macular degeneration (AMD) and cuticular drusen (CD), a clinical subtype of 
AMD, have both been linked to genetic variants in the complement factor H (CFH) gene. In this 
study we aimed to investigate the frequency of rare variants in the CFH gene in 180 cases with CD. 
In addition, we aimed to determine the frequency of a previously reported rare, highly penetrant 
CFH variant (p.Arg1210Cys) in a Dutch-German non-CD type AMD case-control cohort, and to 
describe the phenotype of patients carrying the p.Arg1210Cys variant. 
 
Methods: Study subjects were selected from the European Genetic Database (EUGENDA), a joint 
AMD database of the Radboud University Medical Centre and the University Hospital of Cologne, 
and graded at the Cologne Image Reading Centre and Laboratory (CIRCL). Additionally, two CD 
cases were recruited from the VU Medical Centre in Amsterdam. The CFH gene was analyzed in 
180 CD cases by Sanger sequencing. All identified variants were analysed for potential damaging 
effects by prediction software tools SIFT and PolyPhen. In addition, we genotyped the 
p.Arg1210Cys variant in 813 non-CD type AMD cases and 1175 controls.  
 
Results: Sequencing identified 11 rare, heterozygous missense variants, one frameshift variant, and 
one splice acceptor site variant in 16 CD cases. The p.Arg1210Cys variant was identified in two CD 
cases, but was not identified in our Dutch-German non-CD type AMD case-control cohort. 
 
Conclusions: The present study identified the presence of rare variants in the CFH gene in 16 
(8.8%) of 180 patients with the CD subtype of AMD. The carriers of rare CFH variants displayed a 
significantly earlier age at onset than non-carriers (P = 0.016). The rare missense variant 
p.Arg1210Cys was identified in two CD cases, but was not detected in 813 non-CD type AMD 
cases nor 1175 controls of our Dutch-German cohort. The current study suggests that the 
p.Arg1210Cys variant may be restricted to a subset of AMD patients with CD. Detailed clinical 
phenotyping, including fluorescein angiography, of AMD patients carrying the p.Arg1210Cys 
variant in other cohorts is required to confirm this finding.  
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INTRODUCTION 
Age-related macular degeneration (AMD, MIM 603075) is the most common cause of vision loss 
and irreversible blindness in the Western world among the elderly [1]. A major hallmark of AMD is 
the appearance of drusen in the macula accompanied with loss of sharp and central vision with 
advancing disease [2]. Cuticular drusen (CD, MIM 126700), also termed “basal laminar drusen” or 
“early adult-onset, grouped drusen”, is a clinical subtype of AMD, characterized by the fundoscopic 
findings of innumerable, small (25-75µm), slightly raised, round drusen, scattered throughout the 
central and peripheral retina [3]. CD commonly appear in early adulthood, and are readily visualized 
by fluorescein angiography (FA). In more advanced stages the large number of CD present as a 
typical “stars-in-the-sky” appearance in the early phases of the angiogram [4]. Approximately 10% 
of AMD cases display the CD phenotype [5].  
The early age of onset and the clustering of the CD phenotype in families implies a large genetic 
contribution to the development of CD [5-8]. This is supported by the observation that heterozygous 
mutations in the complement factor H (CFH) gene segregate with the CD phenotype in multiplex 
families [5, 8]. Common variants in and near the CFH gene have been associated with CD and with 
AMD [6, 7]. In addition, a rare, highly penetrant variant (p.Arg1210Cys) in the CFH gene has been 
associated with AMD [9, 10]. However, the p.Arg1210Cysvariant was not detected in an Icelandic 
cohort nor in the Han Chinese population [11, 12]. This suggests that the rare p.Arg1210Cys variant 
does not consistently associate with AMD among different populations.  
In this study we aimed to investigate the frequency of rare variants in the CFH gene in 180 cases 
with CD. In addition, we aimed to determine the frequency of the rare highly penetrant 
p.Arg1210Cys variant in a Dutch-German non-CD type AMD case-control cohort, and to describe 
the phenotype of patients carrying the p.Arg1210Cys variant. 
 
METHODS 
EUGENDA Study 
The study participants were recruited from the European Genetic Database (EUGENDA), a 
multicenter database consisting of subjects from the Nijmegen area, the Netherlands and Cologne 
area, Germany (Table 1). In addition, two CD cases were recruited at the VU Medical Centre in 
Amsterdam. All subjects analyzed in this study are Dutch and German and are of Caucasian 
descent. All subjects underwent ophthalmological examinations, and AMD staging was performed 
by the Cologne Image Reading Centre and Laboratory (CIRCL). CD was classified as a symmetric 
distributed pattern in both eyes of at least 50 scattered, uniformly-sized, small (25-75µm) and 
hyperfluorescent drusen on FA in each eye, with a minimum of 20 drusen located outside the 
Wisconsin age-related maculopathy grading template [6, 13]. AMD was classified by the presence 
of at least 15 intermediate (63-124μm) drusen or at least one large (≥125μm) druse in the Early 
Treatment Diabetic Retinopathy Study (ETDRS) grid (intermediate AMD) or geographic atrophy or 
choroidal neovascularisation secondary to AMD (advanced AMD). Control subjects were ≥65 years 
of age and did not display AMD, which includes cases without drusen, with only small drusen 
34 
 
(<63µm) or with pigmentary abnormalities alone or combined with less than 10 small drusen. Early 
AMD cases with ≥10 small drusen and pigmentary abnormalities or 1-14 intermediate drusen were 
excluded. The age at onset of subjects was noted as the age at which first visual complaints were 
experienced.  
The EUGENDA study was approved by the local research ethics committees (Commissie 
Mensgebonden Onderzoek Regio Arnhem-Nijmegen, the Netherlands, and the Ethics Committee of 
the University Hospital Cologne, Germany). Written informed consent was obtained from all 
participants, and the study was performed in accordance with the tenets of the Declaration of 
Helsinki. 
 
Sequencing 
Sanger sequencing of the CFH (NM_000186) gene was performed in 178 CD cases from the 
EUGENDA database and two CD cases from Amsterdam. Primers were designed to amplify all 22 
exons and flanking intron-exon junctions by Primer3 software (Appendix 1). Polymerase chain 
reactions (PCR) were performed, and amplification products were sequenced using an automated 
sequencer (BigDye Terminator, version 3, 3730 DNA analyzer; Applied Biosystems). All 
sequencing chromatograms were compared to the reference sequence using ContigExpress (Vector 
NTI Advance, Version 11.0, Life Technologies). Each newly identified variant was confirmed by a 
second independent PCR and bidirectional Sanger sequencing. All identified variants were 
annotated based on the Human Genome Variation Society (HGVS) nomenclature. Variants with a 
minor allele frequency <1% (MAF<1%) were considered as rare variants. The number of carriers of 
rare variants discovered in the CD cohort (n = 180) was compared to the general population (n = 
4300) using data from Exome Variant Server (EVS). Rare coding (missense, frameshift, and 
nonsense) and splice site variants in the CFH gene, were utilized in the analysis. The average age at 
onset of CD patients were compared in carriers of rare CFH variants (n = 16; age at onset known = 
13) versus non-carriers of rare CFH variants (n = 164; age at onset known = 64). The predicted 
effects of identified missense variants were examined using Polymorphism Phenotyping (PolyPhen) 
and Sorting Intolerant from Tolerant (SIFT) [14, 15].  
 
Genotyping 
The CFH p.Arg1210Cys variant was genotyped in 813 non-CD type AMD cases and 1175 controls 
from the EUGENDA database using a competitive allele-specific PCR assay (KASPar SNP 
Genotyping System, KBiosciences). KASPar genotyping was performed according to the 
manufacturer’s protocol in a volume of 4µl containing 10ng of genomic DNA, 2.5µl of 2X reaction 
mix, and 0.069µl of assay (Appendix 2). Thermal cycling conditions included a pre-incubation step 
at 94⁰C for 15min, 20 cycles of 94⁰C for 10s, 57⁰C for 5s, 72⁰C for 10s, followed by 23 cycles of 
94⁰C for 10s, 57⁰C for 20s, 72⁰C for 40s. Plates were analyzed on a 7900 Fast Real-Time PCR 
system (Applied Biosystems).  
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Table 1. Demographics of studied subjects of the EUGENDA cohort 
 
Variables CD Intermediate AMD Advanced AMD Controls 
Number (Total) 180 207 606 1175 
Mean age (±SD) 70 ± 13.7 74 ± 6.8 77 ± 7.7 70 ± 5.9 
Gender     
Male 59 (32.8%) 80 (38.6%) 251 (41.4%) 504 (42.9%) 
Female 121 (67.2%) 127 (61.4%) 355 (58.6%) 671 (57.1%) 
 
CD: Cuticular drusen; AMD: Age-related macular degeneration; SD: Standard deviation 
 
 
RESULT 
Through sequencing of the exons and flanking intron-exon boundaries of the CFH gene in 180 
unrelated CD cases 13 heterozygous rare variants in 16 cases (8.8%) were identified (Table 2). Of 
these 13 variants, 11 were missense variants, one was a frameshift variant (p.Ala301Asnfs*25), and 
one was a splice acceptor site variant (c.428-2A>G). Seven variants (c.428-2A>G, p.Ala161Ser, 
p.Ala173Gly, p.Arg175Gln, p.Ser193Leu, p.Ala301Asnfs*25, and p.Trp379Arg) were not present 
in public genetic variant databases (dbSNP, ESP6500/EVS) and therefore represent rare, unique 
variants. Six variants (p.Leu3Val / rs139254423, p.Ile216Thr / rs183474263, p.Gln400Lys / 
rs201671665, p.Gln950His/rs149474608, p.Thr956Met / rs145975787, and p.Arg1210Cys / 
rs121913059) had very low reported minor allele frequencies (MAF) in these databases 
(MAF<0.001). The total number of carriers of rare CFH variants in CD patients (16 (8.8%) of 180) 
is significantly higher than the total number of carriers of rare CFH variants in the general 
population (185 (4.3%) of 4300) (P = 0.008, Fisher’s test). The mean age at onset in carriers of rare 
CFH variants (57.2 ± 16.8 years) is significantly earlier than non-carriers of rare CFH variants (66.1 
± 10.8 years) (P = 0.016, Student’s t-test). Using online prediction algorithms SIFT and PolyPhen, 
potential damaging effects of the missense variants were assessed. Three missense variants 
(p.Ser193Leu, p.Trp379Arg and p.Gln950His) showed a consistent deleterious and damaging score 
by both PolyPhen and SIFT, while three variants were predicted deleterious or damaging by one of 
the prediction algorithms. Five missense variants were not predicted to be deleterious or damaging 
by either algorithm, including the p.Arg1210Cys variant.  
The p.Arg1210Cys variant was identified in two unrelated individuals with CD. To test for a 
possible association of the p.Arg1210Cys variant in our Dutch-German non-CD type AMD case-
control cohort, we genotyped this variant in 813 cases and 1175 controls from the EUGENDA 
database (Table 1). The p.Arg1210Cys variant was not found in our genotyped cohort, besides the 
two CD patients in which the p.Arg1210Cys variant was identified by sequence analysis of the CFH 
gene. 
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Both individuals carrying the p.Arg1210Cys variant presented with hyperfluorescent drusen on FA, 
typical for the CD subtype of AMD (Figure 1). In case 1 drusen were first noted at 50 years, with 
both eyes displaying numerous small drusen in the posterior pole and peripheral retina (Figure 1A to 
1D). Case 2 had an age of onset of visual impairment at 64 years and presented with numerous 
small drusen in the posterior pole in both eyes. Furthermore, case 2 displayed a large fibrotic scar in 
the right eye (Figure 1E and 1G), pigmentary changes and an occult choroidal neovascularisation in 
the left eye (Figure 1F and 1H). 
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Table 2. Rare sequence variants identified in the CFH gene in 180 CD cases 
 
Number  Nucleotide  Protein  SNP Id MAF (%)   Previous disease  Prediction algorithms 
of cases change change   CD cases EVS/dbSNP associations SIFT PolyPhen2 
1 c.7C>G p.Leu3Val rs139254423 0.27 0.02 Novel Tolerated (0.06) Damaging (0.91) 
1 c.428-2A>G Splice-acceptor site NA 0.27 0 Novel NA NA 
1 c.481G>T p.Ala161Ser NA 0.27 0 Novel Tolerated (0.17) Benign (0.09) 
1 c.518C>G p.Ala173Gly NA 0.27 0 Novel Deleterious (0.03) Benign (0.08) 
1 c.524G>A  p.Arg175Gln NA 0.27 0 Novel Tolerated (0.17) Benign (0.00) 
1 c.578C>T p.Ser193Leu NA 0.27 0 Novel Deleterious (0.0) Damaging (0.99) 
1 c.647T>C p.Ile216Thr rs183474263 0.27 0.001 Novel Tolerated (0.19) Benign (0.003) 
1 c.901_902del p.Ala301Asnfs*25 NA 0.27 0 Novel NA NA 
1 c.1135T>C p.Trp379Arg NA 0.27 0 Novel Deleterious (0.0) Damaging (1.0) 
2 c.1198C>A p.Gln400Lys rs201671665 0.55 0.01 aHUS [29] Tolerated (0.94) Benign (0.01) 
2 c.2850G>C p.Gln950His rs149474608 0.55 0.61 aHUS [28] Deleterious (0.0) Damaging (0.80) 
1 c.2867C>T p.Thr956Met rs145975787 0.27 0.16 aHUS [30] Tolerated (0.38) Damaging (0.96) 
2 c.3628C>T p.Arg1210Cys rs121913059 0.55 0.02 aHUS/AMD [10, 24]  Tolerated (0.05) Benign (0.02) 
                  
MAF, Minor Allele Frequency; SIFT, Sorting Intolerant from Tolerant (Intolerance < 0.05); PolyPhen2, Polymorphism Phenotyping (score 0→1) 
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Figure 1. Fundus photographs and fluorescein angiographs of two cases carrying the 
Arg1210Cys variation. Case 1, displayed numerous small drusen (arrow) in the 
posterior pole and in peripheral retina in both eyes (A and B represent colour fundus 
photographs of the posterior pole and the periphery of the left eye respectively, 
whereas C and D represent fluorescein angiographs of the posterior pole and the 
periphery of the left eye respectively). Case 2, showed small drusen of the posterior 
pole in both eyes (E and F represent colour fundus photographs of right and left eye 
respectively, whereas G and H represent fluorescein angiographs of right and left eye 
respectively). In addition, case 2 displayed a large fibrotic scar (G, arrow) in the right 
eye. In the left eye pigmentary changes (F, arrow) and an occult choroidal 
neovascularisation (H, arrow) were observed. 
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Figure 2. Schematic representation of factor H and its functional domains. Factor H 
is composed of 20CCP domains, and the approximate locations of missense 
variations are indicated on top of the diagram. The location of binding sites for C3b 
in black, cofactor activity in purple, heparin in orange, sialic acid in green, and self-
surface recognition in blue bars, are mentioned below. 
 
DISCUSSION 
The present study identified the presence of rare variants (MAF<1%) in the CFH gene in 16 (8.8%) 
of 180 patients diagnosed with the CD subtype of AMD. This number is significantly higher than 
the number of carriers of rare CFH variants in the general population (4.3%, P = 0.008). This study 
evidenced that carriers of rare CFH variants display an earlier age at onset than non-carriers of rare 
CFH variants (P = 0.016). The rare missense variant p.Arg1210Cys was identified in two CD cases, 
but was not detected in 813 non-CD type AMD cases and 1175 controls of our Dutch-German 
cohort. The p.Arg1210Cys variant was previously found to be highly associated with AMD in North 
American cohorts, with a frequency in AMD patients of 40/2,423 (1.65%) [10] and 23/2,335 
(0.99%) [9], respectively. However, the p.Arg1210Cysvariant was not detected in an Icelandic 
cohort (consisting of 1,143 AMD patients) nor in a Han Chinese cohort (consisting of 258 AMD 
patients) [11, 12].  
The current study suggests that the p.Arg1210Cys variant may be restricted to a subset of AMD 
patients with CD. Since the cohort of CD patients analysed in our study was too small to reliably 
test for an association, this finding would need to be confirmed in additional cohorts of patients with 
CD, and/or by detailed clinical phenotyping of AMD patients carrying the p.Arg1210Cys variant 
using FA. An under or overrepresentation of AMD patients with CD-like characteristics between 
cohorts might explain the observed discrepancy of the p.Arg1210Cys association between the North 
American [10], Icelandic [11], Han Chinese [12] and the Dutch-German cohorts. On the other hand 
it is well-known that the distribution of low-frequency alleles varies among populations, since they 
tend to be the result of recent mutation and are expected to geographically cluster around the 
location at which the mutation first arose [16]. Indeed, the frequency of disease-causing variants can 
significantly differ among populations [17], or can even be restricted to a geographical region [18]. 
The CFH protein is an important regulator of the alternative pathway of the complement cascade 
that plays a key role in clearance of pathogens and immune complexes, and modulates adaptive 
40 
 
immunity [19].  CFH is composed of 20 sequential complement control protein (CCP) domains 
(Figure 2). Five of the identified rare variants (p.Ala161Ser, p.Ala173Gly, p.Arg175Gln, 
p.Ser193Leu and p.Ile216Thr) are clustered within the N-terminal domains CCPs 1-4. This region 
has been demonstrated to be involved in cofactor activity [20], suggesting that these variants 
potentially have an impact on CFH cofactor activity. Two variants, p.Trp379Arg and p.Gln400Lys, 
are located within the CCP6 and CCP7 domains respectively, close to the common p.Tyr402His 
[21] AMD risk variant which is known to cause defective heparin binding properties [20]. This 
raises the possibility that these variants may exert a similar effect. Three variants (p.Gln950His, 
p.Thr956Met and p.Arg1210Cys) are clustered in the C-terminal CCP domains 16-20. Functional 
studies have demonstrated that these four C-terminal CCP domains are necessary for host cell 
recognition or discrimination properties of CFH [22]. In addition, we identified one frameshift 
(p.Ala301Asnfs*25) variant and one splice-acceptor site (428-2A>G) variant, which are both 
predicted to abolish CFH function. 
Notably, not all missense variants identified in this study were predicted to be pathogenic by SIFT 
and PolyPhen. In particular this is the case for the p.Arg1210Cys variant, which was not predicted 
to be deleterious or damaging by either algorithm. However, functional studies demonstrate that the 
p.Arg1210Cys variant compromises CFH function, as the mutant protein exhibits defective binding 
to C3d, C3b, heparin, and endothelial cells, and forms a covalent interaction with human serum 
albumin [10, 23-26]. Therefore it should be noted that although prediction software tools like SIFT 
and PolyPhen may assist in the assessment of potential damaging rare variants, functional validation 
of CFH mutant proteins is needed in order to properly assess the functional consequence of these 
genetic variations. 
The majority of identified variants were not present in public databases, nor have they previously 
been linked to other diseases, demonstrating that many CFH variants are novel and unique for 
individual patients. The number of carriers of rare variants is significantly higher in CD patients 
than the number of carriers in the general population (EVS) (P = 0.008). The carriers of rare CFH 
variants displayed an earlier age at onset than non-carriers (P = 0.016). This underlines the 
importance of sequence analysis of the entire CFH coding region and splice junction of the CFH 
gene to identify the causative allele, in particular in individuals with the CD subtype of AMD. The 
p.Arg1210Cys variant has previously been demonstrated to confer a high risk of developing AMD 
[10], underscoring its pathogenicity. However, two CFH variants were recently identified in a large 
scale sequencing study, and were found not to be associated with the disease: p.Glu950His was 
identified in 9/3,343 AMD patients and 10/1,480 controls (P = 0.98), p.Thr956Met was identified in 
4/3,348 AMD patients and 6/1,484 controls (P = 0.99) [27]. This implies that these alleles may not 
be causative for AMD. Interestingly, four of the identified variants (p.Gln400Lys, p.Gln950His, 
p.Thr956Met and p.Arg1210Cys) were previously reported in patients with atypical haemolytic 
uremic syndrome (aHUS), a devastating renal disease, supporting a previously proposed theory that 
an allelic overlap exists between two distinct pathologies, AMD and aHUS [28-30]. CD patients 
carrying aHUS mutations did not have renal complaints at the time of recruitment (Appendix 3). 
This suggests that additional genetic variants and/or external triggers determine the disease outcome 
in individuals carrying these alleles. 
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In conclusion, the present study identified the presence of rare variants in the CFH gene in 16 
(8.8%) of 180 patients with the CD subtype of AMD. The carriers of rare CFH variants displayed an 
earlier age at onset than non-carriers (P = 0.016). A previously reported rare missense variant, 
p.Arg1210Cys, was identified in two CD cases, but was not detected in 813 non-CD type AMD 
cases and 1175 controls of our Dutch-German cohort. The current study suggests that the 
p.Arg1210Cys variant may be restricted to a subset of AMD patients with CD. Detailed clinical 
phenotyping, including fluorescein angiography, of AMD patients carrying the p.Arg1210Cys 
variant in other cohorts is required to confirm this finding. 
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APPENDICES 
Appendix 1: List of CFH gene sequencing primers 
Primers Sequence (5’- 3’) Product (bp) 
Exon 1F tgtaaaacgacggccagtttgtggcttgtggttgattt 409 
Exon 1R caggaaacagctatgacctcaaaagccactcaattgtca   
Exon 2F tgtaaaacgacggccagtcctgtgactgtctaggcattttt 519 
Exon 2R caggaaacagctatgaccatctcaaaattgcgccactg   
Exon 3F tgtaaaacgacggccagtcttgttcccccactcctaca 462 
Exon 3R caggaaacagctatgacctgttttcccactctcccataa   
Exon 4F tgtaaaacgacggccagttggacactcagaatggcatc 395 
Exon 4R caggaaacagctatgaccagatcaggctgcattcgttt   
Exon 5F tgtaaaacgacggccagtcactcccatagaaaagaatcagg 586 
Exon 5R caggaaacagctatgaccgaacttagctcaattacaggcaga   
Exon 6F tgtaaaacgacggccagtcctgatggaaacaacatttctg 527 
Exon 6R caggaaacagctatgacctgaacttttctggccctgtt   
Exon 7F tgtaaaacgacggccagtaagggattaagagcccagga 585 
Exon 7R caggaaacagctatgacctttcggcaacttcgaaaact   
Exon 8F tgtaaaacgacggccagtgcatcatgtgatccacaagacat 592 
Exon 8R caggaaacagctatgacctggtcactttgcttgaacaact   
Exon 9F tgtaaaacgacggccagttctttttgtgcaaacctttgttag 505 
Exon 9R caggaaacagctatgaccccattggtaaaacaaggtgaca   
Exon 10F tgtaaaacgacggccagtcagggaactcttcttgtttgg 517 
Exon 10R caggaaacagctatgaccgcagtgagtaaatgccctcaa   
Exon 11F tgtaaaacgacggccagtgcttatggttatccaggttttcag 424 
Exon 11R caggaaacagctatgacccagcccccacaaaaagacta   
Exon 12F tgtaaaacgacggccagtttggggcttaagcaatgaaa 591 
Exon 12R caggaaacagctatgaccaaactcccttcttttcccagtt   
Exon 13F tgtaaaacgacggccagttctgatgcccctctgtatga 413 
Exon 13R caggaaacagctatgacctgggagcccaaacaaaatta   
Exon 14F tgtaaaacgacggccagtccattcttgattgtttaggatgc 516 
Exon 14R caggaaacagctatgacccagccatgttcaagttcagg   
Exon 15F tgtaaaacgacggccagttgtgttgatggagagtggaca 482 
Exon 15R caggaaacagctatgaccttgaagactggaaatgttgagg   
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Exon 16F tgtaaaacgacggccagttgatgcaatgtgatcaggaa 491 
Exon 16R caggaaacagctatgacccctgccttattcagtagcatttg   
Exon 17F tgtaaaacgacggccagttctatgagaatacaagccaaaagttc 612 
Exon 17R caggaaacagctatgaccagtggtgattgattaatgtgccta   
Exon 18F tgtaaaacgacggccagtggaggaatatatctttgcgagtt 458 
Exon 18R caggaaacagctatgacccctcactttgataacaagagattat   
Exon 19F tgtaaaacgacggccagtttggtgacagtccgatagaca 535 
Exon 19R caggaaacagctatgaccaatttcccacagcagtccag   
Exon 20F tgtaaaacgacggccagttctcaattgctacggctacca 735 
Exon 20R caggaaacagctatgacctggcccacttcaatcttcat   
Exon 21F tgtaaaacgacggccagttcagtgttctagcgaaggatg 660 
Exon 21R caggaaacagctatgaccccaactctcaatttggtcgaa   
Exon 22F tgtaaaacgacggccagtcagtgctgtgtttgcgttt 435 
Exon 22R caggaaacagctatgacccagaaatatttggtaggcaagc   
Exon 23F tgtaaaacgacggccagtacgcagggatcctaaaatga 838 
Exon 23R caggaaacagctatgaccgctttccattttctgtaaaacagtg   
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APPENDICES 
Appendix 2: Arg1210Cys variant KASPar primers 
      
Variant Allele X Primer Allele Y Primer Common Primer 
Allele 
X 
Allele 
Y 
Arg1210Cys/rs1219130
59 
AAACGKGGATATCGTCTTTCATC
AC 
GTAAACGKGGATATCGTCTTTCAT
CAT 
CCCATCCCAACATGTTGTWCGC
AAT C T 
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APPENDICES 
Appendix 3: Clinical description of CD patients with rare variants in the CFH gene 
Number Gender Age Age at onset Variants Family  VA  Retinal phenotype 
        DNA level Protein level history OD OS   
1 F 48 45 c.7C>G p.Leu3Val NO 0.3+ 0.1+ 
ODS: Confluent large drusen in macula and numerous 
small drusen in posterior pole.  OS: Small geographic 
atrophic lesion 
2 F 57 51 c.428-2A>G NA NO 0.5/60 1.0 
OD: Central fibrotic scar.  OS: Confluent large drusen in 
macula. ODS: Small drusen en punched out lesions in 
peripheral retina 
3 F  48  47 c.481G>T p.Ala161Ser YES 1.0 0.8+  
ODS: Confluent large drusen in macula and some small 
drusen in posterior pole 
4 M 74 69 c.518C>G p.Ala173Gly NO 0.8 0.32- 
ODS: Extensive small and large drusen in macula and 
mid-peripheral retina. OS: Large occult subfoveal CNV 
5 M 77 75 c.524G>A  p.Arg175Gln YES 0.6++ 0.25 
ODS: Extensive hard macular drusen and temporal to the 
macula small areas of chorioretinal atrophy  
6 M 73 No visual loss c.647T>C p.Ile216Thr YES 1.25-- 0.8-- 
ODS: Some small drusen in posterior pole and numerous 
small drusen in peripheral retina 
7 F 56 44 c.901_902del p.Ala301AsnfsX25 YES  NA  NA 
ODS: Innumerable small drusen in posterior pole. OD: 
Hard exudates, fluid pocket and CNV. OS: Juxta foveal 
confluent soft drusen 
8 F 86 81 c.1198C>A p.Gln400Lys NA 0.4+ 2/30 
OD: Pigmentary changes, numerous reticular drusen in 
posterior pole and occult CNV. OS: Central fibrotic scar 
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9 M 44 NA c.1198C>A p.Gln400Lys  NA  NA  NA 
ODS: Extensive soft confluent and small hard drusen in 
posterior pole 
10 F 46 20 c.2850G>C p.Gln950His NA 1.25-- 1.0+ 
ODS: Numerous hard drusen, especially from the border 
of the macula to the vascular arcade; fundoscopic 
changes at the age of 20 years  
11 M 80 73 c.2850G>C p.Gln950His NO 2/60 0.1- 
ODS: Para macular drusen. OD: Large fibrotic scar in 
macula. OS: Macular pigmentary changes, occult CNV 
12 F 77 71 c.2867C>T p.Thr956Met NO 0.8++ 0.6 
ODS: Extensive small drusen in posterior pole and 
peripheral retina 
13 F 55 54 c.1135C>T  p.Trp379Arg YES 0.9 0.5+ 
ODS: Extensive small drusen in posterior pole and mid-
peripheral retina OD: Soft large drusen in macula. OS: 
Classic exudative CNV in macula 
14 F 54 50 c.3628C>T p.Arg1210Cys YES 0.6 0.4 
ODS: Numerous small drusen in posterior pole and some 
drusen in peripheral retina 
15 F 76 64 c.3628C>T p.Arg1210Cys NA 1/60 0.5 
ODS: Innumerable small drusen in posterior pole. OD: 
Large fibrotic scar and hard exudates; OS: Pigmentary 
changes and occult CNV 
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ABSTRACT 
Age-related macular degeneration (AMD) is a progressive retinal disorder affecting over 33 million 
people worldwide. Genome-wide association studies (GWASs) for AMD identified common 
variants at 19 loci accounting for 15-65% of the heritability and it has been hypothesized that the 
missing heritability may be attributed to rare variants with large effect sizes. Common variants in 
the complement component 3 (C3) gene have been associated with AMD and recently a rare C3 
variant (Lys155Gln) was identified which exerts a large effect on AMD susceptibility independent 
of the common variants. To explore whether additional rare variants in the C3 gene are associated 
with AMD, we sequenced all coding exons in 84 unrelated AMD cases. Subsequently, we 
genotyped all identified variants in 1474 AMD cases and 2258 controls. Additionally, because of 
the known genetic overlap between AMD and atypical haemolytic uremic syndrome (aHUS), we 
genotyped two recurrent aHUS-associated C3 mutations in the entire cohort. Overall, we identified 
three rare variants (Lys65Gln (P = 0.04), Arg735Trp (OR = 17.4, 95% CI = 2.2-136; P = 0.0003), 
and Ser1619Arg (OR = 5.2, 95% CI = 1.0-25; P = 0.05) at the C3 locus that are associated with 
AMD in our EUGENDA cohort. However, the Arg735Trp and Ser1619Arg variants were not found 
to be associated with AMD in the Rotterdam Study. The Lys65Gln variant was only identified in 
patients from Nijmegen, the Netherlands, and thus may represent a region-specific AMD risk 
variant. 
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INTRODUCTION 
Age-related macular degeneration (AMD, MIM 603075) is a retinal disorder that causes progressive 
visual impairment in individuals aged over 50 years [1]. AMD primarily affects the macula, the 
central region of the retina, eventually leading to loss of central and sharp vision. It has been 
estimated that more than 33 million people suffer from vision loss due to AMD worldwide [2]. 
AMD is a multifactorial disease caused by a combination of genetic and environmental factors. 
GWASs identified common variants at 19 loci that influence disease susceptibility, accounting for 
15-65% of the heritability [3,4]. 
It has been hypothesized that the remaining genetic fraction influencing the risk for development of 
AMD, the so-called missing heritability, may be explained by rare, highly penetrant variants [4]. 
Simulation studies suggested that common variants are insufficient to account for disease burden in 
densely affected AMD families and that rare penetrant variants would offer a likely explanation [5]. 
In addition, a meta-analysis of AMD GWASs suggested that each of the 19 loci may harbour 
several independent variants associated to AMD susceptibility [3]. The rare variant hypothesis is 
supported by the identification of rare missense mutations in the fibulin-5 (FBLN5) gene and the 
hemicentin-1 (HMCN1) gene in AMD patients [6,7]. In addition, rare, highly penetrant variants in 
the genes encoding complement factor H (CFH), complement factor I (CFI), complement 
component 3 (C3) and complement component 9 (C9) have recently been found to be associated 
with AMD [8-12]. 
Genetic studies have identified an important role for the complement cascade in the pathogenesis of 
AMD [13]. Interestingly, recent studies suggested a genetic overlap between AMD and atypical 
haemolytic uremic syndrome (aHUS), a life-threatening renal disease caused by chronic, 
uncontrolled activation of the complement system. It has been reported that 4-10% of aHUS patients 
carry mutations in the C3 gene [14]. Moreover, disease-causing mutations previously identified in 
aHUS patients, such as Arg1210Cys in CFH, Gly119Arg in CFI and Lys155Gln in C3 were found 
to confer a high risk of developing AMD [8-12]. However, the precise nature of this genetic overlap 
between two clinically distinct phenotypes remains unknown. 
In this study, we explored the role of rare variants in the C3 gene in the pathogenesis of AMD. We 
performed a two-stage analysis to identify rare variants in the C3 gene. First, sequence analysis was 
carried out in a discovery set of 84 AMD cases from the EUGENDA cohort, and subsequently the 
frequencies of these variants were determined in replication sets from EUGENDA and from the 
Rotterdam Study consisting of 1474 AMD cases and 2258 controls. In addition, two recurrent 
aHUS-associated C3 mutations were genotyped in the entire AMD case-control cohort [15,16]. 
 
RESULTS 
To investigate the involvement of rare variants in the C3 gene in AMD, the exons and flanking 
introns of C3 were sequenced in a discovery cohort of 84 AMD cases (Table 1) from the Nijmegen 
area, the Netherlands. Sequencing identified three rare variants (MAF<1%; 
Lys155Gln/rs147859257, Arg735Trp/rs117793540 and Ser1619Arg/rs2230210) and two common 
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variants (MAF≥1%; Arg102Gly/rs2230199 and Pro314Leu/rs1047286) (Table 2). None of the rare 
variants were found in 192 ethnicity-matched and age-matched controls. The Lys155Gln variant, 
which has recently been associated with AMD [10-12], was found in five cases, while variants 
Arg735Trp and Ser1619Arg were found in one case each. Bioinformatic algorithms SIFT and 
PolyPhen predicted the variants Arg102Gly, Lys155Gln, and Pro314Leu not to be damaging 
whereas Arg735Trp and Ser1619Arg were predicted to be damaging to the protein function (Table 
2). 
Next, the frequencies of the rare variants Arg735Trp and Ser1619Arg, as well as the common 
variants Arg102Gly and Pro314Leu were determined, in replication cohorts from EUGENDA and 
from the Rotterdam Study, consisting of 1474 AMD cases and 2258 controls of European ancestry 
(Table 3). In addition, two recurrent aHUS mutations (Lys65Gln and Arg161Trp) were included in 
the analysis (Table 3). The common variants Arg102Gly (OR = 1.2 [95% CI 1.1-1.4]; P = 0.001) 
and Pro314Leu (OR = 1.2 [95% CI 1.0-1.4]; P = 0.005) were significantly associated with AMD. In 
the EUGENDA cohort, the rare variant Arg735Trp was found heterozygously in 8 and 
homozygously in one out of 718 AMD cases and heterozygously in one out of 1246 controls (OR = 
17.4 [95% CI 2.2-136]; P = 0.0003). However, in the Rotterdam Study the rare variant Arg735Trp 
was found heterozygously in 1 out of 785 AMD cases and heterozygously in 2 out of 1048 controls, 
and was thus not associated with the disease. Rare variant Ser1619Arg was found heterozygously in 
six out of 718 AMD cases and heterozygously in two out of 1244 controls in the EUGENDA cohort 
(OR = 5.2 [95% CI .1.0-25]; P = 0.05). In the Rotterdam Study the rare variant Ser1619Arg was 
found heterozygously in 6 out of 835 AMD cases and heterozygously in 11 out of 1279 controls, 
and was thus not associated with AMD. The aHUS mutation Lys65Gln was found heterozygously in 
three out of 717 AMD cases and was not observed in 1246 controls (P = 0.05) in the EUGENDA 
cohort, but was not identified in the Rotterdam Study. Arg161Trp was found heterozygously in two 
out of 644 AMD cases and was not observed in 1142 controls (P = 0.13) in the EUGENDA cohort. 
In the Rotterdam Study the aHUS mutationArg161Trp was observed heterozygously in one out of 
320 AMD cases and heterozygously in one out of 483 controls (P = 1.0), and was not significantly 
associated with AMD in the EUGENDA cohort nor in the Rotterdam Study. 
To determine whether the identified variants conferred disease risk independent of the two known 
common C3 variants (Arg102Gly/rs2230199 and Pro314Leu/rs1047286), a conditional logistic 
regression analysis was performed (Table 4). After conditioning on Arg102Gly/rs2230199, 
Arg735Trp remained associated with disease risk in the EUGENDA cohort (OR = 22.1, 95% CI = 
2.8-173; P = 0.003). Similarly, after conditioning on Pro314Leu/rs1047286, Arg735Trp still showed 
association with disease risk in the EUGENDA cohort (OR = 22.0, 95% CI = 2.8-172; P = 0.003). 
In addition, Arg735Trp was significantly associated with disease risk in the EUGENDA cohort (OR 
= 22.1, 95% CI = 2.8-173; P = 0.003) after conditioning on both variants (Arg102Gly and 
Pro314Leu). Independent association with AMD could not be assessed for Lys65Gln and 
Ser1619Arg because too few data points were available to perform a reliable conditional analysis. 
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Table 1. Demographics of studied subjects 
Variables EUGENDA cohort Rotterdam Study 
  Cases Controls Cases Controls 
Controls (n) 1246 
 
1012 
Intermediate AMD (n) 173 
 
636 
 
Advanced AMD (n) 545 
 
120 
 
Mean age (±SD) 76 ± 8 70 ± 5.9 80 ± 6.4 77 ± 6.5 
Gender 
    
Male 271 532 354 497 
Female 447 714 402 515 
 
EUGENDA: a multicenter database comprising participants from Germany and the Netherlands 
 
Table 2. C3 variants identified by sequence analysis of 84 AMD cases 
SNP ID Sequence variants Genotypes Prediction algorithms 
  Nucleotide change Amino acid change Mm mm SIFT PolyPhen2 
rs2230199 c.304 C>G Arg102Gly 34 11 Tolerated (0.5) Tolerated (0) 
rs1047286 c.941 C>T Pro314Leu 30 10 Tolerated (0.1) Tolerated (0.2) 
rs147859257 c.463 A>C Lys155Gln 5 0 Tolerated (0.2) Benign (0.1) 
rs117793540 c.2203 C>T Arg735Trp 1 0 Deleterious (0) Damaging (1) 
rs2230210 c.4855 A>C Ser1619Arg 1 0 Deleterious (0) Damaging (0.8) 
 
Major and minor allele indicated in capital and lower case respectively; Reference sequence of C3 (NM_000064) gene; 
SIFT: Sorting Intolerant  from Tolerant (Intolerance < 0.05); PolyPhen2: Polymorphism Phenotyping (score 0→1) 
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Table 3. Genotyping of C3 variants in EUGENDA and Rotterdam samples 
SNP ID Amino acid EUGENDA cohort Rotterdam Study Combined cohorts (EUGENDA and Rotterdam) 
  change MAF (%) OR (95% CI) p-value MAF (%) OR (95% CI) p-value MAF (%) OR (95% CI) p-value 
    Controls Cases   (2-sided) Controls Cases   (2-sided) Controls Cases   (2-sided) 
Common variants 
            
Rs2230199 Arg102Gly 20.2 24.4 1.2 (1.1-1.4) 0.001 21.2 24 1.1 (1.0-1.3) 0.04 20.6 24.2 1.2 (1.1-1.3) 0.0002 
Rs1047286 Pro314Leu 19.5 23.5 1.2 (1.0-1.4) 0.005 20.6 23.1 1.1 (0.9-1.3) 0.06 20 23.3 1.2 (1.0-1.3) 0.001 
Rare variants 
            
 
Lys65Gln 0 0.2 ND 0.04 0 0 NA 1 0 0.14 NA 0.05 
 
Arg161Trp 0 0.15 ND 0.13 0.1 0.15 1.5 (0.09-24) 1 0.03 0.15 5.0 (0.5-48) 0.14 
rs117793540 Arg735Trp 0.04 0.69 17.4 (2.2-136) 0.0003 0.09 0.06 0.7 (0.06-8.4) 1 0.06 0.36 6.1 (1.7-21.6) 0.003 
Rs2230210 Ser1619Arg 0.08 0.41 5.2 (1.0-25) 0.05 0.43 0.35 0.8 (0.30-2.2) 0.8 0.25 0.38 1.5 (0.6-3.2) 0.31 
 
Major and minor allele indicated in capital and lower case respectively, MAF: Minor allele frequency, ND: OR could not be determined, NA: Not applicable, EUGENDA: a 
multicenter database comprising participants from Germany and the Netherlands 
 
Table 4. Conditional analysis of Arg735Trp for SNPs Arg102Gly/rs2230199 and Pro314Leu/rs1047286 
Condition EUGENDA cohort Combined cohorts (EUGENDA and Rotterdam) 
  OR (95%CI) p-value OR (95%CI) p-value 
Arg102Gly/rs2230199 22.1 (2.8-173) 0.003 6.2 (1.7-22.5) 0.005 
Pro314Leu/rs1047286 22.0 (2.8-172) 0.003 6.2 (1.7-22.4) 0.005 
Arg102Gly & Pro314Leu 22.1 (2.8-173) 0.003 6.2 (1.7-22.5) 0.005 
 
EUGENDA: a multicenter database comprising participants from the Cologne area, Germany and the Nijmegen area, the Netherlands 
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Table 5. Rare variants in AMD studies 
Gene Variant Study Functional implication Conclusions 
    (Population)     
Present 
study 
 
 
C3 Lys65Gln NL CFH binding ↓ [16] Associated with AMD, not present in other populations, proven functionality, 
reported in aHUS [16] 
 Arg161Trp NL CFH binding ↓, CFB binding 
↑ [15, 16, 18] 
Not associated with AMD, proven functionality, reported in aHUS [15, 16, 18] 
 Arg735Trp NL Normal binding [14] Not associated with AMD, normal functionality, reported in aHUS [14] 
 Ser1619Arg NL NA Not associated with AMD, not proven functionality, not found in aHUS 
Other 
studies 
 
 
C3 Lys155Gln ISL, NL, GER, 
USA [10, 11, 12] 
CFH binding ↓ [18] Associated with AMD, replicated in several populations, proven functionality, 
reported in aHUS [18] 
CFI Gly119Arg NL, USA [9] CFI activity ↓ [9] Associated with AMD, replicated in different populations, proven functionality, 
reported in aHUS [9, 30] 
C9 Pro167Ser FRA, USA [10] NA Associated with AMD, replicated in different populations [10] 
CFH Arg1210Cys USA [8] C3b, heparin and endothelial 
cells binding ↓ [31] 
Associated with AMD, not present in other populations, proven functionality, 
reported in aHUS [31] 
          
NL: The Netherlands, ISL: Iceland, GER: Germany, USA: United States of America, FRA: France, NA: Not applicable 
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DISCUSSION 
In this study, three rare variants (Lys65Gln, Arg735Trp and Ser1619Arg) in the C3 gene were 
shown to be associated with AMD disease risk in our EUGENDA cohort. However, the Arg735Trp 
and Ser1619Arg variants were not found to be associated with AMD in the Rotterdam Study. The 
Arg735Trp and Ser1619Arg variants were also not associated with AMD in a recent study that 
analyzed the C3 gene in 2,493 AMD cases and controls [10]. The Lys65Gln variant was only 
identified in AMD patients from the Nijmegen area, while it was not found in the Rotterdam Study, 
nor in a cohort from Boston [10]. The Lys65Gln variant may therefore represent a region-specific 
AMD risk variant, being confined to the east of the Netherlands, which is confirmed by the 
occurrence of Lys65Gln in Dutch aHUS patients [16]. A fourth variant, Arg161Trp, was found in 
three AMD cases and in one control; therefore it cannot be ruled out that the variant is in fact 
associated with AMD but a larger sample size would be required to detect a significant association. 
The complement system plays an important role in the pathogenesis of AMD [8-12]. The C3 gene 
encodes the complement component 3 protein, a central component of the complement cascade that 
plays a crucial role in clearance of pathogens and immune complexes. All three branches of the 
complement system, the classical pathway, the mannose-binding lectin pathway and the alternative 
pathway, converge at C3. At this stage, activation of C3 results in an amplification loop that 
ultimately forms a cytolytic membrane attack complex which targets pathogens. The system is 
tightly controlled by molecules like CFH and CFI. If the complement cascade is improperly 
regulated, host cells may also be subjected to complement attack, resulting in tissue damage and a 
spectrum of complement-mediated diseases [17]. 
The rare variants reported in this study have previously been described for their association with 
aHUS, a chronic renal disorder caused by uncontrolled activation of the complement system, often 
leading to renal failure. Functional experiments have been performed in this context to determine 
the effect of the amino acid substitutions on C3 function. The Lys65Gln variant resides in the 
macroglobulin (MG1) domain of C3 and was shown to cause decreased binding to CFH [16]. 
Although not significantly associated in our study, the Arg161Trp variant was shown to cause 
hyperactive C3 convertase due to increased binding to factor B (CFB), and reduced binding to CFH 
and membrane cofactor protein (MCP; CD46), resulting in higher complement activity [15, 16, 18]. 
Recombinant protein studies have shown that the Arg735Trp variant performs normal in binding 
and cleavage assays [14]. However, since the Arg735Trp residue is located in the anaphylatoxin 
(C3a) domain of C3, it is not likely to show an effect in the performed assays that evaluated binding 
and activation of the C3b fragment. Recent studies in animal models suggest that C3a anaphylatoxin 
has specific functions in the retina and retinal pigment epithelium, but it remains unknown how an 
amino acid substitution in C3a may contribute to the development of AMD [19, 20]. 
The Lys65Gln variant associated with AMD in this study has previously been associated with 
aHUS, further supporting the genetic overlap between AMD and aHUS. To rule out any renal 
pathology, the medical histories of AMD patients who carried this variant were evaluated, but no 
signs of aHUS or other renal pathologies were reported in these patients. Thus, although aHUS and 
AMD may overlap genetically, in this study no clinical overlap was shown, suggesting that 
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compounding (genetic or environmental) factors contribute to a particular clinical phenotype. Such 
a notion is further supported by a study that showed that some aHUS patients carry multiple 
mutations in the complement factor genes [21]. In order to understand the shared associations, 
cross-phenotype studies are warranted to unravel the mechanisms common and unique to aHUS and 
AMD. This will lead to more rational approaches to diagnosis and therapy by targeting these 
specific molecular targets. 
The identification of rare penetrant AMD-associated variants may have relevance for diagnostic, 
predictive and therapeutic purposes, although the exact interpretation may remain a challenge. 
Recent studies have identified several highly penetrant rare variants (Lys155Gln in C3, Gly119Arg 
in CFI, Pro167Ser in C9 and Arg1210Cys in CFH), to be associated with AMD [8-12]. However, 
not all associations hold true among different populations. An example of this is the Arg1210Cys 
variant in CFH which was strongly associated in a North American AMD cohort [8] but not in an 
Icelandic AMD cohort [11] (Table 5). Genetic drift, founder effects or differences in genetic make-
up that could compensate for a rare disruptive variant may underlie this phenomenon. In addition, 
the possibility that environmental effects could mask or enhance the penetrance of certain alleles 
between populations may also exist. To date, it remains unclear how these observations impact the 
predictive value of finding such variants in individuals. In contrast, variants that were proven to be 
functionally impaired and that are associated with AMD in several populations, such as the 
Lys155Gln variant in C3, have a much stronger predictive value. 
In conclusion, we report a rare variant (Lys65Gln) at the C3 locus in patients with AMD, while an 
association with two other variants (Arg735Trp and Ser1619Arg) was not confirmed in other 
cohorts. This study further supports that rare variants contribute to the genetic variance of AMD, 
which may have implications for predictive testing and personalized medicine in AMD [10]. 
 
MATERIALS AND METHODS 
Cases and controls 
Cases and controls included in this study were selected from the population-based Rotterdam Study, 
Rotterdam, the Netherlands and from the European Genetic Database (EUGENDA), a multicenter 
database comprising participants from the Cologne area, Germany and the Nijmegen area, the 
Netherlands. All participants of this study underwent extensive retinal imaging which has been 
described in detail elsewhere [22, 23]. In short, AMD staging was performed by grading of stereo 
fundus photographs according to the standard protocol of the Rotterdam grading center and Cologne 
Image Reading Center (CIRCL). All subjects were classified on the basis of the eye with the more 
severe diagnosis. Cases were aged ≥50 years of age and AMD was classified by the presence of at 
least 15 intermediate (63-124μm) or at least one large drusen (≥125μm) or geographic atrophy or 
choroidal neovascularisation secondary to AMD. Control subjects were aged ≥65 years of age and 
did not have AMD (none or only small, hard drusen or only pigmentary abnormalities or less than 
10 small drusen and pigmentary abnormalities). Written informed consent was obtained from all 
participants. The EUGENDA study was approved by the local research ethics committee, 
Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen, the Netherlands, and Ethics 
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Committee of the University Hospital Cologne, Germany. The Rotterdam study was approved by 
the institutional review board (Medical Ethics Committee) of the Erasmus Medical Center and by 
the review board of The Netherlands Ministry of Health, Welfare and Sports. The study was 
performed in accordance with the tenets of the Declaration of Helsinki. 
 
Sequencing 
Sanger sequencing of the C3 (NM_000064) gene was performed in the discovery set, consisting of 
84 AMD patients selected from the EUGENDA database. Primers were designed for all 41 coding 
exons and intron-exon boundaries by Primer3 software (Supplementary Material, Table S1). 
Polymerase chain reaction (PCR) was performed, and PCR amplicons were sequenced using an 
automated sequencer (BigDye Terminator, version 3, 3730 DNA analyzer; Applied Biosystems). 
Sequences were assembled and analysed using ContigExpress (Vector NTI Advance, Version 11.0, 
Life Technologies). Each newly identified variant was confirmed by a second independent PCR and 
bidirectional Sanger sequencing. The predicted effects of identified missense variants were 
examined using Polymorphism Phenotyping (PolyPhen) [24] and Sorting Intolerant from Tolerant 
(SIFT) [25]. 
 
Genotyping in the EUGENDA cohort 
Variants (Lys65Gln, Arg102Gly, Arg161Trp, Pro314Leu, and Arg735Trp) were genotyped in the 
EUGENDA cohort using competitive allele-specific PCR assays (KASPar SNP Genotyping System, 
KBiosciences). KASPar genotyping was performed according to the manufacturer’s protocol in a 
volume of 4µl containing 10ng of genomic DNA, 2.5µl of 2X reaction mix, and 0.069µl of assay. 
Thermal cycling conditions included a pre-incubation step at 94⁰C for 15min, 20 cycles of 94⁰C for 
10s, 57⁰C for 5s, 72⁰C for 10s, followed by 23 cycles of 94⁰C for 10s, 57⁰C for 20s, 72⁰C for 40s. 
Plates were analyzed on a 7900 Fast Real-Time PCR system (Applied Biosystems). The 
Ser1619Arg variant was genotyped in the EUGENDA cohort by Amplification Refractory Mutation 
System (ARMS) [26] PCR (Supplementary Material, Table S2). PCR reactions were performed in a 
volume of 12.5µl using 20ng genomic DNA, 1x buffer, 2.5mM MgCl 2, 1mM deoxyribonucleotide 
triphosphates, 0.2µM of each primer, and 0.5U Taq DNA polymerase (Invitrogen, Life 
technologies). Thermal cycle conditions included a pre-incubation step at 95⁰C for 5min, 16 cycles 
of 95⁰C for 30s, 69⁰C for 30s, 72⁰C for 45s, followed by 25 cycles of 95⁰C for 30s, 67⁰C for 30s, 
72⁰C for 45s. PCR amplicons were analysed by agarose gel electrophoresis. Each newly identified 
variant was confirmed by a second independent PCR and bidirectional Sanger sequencing. 
 
Exome sequencing, exome chip analysis and genotyping in the Rotterdam Study 
The occurrence of the C3 variants Lys65Gln, Arg161Trp, Arg735Trp, and Ser1619Arg in the 
Rotterdam Study (RS) was retrieved from exome chip and exome sequencing data. For exome 
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sequencing purposes, genomic DNA of RS participants was prepared from blood and fragmented 
into 200-400bp fragments using Covaris Adaptive Focused Acoustics (AFA) shearing according to 
the manufacturer’s instructions (Covaris, Inc., Woburn, MA). Illumina TruSeq DNA Library 
preparation (Illumina, Inc., San Diego, CA) was performed on a CaliperSciclone NGS workstation 
(Caliper Life Sciences, Hopkinton, MA), followed by exome capture using the NimblegenSeqCap 
EZ V2 kit (Roche Nimblegen, Inc., Madison, WI). This capture targets 44Mb of exonic regions 
covering 30,246 coding genes, 329,028 exons and 710 miRNAs. Paired-end 2 x100 sequencing was 
performed on Illumina HiSeq2000 sequencer using Illumina TruSeq V3 chemistry. Downstream 
analyses included demultiplexing (CASAVA software, Illumina), alignment using the burrows-
wheeler alignment tool, followed by data processing and filtering with Picard, SAMtools and the 
Genome Analysis Tool-Kit [27,28]. Finally, variant detection was performed using GATK’s Unified 
Genotyper. For exome chip analysis, DNA samples of the Rotterdam study were included in the 
joint calling experiment of the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium [29]. In short, DNA from the study participants was processed on the 
HumanExome BeadChip v1.0 (Illumina, Inc, San Diego, CA) querying 247,870 variable sites using 
standard protocols at seven genotyping centers. Each center genotyped a common set of 96 HapMap 
samples to be utilized for quality control and determination of batch effects. Raw datafiles for all 
samples were transferred to a central location and assembled into a single joint calling (Illumina 
GenomeStudio v2011.1 software and GenTrain 2.0 clustering algorithm). Call rates >99% were 
used for both study samples as for HapMap controls to define genotype clusters. Finally 8994 
variants were excluded for further analyses. Common variants (Arg102Gly and Pro314Leu) were 
genotyped in the RS cohort using Taqman assays (Applied Biosystems, Foster city, California, 
USA). 
 
Statistical analysis 
A Fisher’s exact test was performed to assess the association between each variant and AMD, and 
also to check for Hardy-Weinberg equilibrium. P-values were calculated two-sided, and values of 
<0.05 were considered as statistically significant. Logistic regression analysis was performed to 
check for genotype interactions, to estimate the odds ratios (OR) with 95% confidence intervals (CI) 
and to adjust for age. Conditional analysis was performed to identify secondary association signals 
at the C3 locus by accounting for two known AMD SNPs. Either Arg102Gly/rs2230199 or 
Pro314Leu/rs1047286 was added independently and combined to the regression model as a 
covariate to test the effect of the variant of interest. Data were analyzed using SPSS software, 
version 18.0. 
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SUPPLEMENTARY MATERIAL 
Table S1, List of C3 gene sequencing primers 
Primers Sequence (5’- 3’) Product (bp) 
Exon 1F TGCTCACTCCTCCCCATC 199 
Exon 1R AAATGTCTGCTTCCACCCC 
 
Exon 2F GGCGTCTCACATCCGTG 333 
Exon 2R GAAGACAGAAGGGGAGGGG 
 
Exon 3F AGATCCGGAAGCTGGACC 444 
Exon 3R TTGCCTCTCCTAAGCCTGTG 
 
Exon 4F AGCGGGTACCTCTTCATCC 300 
Exon 4R CCTTCCGGTGTGTCTTTCTC 
 
Exon 5-6F TAGACACTGTGCACAGAGAAT 516 
Exon 5-6R TTTCTCTGTAGGCTCCACTAT 
 
Exon 7F AAGATCCGAGCCTACTATGAA 311 
Exon 7R GTCCCCCACCTGGTCTTCACC 
 
Exon 8-9F GGAGATCCCATTCTCCAGG 455 
Exon 8-9R TTTCTCTTCTGACCTGGTCTCC 
 
Exon 10-11F GGAGGTCTAATCCTGAGGGG 500 
Exon 10-11R GACCCCACTGTGCAAACAC 
 
Exon 12F CAGGTCTCAGGGATTCGG 349 
Exon 12R GAAGGAGTCCCAGGGGTG 
 
Exon 13F GAGGCCAAGATCCGCTACTAC 546 
Exon 13R GACAGTTGAGAGACAGAGAGGG 
 
Exon 14F AACCTTTCTGTCTTTCCACTC 422 
Exon 14R CATTCCCATCTTCAGCTTCAA 
 
Exon 15-16F CACAGGTGCATATGTGGGG 629 
Exon 15-16R TCCCCTCCTCCCTCTCTG 
 
Exon 17F GGGGAAGTCCTCCCTGG 360 
Exon 17R TCCCTCCTCAGACAGGAGTC 
 
Exon 18-19F TTTCACCATGTTAGCTAGGCT 662 
Exon 18-19R AATGAGATGACACTCAGACAC 
 
Exon 20-21F CTAAGAGCTGAGACCCAGGAG 585 
Exon 20-21R GAAGACCAGGAGCCCTCTC 
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Table S1, List of C3 gene sequencing primers 
Primers Sequence (5’- 3’) Product (bp) 
Exon 22-23F TGCTGACCATCTGTGTGTCTG 421 
Exon 22-23R AATGAGATGGAATTTGGCTCC   
Exon 24F AACCCTTTTCACGCCACC 343 
Exon 24R GGATCTTAGGGGAGGGATGC   
Exon 25F TGAGTCCTTCCCTTTTTAAGG 406 
Exon 25R TCCGTGCTTAAGGATGCTTAA   
Exon 26F GGTTGACATGGCAGTCTCTG 290 
Exon 26R CTCTCGTGTTCATCCTGCG   
Exon 27F GATGACTGCCATGTGTGGAC 241 
Exon 27R CTGTGCTCTGCATCGGG   
Exon 28F AAGTGCTGCTCGAATGATCC 297 
Exon 28R CAGTATCTCCCGCCCTGAAC   
Exon 29F CTCTTTCTGAGCTTTCTCTGA 386 
Exon 29R AACTGATTCTCAACTCCACTG   
Exon 30-31F GATTCTAGCCACTTTCCCAGG 495 
Exon 30-31R AGAGGAGATGGTCCCTCTGG   
Exon 32-33F GACCATCTCCTCTTGTCCCC 432 
Exon 32-33R ACTTGGAAAGTACTGAATATCATGG   
Exon 34-35F TCCTTGTCCAGGAACAGACC 424 
Exon 34-35R CCAGCCAGATAGAGGTCAGG   
Exon 36F CAAGACAATGCTGGACTCCC 244 
Exon 36R CCCCACAATTCATATATACCTGG   
Exon 37-38F TCTTTGGAGGGAGGCCC 504 
Exon 37-38R TGACAACCACACCTACCACC   
Exon 39-40F TGCCCCTCATGGTCAAC 428 
Exon 39-40R ACAATGGTGTGGGCGTG   
Exon 41F CCACACCATTGTCACGCC 280 
Exon 41R GGCAAAGAACTCCAGACACG   
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SUPPLEMENTARY MATERIAL 
Table S2, Genotyping probes: List of Amplification Refractory Mutation System (ARMS) and KASPar primers 
Ser1619Arg variant, Amplification Refractory Mutation System (ARMS) primer list 
Primers Sequence (5’- 3’) Product (bp) 
Wild type-Forward CCTGACCTGCCATTCTTCCCTCCAGCCTTA 298 
Mutant type-Forward CCTGACCTGCCATTCTTCCCTCCAGCCTTC   
Reverse GGTTTCAAGTAGGATGGAGCTGAGCTGCAGGTG  
 
KASPar primers 
    
Variants Allele X Primer Allele Y Primer Common Primer Allele X Allele Y 
Lys65Gln GTCCACGACTTCCCAGGCA GTCCACGACTTCCCAGGCC GTCTTCTCACTGGACAGCACTAGTT A C 
Arg102Gly/ 
rs2230199 CACGGTCACGAACTTGTTGCC CACGGTCACGAACTTGTTGCG GCCAACAGGGAGTTCAAGTCAGAAA C G 
Arg161Trp CAATGTTGACCATGACCGTCCG CAATGTTGACCATGACCGTCCA TTCACCGTCAACCACAAGCTGCTA C T 
Pro314Leu/ 
rs1047286 CCACCAGGTCTTCTGCTCGGA CACCAGGTCTTCTGCTCGGG TACTGCTGGACGGGGTGCAGAA A G 
Arg735Trp/ 
rs117793540 GCAACTACATCACAGAGCTGC CTGCAACTACATCACAGAGCTGT TGGCCAGGCCCAGGTGGCT C T 
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Chapter 4 
A Rare Nonsynonymous Sequence Variant in C3Confers High Risk of Age-related Macular 
Degeneration 
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ABSTRACT 
Through whole genome sequencing of 2,230 Icelanders followed by imputations we identified an 
association between a rare nonsynonymous single nucleotide polymorphism (SNP) (minor allele 
frequency = 0.55%) K155Q in the C3 gene, encoding complement factor 3, and age-related macular 
degeneration (AMD) (OR = 3.45, P = 1.1 × 10-7). This signal is independent from the previously 
reported common SNPs P314L and R102G in C3 that associate with AMD. The association of 
K155Q was replicated in European ancestry AMD case control samples with an OR = 4.22 and P = 
1.6 × 10-10, resulting in an OR of 3.65 and P-value of 8.8 × 10-16 for all studies combined. The 
K155Q mutation reduces C3b binding to factor H in vitro, potentially creating resistance to 
inhibition by complement factor H. This in turn is predicted to result in enhanced complement 
activation. 
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Age-related Macular Degeneration (AMD) is the major cause of blindness in the elderly in the 
Western part of the world1. Previous genome-wide association studies (GWAS) of AMD have 
yielded common variants at twelve loci (Supplementary Table 1 and see GWAS catalog in URLs2). 
Two of these encode components of the complement pathway, CFH on chromosome 1 and C2/CFB 
on chromosome 6,have been reported to harbor more than one independent common association 
signal3. Recently, a very rare nonsynonymous mutation, R1210C in CFH, was identified and 
reported to confer high risk of AMD4. 
 
To search for additional rare and low frequency variants that affect the risk of AMD within the 
previously reported loci, we performed conditional analysis at these loci using SNP and INDEL data 
garnered through whole-genome sequencing (WGS) of 2,230 Icelanders to an average sequencing 
depth of at least 10X. Using imputation assisted by long-range phased haplotypes5,6 the genotype 
probabilities of all the sequence variants were determined for 95,085 Icelanders genotyped with 
Illumina SNP chips (Supplementary Information). Assuming a multiplicative model within and 
between variants, we applied logistic regression using 1,143 Icelanders diagnosed with AMD 
(neovascular, geographic atrophy, or soft drusen) and 51,435 Icelandic controls with WGS genotype 
information (Supplementary Table 2, Supplementary Information).  
 
Of the twelve established AMD loci, the strongest signal at six of them reached the significance 
level of P = 1 x 10-5 in our data, that we set as a threshold for applying the conditional analysis. 
These six loci were APOE, ARMS2/HTRA1, C2/CFB, CFH, C3, and TIMP3. The regression analysis 
was performed in a 500kb window centered on the best signal at each of these six loci. After 
conditioning, we searched for independent signals that were significant taking into account the 
number of markers tested at each locus (Bonferroni correction, P< 0.05/M, M being the number of 
variants tested in the locus; see Supplementary Table 1). At five of the six loci, APOE, 
ARMS2/HTRA1, C2/CFB, CFH, and TIMP3, the strongest signals in our data were highly correlated 
with variants from the recently reported meta-analysis7 (Supplementary Tables 3). We only found 
additional independent signals at one locus, the CFH locus, where we detected the two previously 
reported common signals8, represented by rs1061170 (Y402H) and rs10737680. However, the rare 
variant R1210C in CFH4 is not present in our WGS data or in the Icelandic AMD cases control set 
as evaluated by direct genotyping. At four of the five loci, the strongest signal is highly correlated 
with nonsynonymous variants in nearby genes suggesting that high fraction of AMD risk variants 
are coding (Supplementary Table 3). 
 
At the sixth locus, C3, we identified two equivalence classes of correlated variants at very similar 
significance levels (P = 4.1 × 10-7 and P = 4.5 × 10-7) that represent the top signals (Figure 1). The 
two classes are of very different allelic frequencies, 0.55% and 24%. The 24% class corresponds to 
the previously reported signal at the C3 locus9. We decided to condition on the best variant in the 
24% equivalence class (Supplementary Table 1), rs2230203-T (P = 4.5 × 10-7), that is strongly 
correlated with the reported nonsynonymous coding SNPs P314L (r2 = 0.91) and R102G (r2 = 0.79) 
(Supplementary Table 4) that are themselves highly correlated with each other (r2 = 0.86). Three 
highly correlated (r2> 0.98 for all pairs) rare variants, corresponding to the equivalence class of 
0.55% allelic frequency, remain significant at the C3 locus after conditioning on rs2230203. Of 
these three variants, one is a nonsynonymous coding variant in C3 (K155Q; rs14785925), another is 
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an intergenic variant (rs18129025), and the last is an intronic variant (chr19:6649204 Build 36). Out 
of these three equivalent rare variants we focused on K155Q, given that it is the one most likely to 
affect the biology. The K155Q variant associates with AMD in Iceland with an odds ratio (OR) of 
3.13 (95% CI 1.99-4.91), and P = 7.1 × 10-7 and OR of 3.44 and P = 1.2 × 10-7 when conditioning on 
P314L (Table1). When conditioning on either rs2230203 or R102G, similar results were obtained 
(Supplementary Table 5) which is to be expected given their strong correlation to P314L.  
 
The risk allele of the rare variant K155Q, in the Icelandic data, is never observed on the same 
chromosome background as any of the risk alleles of the correlated common SNPs (rs2230203, 
P314L, or R102G; D' = 1 and r2< 0.002 between K155Q and all three SNPs, Supplementary Table 
6). This means that K155Q is independent of both R102G and P314L. The effects and significance 
levels of the three rare variants (K155Q/rs147859257, rs181290250, and chr19:6649204) improved 
after conditioning on the common variants (Table 1, Supplementary Table 7). Similarly, the effect 
and significance levels of the common variants P314L/R102G improved when conditioning on the 
rare K155Q (Table 1 shows results for P314L). Apart from P314L, R102G, and K155Q, all the 
nonsynonymous variants in C3 seen in the Icelandic sequencing data have a minor allele frequency 
(MAF) below 0.25% and the same applies to the NHLBI GO Exome Sequencing Project (see 
URLs) (Supplementary Table 8). No variant at the C3 locus remained significant after 
conditioning on both signals P314L and K155Q (all 8,791 variants at the locus have conditional P > 
0.0002). We validated the imputation of K155Q by directly genotyping 1,107 AMD cases and 2,869 
population controls. The r2 between the imputed and directly typed genotypes was 0.96 and the case 
control association results based on direct genotyping gave similar results as the analysis using the 
imputed data (OR = 4.33, P = 4.7 × 10-8 when conditioning on P314L, Supplementary Table 9) 
 
Based on data from the NHLBI GO Exome Sequencing Project (see URLs) the K155Q mutation is 
estimated to have an allelic frequency of 0.43% (37 out 8,600 chromosomes) in individuals of 
European ancestry (Supplementary Table 8)10. The K155Q variant thus has substantially higher 
frequency in populations of European ancestry than the previously reported rare mutation R1210C 
in the CFH gene (allelic frequency = 0.04%)4. The presence of K155Q in other European 
populations allowed us to investigate whether K155Q affected the risk of AMD outside of Iceland. 
For that purpose we genotyped K155Q and P314L in 1,170 AMD cases and 1,125 controls without 
AMD from San Diego (United States (US)) and in 355 AMD cases and 163 controls without AMD 
from Utah (US). We also genotyped K155Q in 1,329 AMD cases and 679 controls without AMD 
and 1,010 population controls from Nijmegen (The Netherlands) and Cologne (Germany) (the 
EUGENDA study) (Supplementary Table 2). 
 
The association of K155Q with AMD was replicated in the US samples (OR = 5.25 (95% CI 2.68-
10.30), P = 1.4 × 10-6) (Table 1, Supplementary Table 10). Adjusting K155Q for P314L gave a 
slightly stronger association (OR = 5.75, P = 3.0 × 10-7). Similar association with K155Q was also 
seen in the EUGENDA study samples (OR = 3.58 (95% CI 2.00-6.41), P = 1.8 × 10-5). For the 
replication samples the combined OR was 4.22 (95% CI 2.71-6.56) with P-value of 1.6 × 10-10, and 
for the combined discovery and replication samples the OR was 3.65 (95% CI 2.66-5.00) with P-
value of 8.8 × 10-16 (Table 1). 
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Further independent validation of the K155Q association came through in silico replication in 
targeted sequencing data from the MMAP (Michigan, Mayo, AREDS, and Pennsylvania) and the 
NEI(National Eye Institute) AMD case (N = 2,268) and control samples (N = 2,268, of these control 
samples 1,479 were drawn from the NHLBI Exome sequencing project). In this dataset the OR was 
2.91 with P = 2.8 × 10-5 (manuscript concurrently submitted to Nature Genetics by G. Abecasis, A. 
Swaroop, E. Mardis and colleagues11).  
 
We performed sub-phenotype analysis of the discovery and replication samples for the available 
sub-phenotypes within each study group (Supplementary Table 11). For the Icelandic and the US 
samples we had information on geographic atrophy (GA) and neovascular (NV) subtypes. In a 
combined analysis of the US and the Icelandic data the frequency of the K155Q mutation was 
significantly higher in cases with GA than in those with NV (P = 0.0047) (Supplementary Table 
11). For the Icelandic data we had information on advanced AMD and soft drusen only; no 
difference in frequency of the K155Q mutation was observed between these two groups (P = 1.0) 
(Supplementary Table 11).There was no difference in the allelic frequencies of K155Q between 
male and female cases in the Icelandic data based on direct genotyping (P = 0.29, MAF for male 
cases 1.17%, MAF for female cases 1.80%). 
 
The K155Q mutation is located in the 4th exon of the C3 gene (transcript NM_000064). The C3 
protein is central in the complement pathway and interacts with the complement factor H that 
negatively regulates the alternative complement pathway, by blocking the formation of C3 
convertase. C3 is cleaved proteolytically into C3a and C3b and these two fragments participate in 
the most important functions of the complement system. C3a is a mediator of inflammation and C3b 
is a major opsonin. By binding complement factor B, C3b also forms a C3 convertase that initiates 
the amplification of the alternative pathway. The mutation K155Q is at position 133 of C3b and 
falls into its macroglobulin (MG2) domain. The common SNPs R102G and P314L previously 
reported to associate with AMD are also located in C3b (Supplementary Table 12). 
Crystallographic studies have shown that the MG2 domain of the C3b protein is important for 
interaction with the factor H protein and this interaction is essential for regulation of the 
complement pathway by decay acceleration of the C3 convertase (C3bBb)12. Recently it was shown 
that the presence of the K155Qvariant in the C3b protein causes reduced binding to factor H which 
in turn can lead to a gain of function of the C3 convertase activity through resistance to decay13. The 
rare mutation R1210C recently described in CFH that associates with AMD also results in defective 
binding to C3b thus potentially acting through similar mechanism as the K155Q mutation4. 
 
We conclude that the association of the rare high risk K155Q mutation in C3 with AMD is 
independent of the association of the previously reported common SNPs R102G and P314L and that 
the effect of this rare mutation could be mediated through enhanced complement activation by 
reduced binding of C3b to complement factor H. 
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Figure 1.Overview of the association in the C3 gene region. Black circles show -log10P as a function of build 36 coordinates for unconditional 
association with age-related macular degeneration in the Icelandic sample set for imputed SNPs. Red crosses show results conditional on the 
common variant rs2230203. Genes are shown in blue and recombination rates are reported in cM/Mb. Left plot: Horizontal dotted line corresponds 
to the threshold P = 1 × 10-5 used for choosing variants to condition on. Right plot (zoom in on C3): The vertical broken lines correspond to the 
location of P314L (left) and R102G (right) in C3; the solid red line corresponds to the location of K155Q; horizontal dotted line corresponds to 
threshold P = 5.7 × 10-6 for significance based on the number of SNPs tested at this locus. The common variants rs2230203, P314L, and R102G are 
highly correlated (r2 > 0.78 for all pairs). 
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Table 1: Association between AMD and the C3 variants P314L and K155Q 
     unconditional  condition on P314L  condition on K155Q 
Variant name Amino acid 
substitution A1 A2 
Control 
Freq. A1 
OR A1  
(95% CI) P-value  OR A1 P-value  OR A1 P-value 
Iceland (N AMD cases = 1,143; N population controls = 51,435) 
rs1047286 P314L A G 24.5%  1.31 (1.18, 1,46) 7.6 × 10-7  – –  1.34 1.0 × 10-7 
rs147859257 K155Q G T 0.55%  3.13 (1.99, 4.91) 7.1 × 10-7  3.45 1.1 × 10-7  – – 
 
US (N AMD cases = 1,525; N controls =1,288) 
rs1047286 P314L A G 17.5%  1.52 (1.34, 1.73) 2.4 × 10-10  – –  1.55 5.3× 10-11 
rs147859257 K155Q G T 0.27%  5.25 (2.68, 10.30) 1.4 × 10-6  5.75 3.0 × 10-7  – – 
EUGENDA (N AMD cases = 1,329; N controls 1,689)* 
rs147859257 K155Q G T 0.41%  3.58 (2.00, 6.41) 1.8 × 10-5  – –  – – 
Combined replication - US and EUGENDA (N AMD cases = 2,854; N controls = 2,977) 
rs147859257 K155Q G T –  4.22 (2.71, 6.56) 1.6 × 10-10  – –  – – 
 
Combined Iceland, US, and EUGENDA (N AMD cases = 3,997; N controls = 54,412)** 
rs147859257 K155Q G T –  3.65 (2.66, 5.00) 8.8 × 10-16  – –  – – 
 
P314L is in the previously reported 24% equivalence class (which includes R102G). 
*The EUGENDA samples are individuals from the Netherlands and Germany; the controls consist of 679 eye-examined controls and 1,010 population controls. 
** No significant heterogeneity in the odds ratio estimates was observed between study groups (P het = 0.46, I2=0). 
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URLs. 
Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. URL: 
http://evs.gs.washington.edu/EVS/. Accessed November 2012. 
 
GWAS catalog, Hindorff, L. A. et al. A catalog of published genome-wide association studies. 
Available at: www.genome.gov/gwastudies. Accessed November 22nd, 2012. 
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SUPPLEMENTARY INFORMATION 
 
Study populations 
Iceland: 
The cases consist of 1,143 Icelandic AMD patients. These include 719 neovascular AMD, 318 
geographic atrophy, and 535 with early AMD with soft drusen. Some individuals had more than one 
diagnosis. The total number of advanced AMD patients (neovascular or geographic atrophy) was 
923. Considering patients with one diagnosis only, there were 458 neovascular AMD, 108 
geographic atrophy, and 220 with early AMD with soft drusen. AMD patients were diagnosed at the 
University Eye Clinic, Reykjavik, or listed in the Icelandic Registry for the Blind during the years 
1980–2001. 35% of the patients are males. All patients have been chip-typed. The controls consist 
of 51,435 Icelanders recruited through different genetic research projects at deCODE. The controls 
have been diagnosed with common diseases of the cardio-vascular system, psychiatric and 
neurological diseases, endocrine and autoimmune system, neoplasia, as well as individuals 
randomly selected from the Icelandic genealogical database. The controls were all chip-typed and 
sex-matched to the cases. The study was approved by the Data Protection Authority of Iceland and 
the National Bioethics Committee of Iceland, All participants signed written informed consent prior 
to participation in the study. All personal identifiers associated with blood samples, medical 
information, and genealogy were encrypted. Encryption was carried out by the Data Protection 
Authority, using a third-party encryption system. 
 
Utah, US:  
The cases consist of 355 patients from Utah, USA. These include 155 neovascular AMD, 82 
geographic atrophy, and 122 early AMD with soft drusen. The total number of advanced AMD 
patients was 237 and 118 individuals were only diagnosed with soft drusen. These AMD patients 
were recruited in Utah at the Moran Eye Center of the University of Utah. The controls consist of 
163 individuals from Utah. They were age-matched with the cases and had normal eye examinations 
(individuals aged 60 years or older, with no drusen or retinal pigment epithelium changes). The 
study was approved by the Institutional Review Board of the University of Utah. All personal 
identifiers associated with samples were encrypted 
 
San Diego, US: 
The cases consist of 1,170 advanced AMD patients from San Diego, USA. These include 823 
neovascular AMD, 347 geographic atrophy.  These AMD patients were recruited at University of 
California San Diego. The controls consist of 1,125 individuals from San Diego. They do not have 
any signs of drusen, pigmentary changes, GA or CNV on examinations. The study was approved by 
the Institutional Review Board of the University of California San Diego.   
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Nijmegen, The Netherlands and Cologne, Germany (EUGENDA study): 
The cases consist of 1,329 AMD patients (≥50 years of age) from the Nijmegen, the Netherlands 
and Cologne, Germany area. The cases had early or advanced AMD according to the Rotterdam 
classification. 750 patients were diagnosed with neovascular AMD. The controls consist of (i) 1,010 
population controls from the Nijmegen area who we directly genotyped and have been used 
previously in a study of bladder1 cancer and (ii) 679 control subjects without AMD (≥60 years of 
age) from the Nijmegen and Cologne area. The control subjects in (ii) did not have AMD (no or 
only small hard drusen) in either eye and exhibited no other macular pathology. The study was 
approved by the Institutional Review Boards of the Radboud University Nijmegen Medical Centre 
and the University of Cologne. 
All cases in Iceland, all cases and controls in Utah and San Diego, and all cases and 679 controls 
from the EUGENDA study went through a standard examination protocol and visual-acuity 
measurements. Slit lamp biomicroscopy of the fundi using 90-diopter lenses was performed. A pair 
of stereoscopic color fundus photographs (50°) were taken, centered on the fovea using a Topcon 
fundus camera (Topcon TRV-50VT, Topcon Optical Company, Tokyo, Japan) by a trained 
ophthalmic photographer. Grading was carried out using a standard grid classification suggested by 
the International Age-Related Maculopathy Epidemiological Study Group for age-related 
maculopathy and AMD2 in Iceland and Utah and the Rotterdam classification3 in the Netherlands. 
All abnormalities in the macula were recorded, including type, size, and number of drusen as well as 
the presence of hyperpigmentation and hypopigmentation, together with advanced AMD. 
 
Genotyping 
Illumina SNP Chip Genotyping: 
The Icelandic chip-typed samples were assayed with the Illumina HumanHap300, HumanCNV370, 
HumanHap610, HumanHap1M, HumanHap660, Omni-1, Omni 2.5 or Omni Express bead chips at 
deCODE genetics. SNPs were excluded if they had (i) yield less than 95%, (ii) minor allele 
frequency less than 1% in the population or (iii) significant deviation from Hardy-Weinberg 
equilibrium in the controls (P < 0.001), (iv) if they produced an excessive inheritance error rate 
(over 0.001), (v) if there was substantial difference in allele frequency between chip types (from just 
a single chip if that resolved all differences, but from all chips otherwise). All samples with a call 
rate below 97% were excluded from the analysis. For the HumanHap series of chips, 304,937 SNPs 
were used for long range phasing, whereas for the Omni series of chips 564,196 SNPs were 
included. The final set of SNPs used for long-range phasing was composed of 707,525 SNPs. 
 
Single track SNP assay genotyping: 
Single SNP genotyping applying the Centaurus (Nanogen) single track genotyping assay4 was done 
to verify the accuracy of the imputation of the C3 K155Q mutation in the Icelandic samples, to 
genotype the K155Q mutation in the Utah case control samples and to genotype the population 
controls from Nijmegen used with the EUGENDA samples. For the samples of the EUGENDA 
study the K155Q mutation was genotyped using a custom-made single track KASPar assay 
84 
 
(KBiosciences). Samples identified as carriers by this assay were confirmed by independent PCR 
and sequencing. For the AMD case and control samples from San Diego the K155Q and P314L in 
C3 were genotyped using single-nucleotide primer extension assay (ABI Prism SNaPShot Multiplex 
Kit, Applied Biosystems) on an ABI 3130xl genetic analyzer5. 
 
Whole Genome Sequencing and SNP calling: 
Whole genome sequence was done for 2,230 Icelanders, selected for various conditions. All of the 
individuals were sequenced at a depth of at least 10X. 
 
Sample preparation:  
Paired-end libraries for sequencing were prepared according to the manufacturer's instructions 
(Illumina, TruSeq™). In short, approximately 1μg of genomic DNA, isolated from frozen blood 
samples, was fragmented to a mean target size of 300 bp using a Covaris E210 instrument. The 
resulting fragmented DNA was end repaired using T4 and Klenow polymerases and T4 
polynucleotide kinase with 10 mM dNTP followed by addition of an 'A' base at the ends using 
Klenowexo fragment (3′ to 5′-exo minus) and dATP (1 mM). Sequencing adaptors containing 'T' 
overhangs were ligated to the DNA products followed by agarose (2%) gel electrophoresis. 
Fragments of about 400-500 bp were isolated from the gels (QIAGEN Gel Extraction Kit), and the 
adaptor-modified DNA fragments were PCR enriched for ten cycles using Phusion DNA 
polymerase (Finnzymes Oy) and a PCR primer cocktail (Illumina). Enriched libraries were further 
purified using AMPure XP beads (Beckman-Coulter). The quality and concentration of the libraries 
were assessed with the Agilent 2100 Bioanalyzer using the DNA 1000 LabChip (Agilent). Barcoded 
libraries were stored at −20 °C. All steps in the workflow were monitored using an in-house 
laboratory information management system with barcode tracking of all samples and reagents. 
 
DNA sequencing: 
Template DNA fragments were hybridized to the surface of flow cells (GA PE cluster kit (v2) or 
HiSeq PE cluster kits (v2.5 or v3)) and amplified to form clusters using the Illumina cBot. In brief, 
DNA (2.5–12pM) was denatured, followed by hybridization to grafted adaptors on the flowcell. 
Isothermal bridge amplification using Phusion polymerase was then followed by linearization of the 
bridged DNA, denaturation, blocking of 3´ ends and hybridization of the sequencing primer. 
Sequencing-by-synthesis (SBS) was performed on Illumina GAIIx and/or HiSeq 2000 instruments. 
Paired-end libraries were sequenced at 2 × 101 (HiSeq) or 2 × 120 (GAIIx) cycles of incorporation 
and imaging using the appropriate TruSeq™ SBS kits. Each library or sample was initially run on a 
single GAIIx lane for QC validation followed by further sequencing on either GAIIx (≥4 lanes) or 
HiSeq (≥1 lane) with targeted raw cluster densities of 500–800 k/mm2, depending on the version of 
the data imaging and analysis packages (SCS2.6-2-9/RTA1.6-1.9, HCS1.3.8-1.4.8/RTA1.10.36-
1.12.4.2). Real-time analysis involved conversion of image data to base-calling in real-time. 
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Alignment: 
Reads were aligned to NCBI Build 36 of the human reference sequence using Burrows-Wheeler 
Aligner (BWA) 0.5.9 6. Alignments were merged into a single BAM file and marked for duplicates 
using Picard 1.55 (http://picard.sourceforge.net/). Only non-duplicate reads were used for the 
downstream analyses. 
 
SNP calling: 
Variants were called using Genome Analysis Toolkit, (GenomeAnalysisTK) 1.2-29-g0acaf2d7, by 
applying base quality score recalibration, INDEL realignment and performing SNP and INDEL 
discovery and genotyping using standard hard filtering8. Variants were annotated using SNP effect 
predictor (snpEff) and Genome AnalysisToolkit 1.4-9-g1f1233b with only the highest-impact 
effect7,9. 
 
Sequence coverage at the C3 locus:  
The average coverage per base (i.e., total sequence coverage over a base divided by the number of 
sequenced individuals) for the exonic part of the C3 gene had a mean depth of 16.8X with standard 
deviation of 4.1. 97.5% of the bases had average coverage of at least 8X and none of the exonic C3 
bases had less than 4X coverage. The average coverage over K155Q was 15.0X. 
 
Genotype imputation in the Icelandic samples 
Long range phasing: 
Long range phasing of all chip-genotyped individuals was performed with methods described 
previously10,11. In brief, phasing is achieved using an iterative algorithm which phases a single 
proband at a time given the available phasing information about everyone else who shares a long 
haplotype identically by state with the proband. Given the large fraction of the Icelandic population 
that has been chip-typed, accurate long range phasing is available genome-wide for all chip-typed 
Icelanders. For long range phased haplotype association analysis, we then partitioned the genome 
into non-overlapping fixed 0.3 cM bins. Within each bin, we observed the haplotype diversity 
described by the combination of all chip-typed markers in the bin. Haplotypes with frequencies over 
0.001 were tested in a case-control analysis. 
 
Genotype imputation: 
We imputed the SNPs and INDELs identified through sequencing into all chip typed Icelanders who 
had been phased with long range phasing using the same model as used by IMPUTE12. The 
genotype data from sequencing can be ambiguous due to low sequencing coverage. In order to 
phase the sequencing genotypes, an iterative algorithm was applied for each SNP with alleles 0 and 
1. We let H be the long range phased haplotypes of the sequenced individuals and applied the 
following algorithm: 
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1. For each haplotype h in H, use the Hidden Markov Model of IMPUTE to calculate for every 
other k in H, the likelihood, denoted γh,k, of h having the same ancestral source as k at the SNP. 
2. For every h in H, initialize the parameter θh, which specifies how likely the one allele of the 
SNP is to occur on the background of h from the genotype likelihoods obtained from 
sequencing. The genotype likelihood Lg is the probability of the observed sequencing data at 
the SNP for a given individual assuming g is the true genotype at the SNP. If L0, L1 and L2 are 
the likelihoods of the genotypes 0, 1 and 2 in the individual that carries h, then set    
   
 
   
        
. 
3. For every pair of haplotypes h and k in H that are carried by the same individual, use the other 
haplotypes in H to predict the genotype of the SNP on the backgrounds of h and k:    
              and                  . Combining these predictions with the genotype 
likelihoods from sequencing gives un-normalized updated phased genotype probabilities: 
                  ,             
 
 
  ,             
 
 
   and           . 
Now use these values to update θh and θk to    
       
               
and    
       
               
. 
4. Repeat step 3 when the maximum difference between iterations is greater than a convergence 
threshold ε. We used ε = 10−7. 
Given the long range phased haplotypes and θ, the allele of the SNP on a new haplotype h not in H, 
is imputed as           . 
 
Association testing 
Case control association testing: 
Logistic regression was used to test for association between SNPs and disease, treating disease 
status as the response and expected genotype counts from imputation or allele counts from direct 
genotyping as covariates in Iceland. Testing was performed using the likelihood ratio statistic. For 
the US and EUGENDA case and control groups we calculated the odds ratio based on the direct 
genotype count and calculated the significance level using the Fisher‘s exact test. 
 
Conditional analysis: 
In Iceland, multivariate logistic regression analysis was performed conditioning for a given marker 
by adjusting for the estimated allele count on the basis of imputation of this marker in Iceland. The 
genomic control correction factor was the same as used for the unadjusted association analysis. A 
forward selection multiple logistic regression model was used to further define the extent of the 
genetic association. Briefly, all imputed SNPs located within the interval of 500 kb were tested for 
possible incorporation into a multiple-regression model. In stepwise fashion, a SNP was added to 
the model if it had the smallest P-value among all SNPs not yet included in the model and if it had a 
P-value below the locus-wide significance threshold. 
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Inflation factor adjustment:  
To account for the relatedness and stratification within our case and control sample sets, we applied 
the method of genomic control based on chip makers. For the AMD versus control comparison, the 
correction factors based on the genomic control was 1.292. 
 
Supplementary Table 1. Variants and loci selected for conditional analysis to screen for 
additional signals at previously reported AMD loci. 
 
rs ID Nearby genes Chr Pos (hg18) A1 A2 Freq. A1 OR A1 P-value 
Num. 
variants 
rs144305405 CFH 1 194946532 GT G 38.7% 0.46 1.4 × 10-47 4794 
rs11200630 ARMS2/HTRA1 10 124199674 C T 22.2% 2.46 8.0 × 10-70 5308 
rs2230203 C3 19 6661782 T G 23.3% 1.32 4.5 × 10-7 8791 
rs429358 APOE 19 50103781 C T 17.9% 0.73 6.8 × 10-6 7235 
NA C2/CFB 6 32052712 A G 4.9% 0.43 5.0 × 10-9 5161 
rs5754226 TIMP3/SYN3 22 31434348 G A 17.9% 0.70 1.9 × 10-7 6025 
 
Variants at twelve established AMD loci, i.e. ARMS2/HTRA1, CFH, C2/CFB, C3, TIMP3, APOE, 
CETP, VEGFA, TNFRSF10A, LIPC, CFI, and FRK/COL10A1 (these are listed in a recent meta-
analysis13), were tested for association with AMD in the Icelandic data. For the conditional analysis 
we only considered those loci with the strongest association signal satisfying P < 1 × 10-5. Six of the 
twelve loci fulfilled this criterion and the data for the strongest markers at these loci are presented. 
 
Description of columns: 
rs ID: dbSNP number; 
Chr: chromosome number; 
Pos (hg18): Genomic coordinates in hg18 (Build 36); 
A1 and A2: the two alleles for the variant; 
Freq. A1: frequency of allele A1 in the Icelandic population; 
OR A1: Odds ratio for allele A1; 
Num. variants: number of variants detected in the WGS data in a 500kb window centered on the 
variant under consideration. 
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Supplementary Table 2. Description of the AMD case control sample sets in the study 
 
  AMD Cases   Controls  
Study populations Total (% males) Total advanced 
AMD 
GA NV Early AMD/soft 
drusen only 
  Total (% males) non-AMD Population 
controls 
Iceland  1,143 (35.3%)   923 318* 719* 220 
 
51,435 (35.3%) 0 51,435 
          US (Utah) 355 (47.0%) 237 82 155 118 
 
163 (52.1%) 163 0 
US (San Diego) 1,170 (51.7%) 1,170 347 823 0   1,125 (48.1%) 1,125 0 
          EUGENDA 
(Netherlands/Germany) 
1,329 (39.7%) – – 750 579**   1,689 (47.2%) 679 1,010 
 
GA, geographic atrophy; NV, neovascular 
* 114 advanced AMD cases have both GA and NV 
       ** intermediate AMD and GA 
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Supplementary Table 3. Correlation (r2) between the variant conditioned on at each of the six 
loci and the strongest variants from the meta-analysis13 at these loci. 
 
 Variant 
conditioned on 
 Strongest  variant in meta-analysis13 
Gene loci rs ID Pos (hg18)  rs ID Pos (hg18) Freq. risk allele r2 
CFH rs144305405 194946532  rs10737680 194946078 61.4% 0.99 
ARMS2/HTRA1 rs11200630 124199674  rs10490924 124204438 22.3% 0.99 
C3 rs2230203 6661782  rs2230199 6669387 24.1% 0.79 
APOE rs429358 50103781  rs4420638 50114786 80.0% 0.72 
C2/CFB NA 32052712  rs9332739 32011783 94.9% 0.97 
TIMP3/SYN3 rs5754226 31434348  rs5749482 31389665 82.9% 0.78 
 
Description of columns: 
rs ID: dbSNP number; 
Pos (hg18): Genomic coordinates in hg18 (Build 36); 
Freq. risk allele: Frequency of the risk allele in the Icelandic population. 
 
90 
 
Supplementary Table 4. Correlation (r2) of the variants conditioned on (the strongest signals) 
with nonsynonymous variants in nearby genes. 
 
 
 Variants conditioned on  Coding variants  
Gene rs ID Pos (hg18)  rs ID Pos (hg18) Freq. 
risk 
allele 
Amino 
acid 
change 
r2 
CFH rs144305405 194946532  rs1061170 194925860 39.9% Y402H 0.42 
 rs800292 194908856 75.6% V62I 0.43 
ARMS2 rs11200630 124199674  rs10490924 124204438 22.3% A69S 0.99 
C3 rs2230203 6661782  rs1047286 6664262 24.5% P314L 0.91 
 rs2230199 6669387 24.1% R102G 0.79 
APOE rs429358 50103781  rs429358 50103781 82.1 C130R 1.00* 
C2 NA 32052712  rs9332739 32011783 94.9% E318D 0.97 
CFB rs5754226 32052712  rs4151667 32022003 94.9% L9H 0.97 
 
*The variant rs429358 used in the conditional analysis for APOE is a nonsynonymous coding variant.  
TIMP3/SYN3 had no correlated coding variant and is omitted in this table. 
 
Description of columns: 
rs ID: dbSNP number; 
Pos (hg18): Genomic coordinates in hg18 (Build 36); 
Freq. risk allele: Frequency of the risk allele for the coding variant in the Icelandic population. 
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Supplementary Table 5. Association between AMD and the C3 variants R102G, P314, and K155Q in the Icelandic data set(N AMD cases = 
1,143; N population controls = 51,435). 
 
      Unconditional  Condition on P314L  Condition on K155Q  Condition on R102G 
Variant name Amino acid 
substitution A1 A2 
Control 
Freq. A1  OR A1 P-value  OR A1 P-value  OR A1 P-value  OR A1 P-value 
rs1047286 P314L A G 24.5%  1.31 7.6 × 10-7  – –  1.34 1.0 × 10-7  1.23 0.16 
rs147859257 K155Q G T 0.55%  3.13 7.1 × 10-7  3.45 1.1 × 10-7  – –  3.45 1.2 × 10-7 
rs2230199 R102G C G 24.0%  1.31 1.0 × 10-6  1.08 0.61  1.33 2.5 × 10-7  – – 
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Supplementary Table 6.  r2 calculations between rs2230203 and the three markers in the 0.55% 
equivalent class that remain significant after conditioning on rs2230203. 
Pos (hg18) 6661782 (rs2230203) 6649204 6673565 6669146 
6661782 (rs2230203)  0.0017 0.0017 0.0017 
6649204   0.9818 0.9831 
6673565    0.9977 
6669146    
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Supplementary Table 7. Association results for the three variants in C3 that remain significant 
after conditioning on rs2230203. 
 
     Unconditional Conditional on rs2230203 
rs ID Pos (hg18) A1 A2 Control 
Freq. A1 
OR A1 P-value OR A1 P-value 
NA 6649204 AT A 0.55% 3.21 4.1 × 10-7 3.52 6.8 × 10-8 
rs181290250 6673565 T C 0.55% 3.15 6.5 × 10-7 3.45 1.1 × 10-7 
rs147859257 6669146 G T 0.55% 3.13 7.1 × 10-7 3.44 1.2 × 10-7 
 
Description of columns: 
rs ID: dbSNP number; 
Pos (hg18): Genomic coordinates in hg18 (Build 36); 
A1 and A2: the two alleles for the variant; 
Control Freq. A1: frequency of allele A1 in the Icelandic population; 
OR A1: Odds ratio for allele A1; 
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Supplementary Table 8. Nonsynonymous variants in C3 observed in deCODE sequencing data and on at least two chromosomes in the NHLBI GO 
Exome Sequencing Project (see URLs). 
 
 
pos (hg19)  rs ID  Alleles  EA allele count  AA allele count  Iceland Seq. Freq  Iceland Info  Grantham score  GERP score
6720575  rs138214338  P9L  G/A  G=5/A=8591  G=0/A=4398  NA  ---  benign 98 2.88
6669387  rs2230199  G102R  C/G  C=1801/G=6799  C=212/G=4194 22.29% 0.98  benign 125 -0.59
6669146  rs147859257  Q155K  G/T  G=37/T=8563  G=1/T=4405 0.43% 0.97  possibly-damaging 53 1.27
6714230  unknown  C210Y  C/T  C=2/T=8598  C=0/T=4406  NA  ---  probably-damaging 194 4.96
6714079  unknown  K233E  T/C  T=2/C=8598  T=0/C=4406  NA  ---  probably-damaging 56 4.83
6713468  unknown  E276Q  C/G  C=0/G=8600  C=2/G=4404  NA  ---  possibly-damaging 29 3.46
6713275  rs139527231  R310G  T/C  T=3/C=8597  T=0/C=4406  NA  ---  probably-damaging 125 3.66
6664262  rs1047286  L314P  A/G  A=1760/G=6840  A=177/G=4229 22.27% 0.98  benign 98 2.84
6712596  rs141737564  V348I  C/T  C=3/T=8597  C=1/T=4405  NA  ---  possibly-damaging 29 5.13
6711123  rs143430438  T452S  T/A  T=0/A=8600  T=2/A=4404  NA  ---  possibly-damaging 58 4.79
6711070  rs11569422  D469E  G/C  G=3/C=8597  G=180/C=4226  NA  ---  benign 45 -10.1
6710712  unknown  S542G  T/C  T=1/C=8599  T=1/C=4405  NA  ---  possibly-damaging 56 1.8
6709721  rs140637006  E607K  C/T  C=2/T=8598  C=0/T=4406  NA  ---  probably-damaging 56 4.98
6658931  rs146613648  M619V  T/C  T=5/C=8595  T=1/C=4405 0.07% 1.00  possibly-damaging 21 -2.75
6707913  rs144432231  F625I  A/T  A=2/T=8598  A=0/T=4406  NA  ---  benign 21 4.83
6658888  rs140655115  R633K  C/T  C=8/T=8592  C=1/T=4405 0.21% 1.00  benign 26 1.43
6658876  rs149850773  V637G  G/C  G=2/C=8598  G=1/C=4405 0.16% 0.98  probably-damaging 125 3.79
6707536  rs112187261  R663P  C/G  C=2/G=8596  C=0/G=4404  NA  ---  benign 103 3.26
6707129  rs117793540  W735R  A/G  A=32/G=8542  A=2/G=4392  NA  ---  probably-damaging 101 3.79
6694466  rs146026441  R1044G  G/C  G=0/C=8600  G=2/C=4404  NA  ---  benign 125 1.07
6686274  rs11569534  D1224G  T/C  T=0/C=8600  T=91/C=4315  NA  ---  benign 94 2.53
6636015  unknown  R1318L  C/A  NA  NA 0.16% 0.97  ---  ---  ---
6684591  rs11569541  T1367I  G/A  G=0/A=8600  G=46/A=4360  NA  ---  benign 89 5.41
6684417  rs146172605  N1385I  T/A  T=0/A=8600  T=3/A=4403  NA  ---  benign 149 0.22
6632983  rs147116781  A1440D  G/T  G=5/T=8595  G=1/T=4405 0.23% 0.98  possibly-damaging 126 3.43
6680256  rs113742728  H1457D  G/C  G=0/C=8600  G=15/C=4391  NA  ---  probably-damaging 81 3.93
6680246  rs147883317  G1460A  C/G  C=0/G=8600  C=5/G=4401  NA  ---  benign 60 2.59
6679429  rs142868256  H1512R  T/C  T=3/C=8597  T=0/C=4406  NA  ---  possibly-damaging 29 4.6
6630172  unknown  W1532R  A/G  NA  NA 0.09% 0.99  ---  ---  ---
6678452  rs149202905  M1549L  T/G  T=0/G=8600  T=44/G=4362  NA  ---  probably-damaging 15 -0.8
6678430  rs139381845  S1556N  C/T  C=2/T=8598  C=0/T=4406  NA  ---  benign 46 -0.5
6629030  rs2230210  R1619S  G/T  G=24/T=8576  G=5/T=4401 0.11% 0.79  probably-damaging 110 3.96
 Protein subst.  Polyphen 
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The variants displayed for the Icelandic sequencing data are those that had observed allelic frequency at least 0.04% among the sequenced Icelandic individuals and with 
imputation information value of 0.75 or higher. 
Description of columns: 
Pos (hg19): Genomic coordinates in hg19 (Build 37); 
rs ID: dbSNP number; 
Protein Subst.: amino acid substitution as reported in EVS6500 (NHLBI GO Exome Sequencing Project; see URLs); 
Alleles: alleles reported in EVS6500; 
EA allele count: allele counts for European Americans reported in EVS6500; 
AA allele count: allele counts for African Americans reported in EVS6500; 
Iceland Seq. Freq: minor allele frequency in deCODE sequencing data; 
Iceland Info: Information for variant in deCODE data; 
Polyphen: Polyphen prediction reported in EVS6500; 
Grantham Score: Grantham score reported in EVS6500; 
GERP score: GERP score reported in EVS6500.
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Supplementary Table 9. Association in the Icelandic data set between AMD and the C3 variants P314 and K155Q directly genotyped (N AMD 
cases = 1,107, fraction males 34.8%; N population controls = 2,869, fraction males 40.7%). 
 
      
unconditional 
 
condition on P314L 
 
condition on K155Q 
Variant name Amino acid 
substitution A1 A2 
Case Freq. 
A1 
Control 
Freq. A1 OR A1 P-value  OR A1 P-value  OR A1 P-value 
rs147859257 K155Q G T 1.6% 0.40% 3.99 2.2 × 10-7 
 
4.33 4.7 × 10-8 
 
– – 
rs1047286 P314L A G 29.9% 24.5% 1.32 7.5 × 10-7 
 
– – 
 
1.34 1.6 × 10-7 
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Supplementary Table 10. Association between AMD and the C3 variants P314 and K155Q in the replication samples. 
 
      
unconditional 
 
condition on P314L 
 
condition on K155Q 
Variant name 
Amino acid 
substitution A1 A2 
Case Freq. 
A1 
Control 
Freq. A1 
OR A1 P-value 
 
OR A1 P-value 
 
OR A1 P-value 
EUGENDA (N AMD cases = 1,329; N controls = 1,689)* 
rs147859257 K155Q G T 1.5% 0.41% 3.58 1.8 × 10-5     – – 
UCSD (N AMD cases = 1,170; N controls = 1,125) 
 
rs147859257 K155Q G T 1.2% 0.27% 4.37 0.00021  4.75 8.4 × 10-5  – – 
rs1047286 P314L A G 24.0% 20.9% 1.48 1.0 × 10-7  – –  1.49 4.2 × 10-8 
Utah (N AMD cases = 355; N eye-examined controls = 163) 
rs147859257 K155Q G T 2.25% 0.31% 7.49 0.0183  8.48 0.0094  – – 
rs1047286 P314L A G 25.5% 16.3% 1.76 7.4 × 10-4  – –  1.81 4.1 × 10-4 
US – UCSD and Utah combined (N AMD cases = 1,525; N controls =1,288) 
rs147859257 K155Q G T 1.41% 0.27% 5.25 1.4 × 10-6  5.75 3.0× 10-7  – – 
rs1047286 P314L A G 24.4 17.5% 1.52 2.4 × 10-10  – –  1.55 5.3× 10-11 
 
The minor allele count in each group is higher than 5 except for K155Q Utah where the count is 1 for the controls (there we used the Fisher’s exact test to calculate the P-value). 
*The EUGENDA controls consist of 679 eye-examined controls and 1,010 population controls. 
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Supplementary Table 11.  
Genotype counts and analysis for suphenotypes and K155Q genotype status. 
Cohort Subphenotype K155Q, GT genotype (N) K155Q, TT genotype (N) K155Q – G 
allele freq 
P-value 
Iceland NV not GA 15 557 1.31% 0.347* 
 GA not NV 8 197 1.95% 
 GA and NV 5 107 2.23%  
 Advanced AMD 28 861 1.57% 1.0 
 Soft drusen only 7 211 1.61% 
San Diego NV 15 808 0.91% 0.094 
 GA 12 335 1.73% 
      
Utah NV 4 151 1.29% 0.0143 
 GA 9 73 5.49% 
 Soft drusen only 3 118 1.27%  
US combined – – – – 0.0048 
US and Iceland combined* – – – 0.0047 
EUGENDA NV 17 733 1.13% 
0.107  GA or intermediate 
AMD 
22 557 1.90% 
 
* Comparison of ‘NV not GA’ versus ‘GA not NV’ for Icelandic cases.P-value corresponds to a two-sided test on allele counts. For ‘US and Iceland combined’ P-values were 
combined using the Mantel-Haenszel method.  
Description of subphenotypes: 
‘NV’: Cases that have neovascular AMD. 
‘GA’: Cases that have geographic atrophy. 
‘NV not GA’: Cases that have neovascular AMD and not geographic atrophy. 
‘GA not NV’: Cases that have geographic atrophy and not neovascular AMD. 
‘GA and NV’: Cases that have both geographic atrophy and neovascular AMD. 
‘Soft drusen only’: Cases that have soft drusen but neither geographic atrophy nor neovascular AMD. 
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Supplementary Table 12. Genomic and protein information for the nonsynomousC3 variants that associate with AMD. 
 
rs ID Pos. (hg18) Pos. (hg19) Nucleotide substitution C3 protein substitution C3b protein substitution 
rs2230199 6669387 6718387 c.C304>G R102G R80G 
rs147859257 6669146 6718146 c.A463>C K155Q K133Q 
rs1047286 6664262 6713262 c.C941>T P314L P292L 
 
The C3 protein transcript has the accession identifier NM_000064 and is of length 1664 amino acids; the C3b protein is of length 645 amino acids. 
 
Description of columns: 
rs ID: dbSNP number;  
Pos. (hg18): position of variant in hg18 (Build 36);  
Pos. (hg19): position of variant in hg19 (Build 37); 
Nucleotide substitution: nucleotide substitution described using the HGVS nomenclature; 
C3 protein substitution: amino acid substitution in C3 protein coordinates; 
C3b protein substitution: amino acid substitution in C3b protein coordinates. 
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Abstract 
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in elderly 
people worldwide. Cuticular drusen (CD) is a clinical subtype of AMD, which typically displays an 
earlier age at onset, and has a strong genetic component. Genetic studies support a role for rare 
sequence variants in CD susceptibility, and rare sequence variants in the CFH gene have been 
identified in 8.8% of CD cases. To further explore the role of rare variants in CD, we performed 
whole exome sequencing (WES) in 14 affected members of six families and 12 sporadic cases with 
CD. We detected rare sequence variants in CFH and FBLN5, which previously were shown to 
harbor rare variants in patients with CD. In addition, we detected heterozygous rare sequence 
variants in several genes encoding components of the extracellular matrix (ECM), including FBLN1, 
FBLN3/EFEMP1, FBLN5, FBLN6/HMCN1, FBN2, and COL15A1. Two rare pathogenic variants 
were identified in the COL15A1 gene: one in a sporadic cases and another was found to segregate in 
a family with six affected individuals with CD. In addition, two rare pathogenic variants were 
identified in the FGL1 gene in three unrelated CD cases. These findings suggest that alterations in 
the ECM and in the coagulation pathway may play a role in the pathogenesis of CD. The identified 
candidate genes require further analyses in larger cohorts to confirm their role in the CD subtype of 
AMD.  
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Introduction 
Age-related macular degeneration (AMD, OMIM 603075) is a leading cause of visual impairment 
and affects 8.7% of elderly people worldwide [1]. An early pathological symptom is the formation 
of drusen in the macula, the central region of the retina that is necessary for sharp and central vision. 
AMD is a clinically heterogeneous disorder that displays a broad spectrum of clinical appearances 
[2-5]. Cuticular drusen (CD, OMIM 126700) is a clinical subtype of AMD, characterized by the 
presence of at least 50 small (25-75µm) uniformly sized hyperfluorescent drusen, scattered 
primarily in the macular region on fluorescein angiography (FA) [6]. There is evidence that CD has 
a strong genetic component; CD often occurs in families and it presents clinically at an earlier age at 
onset than AMD [7,8]. Also, the most commonly associated environmental factor, smoking, shows a 
weaker association with CD than with the non-CD type AMD [9]. Genetic studies further support 
that CD has a strong genetic component by showing significant associations of CD with common 
variants (minor allele frequency [MAF] ≥ 1%) in the CFH (ID 3075; OMIM 134370), ARMS2 (ID 
387715, OMIM 611313) C2 (ID 717, OMIM 613927)/CFB (ID 629, OMIM 138470), C3 (ID 718, 
OMIM 120700), and APOE (ID 348, OMIM 107741) genes [7,9]. Moreover, heterozygous 
mutations in CFH segregate in multiplex CD families [10,11] and a highly penetrant AMD risk 
variant, p.Arg1210Cys in CFH, was identified in two CD cases [12]. Furthermore, we recently 
demonstrated that 8.8% of CD cases harbor rare sequence variants (MAF ≤ 1%) in CFH[12]. This 
evidence supports a strong genetic component in CD, but additional genetic factors that contribute 
to CD susceptibility are yet to be discovered. Whole exome sequencing (WES) selectively 
sequences all protein-coding regions of the genome, known as the exome. Protein-coding regions 
are collectively approximately 30 megabases in size, spread across 180,000 exons that constitute 1% 
of the human genome [13], and are estimated to harbor 85% of disease-causing mutations [14]. 
Therefore, WES offers an unprecedented opportunity to study the role of rare sequence variants in 
protein-coding regions in complex diseases. In the present study, we sought to determine the role of 
rare sequence variants in CD using WES. We performed WES in 14 affected members of six 
families and 12 sporadic cases with CD. In addition, we conducted segregation analysis for rare 
sequence variants that were identified by WES, in affected individuals of six families. 
 
Materials and Methods 
Patients 
We performed WES in 14 affected members of six families and 12 sporadic cases with the CD 
subtype of AMD (Figures 1 and 2). All study participants were selected from the European Genetic 
Database (EUGENDA) and are of Caucasian descent. All participants underwent extensive retinal 
examinations, which is described elsewhere in detail [12,15]. CD was diagnosed on the basis of the 
clinical observation of a symmetrically distributed pattern in both eyes of at least 50 scattered, 
uniformly-sized, small (25-75µm), and hyperfluorescent drusen on FA in each eye, and with a 
minimum of 20 drusen located outside the Wisconsin age-related maculopathy grading template 
[16,17]. The EUGENDA study was approved by the local research ethics committees (Commissie 
Mensgebonden Onderzoek Regio Arnhem-Nijmegen, the Netherlands, and Ethics Committee of the 
University Hospital Cologne, Germany). The study adhered to the ARVO statement for the use of 
human subjects in ophthalmic and vision research, and was performed in accordance with the tenets 
of the Declaration of Helsinki. Written informed consent was obtained from all participants. 
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Peripheral blood samples were collected from all participants, and genomic DNA was isolated using 
the Chemagic STAR DNA Blood4k kit (PerkinElmer, Waltham, MA, USA). 
 
Whole exome sequencing 
The exomes of all study participants were captured using the SureSelect Human All Exon kit 
version 2 (50Mb; Agilent Technologies, Santa Clara, CA, USA) using 3µg of genomic DNA. 
Subsequently, captured libraries were sequenced on SOLiD4 or 5500xl sequencing platforms (Life 
Technologies, Carlsbad, CA, USA). Reads were aligned to the reference human genome (NCBI 
hg19) with SOLiD LifeScope version 2.1 or SOLiD BioScope version 1.3 software (Life 
Technologies). Single nucleotide variants (SNVs) were called using the high-stringency DiBayes 
algorithm, and small insertions and deletions were detected using the SOLiD small Indel Tool (Life 
Technologies). The pathogenicity of missense variants were predicted in silico using Polymorphism 
Phenotyping version 2 (PolyPhen-2) and Sorting Intolerant from Tolerant (SIFT) tools. 
 
The exomes were analyzed for variants in 289 candidate genes for CD and atypical hemolytic 
uremic syndrome (aHUS), because of their known allelic overlap [15,18,19]. The candidate genes 
were selected from known CD genes [5,7], known AMD loci [20], genes known to be involved in 
monogenic macular degeneration (Retnet), and genes encoding components of the complement 
system, coagulation system, innate immunity, endothelial cells, and the glomerular basement 
membrane (Tables S1) (Westra et al, in preparation). 
 
Sanger sequencing 
Sanger sequencing was performed to validate rare sequence variants identified by WES. In families, 
confirmed rare sequence variants were analyzed for segregation by Sanger sequencing in available 
family members. Primers were designed with Primer3Plus software (Primer3Plus). PCR was 
performed, and amplification products were sequenced using an automated sequencer (BigDye 
Terminator, version 3, 3730 DNA analyzer; Applied Biosystems, Waltham, MA, USA). Sequencing 
chromatograms were compared to the reference sequence using ContigExpress (Vector NTI 
Advance, version 11.0, Life Technologies). 
 
Results 
Whole exome sequence analysis 
WES was performed in 14 affected members of six families and 12 sporadic cases with the CD 
subtype of AMD. We detected an average of 34,784 sequence variants per exome, with an average 
coverage of 70-fold. We subsequently focused our analyses on 289 candidate genes (Table S1) and 
detected an average of 780 sequence variants in these genes per sporadic case (Tables S2). In the six 
families, sequence variants were selected that were found in all affected individuals of each family. 
An average of 508 overlapping variants were detected in these candidate genes per family (Table 
S2). We next applied rigorous filtering criteria to identify rare, functionally relevant sequence 
variants in the candidate genes. The sequence variants were selected when they were present on 10 
or more (≥10) variant reads, and when they were present in 20 percent or more (≥20%) of the 
variant reads. We then selected non-synonymous, coding insertion-deletions (indels), and splice 
acceptor and donor site variants in the candidate genes, and detected an average of 133 variants in 
each sporadic case, while on average 88 overlapping variants were detected in each family. Finally, 
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we selected rare sequence variants with a minor allele frequency of ≤1% (MAF ≤0.01) in the 1000 
Genomes project (1000 Genomes project) and the global MAF listing in the dbSNP database 
(dbSNP database). These filtering criteria resulted a total of 98 rare sequence variants in 12 sporadic 
cases, with an average of eight rare sequence variants per sporadic case (Table S2; Tables S3-14). A 
total of nine overlapping variants were detected in four families, with an average of two variants in 
each family. In two families, no overlapping rare variants were identified (Table S2). 
 
Rare variants in sporadic CD cases 
We first examined genes that have previously been described to carry rare variants in macular 
degeneration, for rare sequence variants in 12 sporadic CD cases. In eight sporadic cases, we 
detected eight rare sequence variants in six macular degeneration genes (CFH; FBLN1, ID 2192, 
OMIM 135820; FBLN3/EFEMP1, ID 2202, OMIM 601548; FBLN5, ID 10516, OMIM 604580; 
HMCN1, ID 83872, OMIM 608548; FBN2, ID 2201, OMIM 612570) (Table 1). All rare sequence 
variants in the CFH (p.Ala173Gly; p.Gln950His/rs149474608), FBLN1 (p.His695Arg/rs13268), 
EFEMP1 (p.Asp49Ala/rs55849640), FBLN5 (p.Val126Met/rs61734479), HMCN1 
(p.Lys2559Asn/rs139899015), and FBN2 (p.Pro326Ser/rs28763954; p.His1381Asn/rs78727187) 
genes were confirmed by Sanger sequencing. Five of these variants (p.Gln950His (CFH), 
p.His695Arg (FBLN1), p.Val126Met (FBLN5), p.Lys2559Asn (HMCN1), and p.His1381Asn 
(FBN2)) are predicted to be damaging by prediction tools SIFT and PolyPhen2. However, three 
variants (p.Ala173Gly (CFH), p.Asp49Ala (EFEMP1), and p.Pro326Ser (FBN2)) are predicted to 
be damaging by one of these prediction tools. Evolutionary conservation of altered bases were 
predicted using the Phylop program. The variants in the FBLN1, EFEMP1, FBLN5, HMCN1, and 
FBN2 genes are conserved, whereas the c.518C>G (p.Ala173Gly) and c.2850G>T (p.Gln950His) 
variants in the CFH gene are less conserved (Table 1). 
 
We next sought for genes that were burdened recurrently with rare sequence variants in at least three 
sporadic cases. We detected two recurrent candidate genes (FGL1, ID 2267, OMIM 605776; 
COL15A1, ID 1306, OMIM 120325) that harboured rare sequence variants in a total of six sporadic 
cases (Table 2). Sanger sequencing confirmed variants in the FGL1 (p.Tyr140Phe/rs35431851; 
p.Trp256Leu/rs2653414), and COL15A1 (p.Phe851Leu/rs35901514) genes, while a variant in the 
COL15A1 (p.Lys1365Ile) gene was not confirmed by Sanger sequencing (Table S15). Of the 
confirmed variants, a rare variant (FGL1, p.Trp256Leu/rs2653414) is detected recurrently in two 
sporadic cases. Two variants in FGL1 (p.Tyr140Phe; p.Trp256Leu) gene are predicted to be 
damaging by both SIFT and PolyPhen2. The variant in the COL15A1 gene (p.Phe851Leu) is 
predicted to be damaging by one of two algorithms. The Phylop program predicted that all three 
variants in the FGL1 and COL15A1 genes are evolutionarily conserved (Table 2). 
 
Rare variants in CD families 
We detected four overlapping rare sequence variants in four candidate genes (TFPI, ID 7035, 
OMIM 152310; TLR1, ID 7096, OMIM, 601194; COL15A1; C1QBP, ID 708, OMIM 601269) in 
affected members of family 1 (Table 3). Family 3 harboured three overlapping rare sequence 
variants in three candidate genes (DDR1, ID 780, OMIM 600408; VWF, ID 7450, OMIM 613160; 
SLC12A3, ID 6559, OMIM 600968) (Table 3). Families 2 and 6 harboured one overlapping rare 
variant in one candidate gene each (Family 2: ADAMTS20, ID 80070, OMIM 611681; Family 6: 
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ITGA1, ID 3672, OMIM 192968), but both variants were not confirmed by Sanger sequencing 
(Table S15). No overlapping rare sequence variants were detected in candidate genes in affected 
members of families 4 and 5 (Table S2). 
 
In family 1, all overlapping rare sequence variants (p.Val292Met/rs5940, TFPI; p.Gln380*, TLR1; 
p.Pro705Leu/rs41308900, COL15A1; p.Thr130Met/rs56014026, C1QBP) in candidate genes were 
confirmed by Sanger sequencing (Table 3). Two variants, p.Val292Met (TFPI) and p.Pro705Leu 
(COL15A1), are predicted to be damaging by both SIFT and PolyPhen2, while a variant 
p.Thr130Met (C1QBP) is predicted to be damaging by one of two algorithms. Evolutionary 
conservation suggested that variants in the TFPI, TLR1, COL15A1, and C1QBP genes are 
conserved. We next checked for segregation of all confirmed variants with CD in the additional 
members of family 1 by Sanger sequencing. Variant p.Pro705Leu in the COL15A1 gene segregated 
heterozygously with CD in this family, although unaffected family members above age 60 were not 
available in this family. All other variants were not present in one or two affected members of a 
family, and thus did not segregate with CD in family 1 (Figure 3). 
 
Family 3 harboured three overlapping rare sequence variants (p.Ile365Phe/rs143367160, DDR1; 
p.Arg924Gln/rs33978901, VWF; c.2883+1G>T/rs199974259, SLC12A3), which were all confirmed 
by Sanger sequencing. Variant p.Ile365Phe in the DDR1 gene is predicted to be damaging by one of 
two prediction algorithms, while the p.Arg924Gln variant in the VWF gene is predicted not to be 
damaging by both SIFT and PolyPhen2 prediction algorithms. All three variants are evolutionarily 
conserved. These variants subsequently were analyzed for segregation with CD in two additional 
family members of family 3. Variant p.Ile365Phe in the DDR1 gene did not show segregation, as it 
was not present in an affected member of the family. The splice donor variant, c.2883+1G>T, in the 
SLC12A3 gene also did not segregate, as it was found to be present in an unaffected member and 
was not present in an affected member of the family. The missense variant p.Arg924Gln in the VWF 
gene is present in three affected members and one unaffected member of the family (Figure 3). 
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Figure 1.  
Pedigrees of six cuticular drusen (CD) families in which whole exome sequencing (WES) was performed. Circle and square symbols indicate female and male individuals, 
respectively. Symbols with slashes indicate deceased individuals. Black and empty symbols indicate affected and unaffected individuals, respectively. Asterisks indicate the 
family members for whom exome sequencing was performed. The numbers below the symbols indicate the age at participation of family members. 
110 
 
 
111 
 
 
Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Retinal images of 12 sporadic cuticular drusen (CD) cases for whom exome sequencing (WES) was performed. Panels A and B represent colour fundus photographs 
(1A-12A) and fluorescein angiograms (FAs) (1B-12B) of 12 cases respectively. For cases 1-5 retinal images of the right eye are shown, whereas for cases 6-12 retinal images of 
the left eye are shown. The CD phenotype presents with a large number of small and uniformly sized hyperfluorescent drusen on FA.  
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Figure 3.  Segregation analysis of rare sequence variants identified in candidate genes in cuticular drusen (CD) families by whole exome sequencing (WES). Circles, females; 
squares, males; empty symbols, unaffected; black symbols, affected; asterisks, exome sequenced individuals; ‘+’ symbol, wild type allele; ‘m’ symbol, mutant type allele. The 
age at participation is specified below the symbols.  
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Table 1. 
Rare missense variants identified in known macular degeneration genes in 12 sporadic CD subtype of AMD cases by WES. 
 
Gene Change in  dbSNP Prediction algorithms Conservation # Cases (Figure 2) 
  Nucleotide Protein ID MAF (%) SIFT PolyPhen2 Phylop (Base level)   
CFH c.518C>G p.Ala173Gly  NA 0 Deleterious Benign 0.3 1 (3AB) 
CFH c.2850G>T p.Gln950His  rs149474608 0.002 Deleterious Damaging -0.7 1 (9AB) 
FBLN1 c.2084A>G p.His695Arg  rs13268 0.007 Deleterious Damaging 4.2 1 (2AB) 
FBLN3/EFEMP1 c.146T>G p.Asp49Ala rs55849640 0.0004 Deleterious Benign 2.3 1 (12AB) 
FBLN5 c.376C>T p.Val126Met  rs61734479 0.0008 Deleterious Damaging 4.0 1 (10AB) 
FBLN6/HMCN1 c.7677G>C p.Lys2559Asn  rs139899015 0 Deleterious Damaging 1.2 1 (8AB) 
FBN2 c.976G>A p.Pro326Ser  rs28763954 0.003 Deleterious Benign 2.7 1 (9AB) 
FBN2 c.4141G>T p.His1381Asn  rs78727187 0 Deleterious Damaging 5.9 1 (7AB) 
 
CD, cuticular drusen; AMD, age-related macular degeneration; WES, whole exome sequencing; MAF, minor allele frequency; SIFT, sorting intolerant from tolerant; 
PolyPhen2, polymorphism phenotyping; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation); NA, not applicable 
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Table 2. 
Recurrent missense variants identified in two of 289 candidate genes in 12 sporadic CD subtype of AMD cases by WES. 
 
Gene Change in  dbSNP Prediction algorithms Conservation # Cases (Figure 2) 
  Nucleotide Protein ID MAF (%) SIFT PolyPhen2 Phylop (Base level)   
FGL1 c.419T>A p.Tyr140Phe rs35431851 0.007 Deleterious Damaging 4.6 1 (11AB) 
FGL1 c.767C>A p.Trp256Leu rs2653414 0.009 Deleterious Damaging 5.1 2 (4AB; 6AB) 
COL15A1 c.2551T>C p.Phe851Leu rs35901514 0.003 Tolerated Damaging 2.8 1 (2AB) 
 
CD, cuticular drusen; AMD, age-related macular degeneration; WES, whole exome sequencing; MAF, minor allele frequency; SIFT, sorting intolerant from tolerant; 
PolyPhen2, polymorphism phenotyping; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
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Table 3. 
Overlapping rare sequence variants identified in seven of 289 candidate genes in affected members of CD families by WES. 
 
Gene Change in dbSNP Prediction algorithms Conservation Family number 
  Nucleotide Protein ID MAF (%) SIFT PolyPhen2 Phylop (Base level)   
TFPI c.874G>A p.Val292Met rs5940 0.008 Deleterious Damaging 0.5 1 
TLR1 c.1138C>T p.Gln380* NA 0 NA NA 1.3 1 
COL15A1 c.2114C>T p.Pro705Leu rs41308900 0.007 Deleterious Damaging 1.9 1 
C1QBP c.389C>T p.Thr130Met rs56014026 0.007 Tolerated Damaging 3.4 1 
DDR1 c.1093A>T p.Ile365Phe rs143367160 0.003 Deleterious Benign 1.6 3 
VWF c.2771C>T p.Arg924Gln  rs33978901 0.007 Tolerated Benign 1.4 3 
SLC12A3 c.2883+1 G>T Splice-donor rs199974259 0 NA NA 5.2 3 
 
CD, cuticular drusen; WES, whole exome sequencing; MAF, minor allele frequency; SIFT, sorting intolerant from tolerant; PolyPhen2, polymorphism phenotyping; Phylop 
score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation); NA, not applicable 
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Discussion 
In the present study, we found rare sequence variants in two genes which previously were shown to 
harbour rare variants in CD (CFH and FBLN5) [5,11]. In addition, we found heterozygous rare 
sequence variants (MAF ≤0.01) in several extracellular matrix (ECM) genes, which include FBLN1, 
FBLN3/EFEMP1, FBLN5, FBLN6/HMCN1, FBN2, and COL15A1, in sporadic cases and families 
with the CD subtype of AMD by WES (Tables 1 and 2). Two rare pathogenic variants were 
identified in the COL15A1 gene: one in a sporadic cases and another was found to segregate in a 
family with six affected individuals with CD. In addition, two rare pathogenic variants were 
identified in the FGL1 gene in three unrelated CD cases. 
 
Variants in the CFH gene are major risk factors for both AMD and CD [10,11,19]. In this study, we 
identified two missense variants (p.Ala173Gly and p.Gln950His) that were previously identified by 
Sanger sequencing of the CFH gene in the same patients of the CD subtype of AMD phenotype 
[12]. 
 
The fibulins are ECM proteins that are characterized by tandem arrays of epidermal growth factor 
(EGF) - like domains, and are widely expressed in basement membranes. A previous study suggests 
that a single mutation (p.Arg345Trp) in the last EGF domain of FBLN3/EFEMP1 gene causes 
Doyne honeycomb retinal dystrophy (DHRD; OMIM 126600) [21]. We identified an evolutionarily 
conserved rare sequence variant (p.Asp49Ala) in the first EGF domain of FBLN3/EFEMP1 gene in 
a sporadic CD patient. This suggests that variants in the FBLN3/EFEMP1 gene may represent risk 
factors for the CD phenotype. We also identified a missense variant (p.Val126Met) in the FBLN5 
gene, which was previously reported in the Dutch population (AMD cases 1/291; controls 5/91), 
suggesting that this variant is not rare in the Dutch population [22]. Therefore, the p.Val126Met 
variant in the FBLN5 gene may not be a causal variant for CD. However, missense variants in the 
FBLN5 gene have previously been associated with AMD (P < 0.01) and the retinal images of 
patients showed a peculiar CD phenotype, which suggests that other variants in the FBLN5 gene are 
a risk factor for both the AMD and CD phenotypes [5,22]. 
 
The ECM is an acellular component that provides physical and biochemical support for surrounding 
cells in all tissues and organs, and constantly undergoes remodeling processes which are 
indispensible for tissue architecture [23]. A pathological symptom of AMD phenotypes is the 
formation of drusen between the retinal pigment epithelium (RPE) and Bruch’s membrane (BrM), 
which is a multi-layered ECM structure. The BrM is composed of central elastin fibers sandwiched 
between layers of collagen [24,25]. The BrM acts as a blood-retinal barrier that regulates the 
diffusion of nutrients and oxygen from the choroid through the BrM to the RPE, while the metabolic 
waste diffuses in an opposite direction to the choroid [26]. Several lines of evidence suggest that 
ageing processes (thickening, calcification, degeneration of collagens and elastic fibers) and 
alterations in the structural components in the BrM result in loss of normal function of the BrM 
[27], which may result in accumulation of drusen deposits in AMD patients. Emerging evidence 
suggests that alterations in specific genes encoding ECM proteins (TIMP3, CTRP5, FBN2, and 
FBLN 1-6) are implicated in macular degeneration [5,21,28-30]. Recent genome-wide association 
studies have also identified risk variants in several ECM genes (COL8A1, COL10A1, ADAMTS9, 
DDR1, TGFBR1, HTRA1, and TIMP3) [20]. 
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The present study identified two evolutionarily conserved rare sequence variants (p.Pro705Leu and 
p.Phe851Leu) in COL15A1 in 6 affected members of a family and in a sporadic CD patient, 
respectively. The p.Pro705Leu variant is predicted to be deleterious by both prediction algorithms, 
while the p.Phe851Leu variant is predicted to be deleterious by one of two prediction algorithms. 
These prediction algorithms provide a quick functional annotation of variants, but experimental 
validation is required to properly access the functional consequences of these variants. The 
COL15A1 gene encodes collagen, type XV, alpha 1, which is widely expressed in basement 
membranes [31], and in choroidal endothelial cells [32]. Since the choroid plays a vital role in 
maintenance of BrM, variants in the COL15A1 gene might lead to altered properties of the choroid 
and/or of BrM, resulting in the formation of drusen in patients with CD. 
 
In this study we also identified two highly conserved rare sequence variants in the FGL1 gene in 
three of 12 sporadic CD cases (Table 2). Both variants are predicted to be deleterious to the normal 
function of the protein by prediction algorithms. Fibrinogen and fibrinogen-like protein 1 (FGL1) 
belong to the fibrinogen superfamily. Fibrinogen is a precursor of fibrin clot formation of the 
coagulation cascade [33,34]. A proteomic study demonstrated that FGL1 is bound to the fibrin 
matrix during clot formation, suggesting that FGL1 is involved in the coagulation cascade [35,36]. 
Interestingly, the molecular composition of drusen consist of fibrinogen as one of several 
constituents [37]. This suggests that FGL1 variants may be causative in CD, although it is unclear 
on how the coagulation cascade and variants in FGL1 gene may be implicated in AMD phenotypes. 
 
We found no segregating rare variants among affected members of four of the six CD families in the 
289 candidate genes that were analyzed in this study, suggesting that these families need to be 
evaluated for novel rare variants in other genes. Alternatively, the disease risk in some individuals 
of these families may be attributable to a combination of common genetic and environmental 
factors, and as a consequence rare variants may not completely segregate in these families. In a 
recent study we identified a clustering of known risk factors in affected members of families with 
AMD, suggesting that such families may not be explained by rare genetic variants. However, some 
families cannot be explained by known risk factors, and are more likely to carry rare, highly 
penetrant variants (Saksens et al, manuscript submitted). Some affected family members in the CD 
families examined in this study might thus have CD due to the presence of known risk factors, and 
not merely by rare sequence variants. Therefore, WES based segregation analyses may not always 
be the best strategy to solve AMD or CD families. However, other studies have successfully 
identified rare sequence variants in AMD families by WES, e.g. in the CFH and FBN2 genes 
[28,38].  
 
In summary, WES in sporadic cases and families with the CD subtype of AMD identified rare 
variants in known CD genes and several genes encoding ECM components. Rare pathogenic 
variants were recurrently identified in the COL15A1 and FGL1 genes. These findings suggest that 
alterations in the ECM and in the coagulation pathway may play a role in the pathogenesis of CD. 
These candidate genes require further analyses in larger cohorts to confirm their involvement in the 
CD subtype of AMD. 
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Table S1. List of 289 candidate genes selected from known AMD loci, genes known to be involved in monogenic macular degeneration, genes from 
the complement system, the coagulation system, innate immunity, endothelial cell components, and glomerular basement membrane components 
(Westra et al, in preparation). 
 
Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM 
A2M 2 103950 ARMS2 387715 611313 C2 717 613927 CD19 930 107265 CFHR5 81494 608593 
ABCA4 24 601691 B3GALTL 145173 610308 C3 718 120700 CD36 948 173510 CFI 3426 217030 
ACAN 176 155760 BAIAP2L2 80115 NA C3AR1 719 605246 CD40 958 109535 CFP 5199 300383 
ACE 1636 106180 BCAM 4059 612773 C4A 720 120810 CD44 960 107269 CHMP7 91782 611130 
ADAMTS13 11093 604134 BDKRB1 623 600337 C4B 721 120820 CD46 4179 120920 CLPTM1 1209 604783 
ADAMTS17 170691 607511 BDKRB2 624 113503 C4BPA 722 120830 CD55 1604 125240 CLU 1191 185430 
ADAMTS19 171019 607513 BEST1  7439 607854 C4BPB 725 120831 CD59 966 107271 COL10A1 1300 120110 
ADAMTS2 9509 604539 C1QA 712 120550 C5 727 120900 CD74 972 142790 COL15A1 1306 120325 
ADAMTS20 80070 611681 C1QB 713 120570 C5AR1 728 113995 CD79A 973 112205 COL8A1 1295 120251 
ADAMTS9 56999 605421 C1QBP 708 601269 C6 729 217050 CD79B 974 147245 CPB2 1361 603101 
AGT 183 106150 C1QC 714 120575 C6orf223 221416 NA CD93 22918 120577 CR1 1378 120620 
AGTR1 185 106165 C1QL1 10882 611586 C7 730 217070 CETP  1071 118470 CR1L 1379 605886 
ALG2 85365 607905 C1QL2 165257 614330 C8A 731 120950 CFB 629 138470 CR2 1380 120650 
APOB 338 107730 C1QL3 389941 615227 C8B 732 120960 CFD 1675 134350 CSMD1 64478 608397 
APOC1 341 107710 C1QL4 338761 615229 C8G 733 120930 CFH 3075 134370 CX3CR1 1524 601470 
APOC1P1 342 NA C1QTNF5 114902 608752 C9 735 120940 CFHR1 3078 134371 CYP21A2 1589 613815 
APOC2 344 608083 C1R 715 613785 CASP6 839 601532 CFHR2 3080 600889 DAPL1 92196 NA 
APOC4 346 600745 C1RL 51279 608974 CCDC109B 55013 NA CFHR3 10878 605336 DDR1 780 600408 
APOE 348 107741 C1S 716 120580 CD14 929 158120 CFHR4 10877 605337 DGKE 8526 601440 
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Table S1 continued. 
Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM 
DMBT1 1755 601969 FCN1 2219 601252 GP1BA 2811 606672 ICAM4 3386 614088 ITGA7 3679 600536 
EFEMP1  2202 601548 FCN2 2220 601624 GP6 51206 605546 IER3 8870 602996 ITGA8 8516 604063 
EHMT2 10919 604599 FCN3 8547 604973 GPC1 2817 600395 IFNG 3458 147570 ITGA9 3680 603963 
ELOVL4 6785 605512 FGA 2243 134820 GPC2  221914 NA IL10 3586 124092 ITGAD 3681 602453 
ERCC6 2074 609413 FGB 2244 134830 GPC3 2719 300037 IL12A 3592 161560 ITGAE 3682 604682 
F10 2159 613872 FGD5 152273 614788 GPC4 2239 300168 IL12RB1 3594 601604 ITGAL 3683 153370 
F11 2160 264900 FGD6  55785 613520 GPC5 2262 602446 IL1A 3552 147760 ITGAM 3684 120980 
F12 2161 610619 FGG 2266 134850 GPC6 10082 604404 IL2 3558 147680 ITGAV 3685 193210 
F13A1  2162 134570 FGL1 2267 605776 GPR108 56927 NA IL6 3569 147620 ITGAW 3686 NA 
F13B 2165 134580 FGL2 10875 605351 GTF2H4 2968 601760 IMPG1 3617 602870 ITGAX 3687 151510 
F2 2147 176930 FGR 2268 164940 GUCA1B 2979 602275 ITGA1 3672 192968 ITGB1 3688 135630 
F2R 2149 187930 FIGF 2277 300091 HERPUD1 9709 608070 ITGA10 8515 604042 ITGB2 3689 600065 
F3 2152 134390 FILIP1L 11259 612993 HMCN1 83872 608548 ITGA11 22801 604789 ITGB3 3690 173470 
F5 2153 612309 FLOT1 10211 606998 HSPG2 3339 142461 ITGA2 3673 192974 ITGB4 3691 147557 
F7 2155 613878 FLT1 2321 165070 HSPH1 10808 610703 ITGA2B 3674 607759 ITGB5 3693 147561 
F8 2157 300841 FLT4 2324 136352 HTRA1 5654 602194 ITGA3 3675 605025 ITGB6 3694 147558 
F9 2158 300746 FN1 2335 135600 ICAM1 3383 147840 ITGA4 3676 192975 ITGB7 3695 147559 
FBLN5 10516 604580 FRK 2444 606573 ICAM2 3384 146630 ITGA5 3678 135620 ITGB8 3696 604160 
FBN2 2201 612570 FSCN2 25794 607643 ICAM3 3385 146631 ITGA6 3655 147556 KDR 3791 191306 
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Table S1 continued. 
Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM Gene  ID OMIM 
KLKB1 3818 229000 PDGFA 5154 173430 R3HCC1 203069 NA SLC12A3 6559 600968 TNF 7124 191160 
KNG1 3827 612358 PDGFB 5155 190040 RAD51B 5890 602948 SLC16A8 23539 610409 TNFRSF10A 8797 603611 
LIPC 3990 151670 PDGFRA 5156 173490 RAX2 84839 610362 SLC44A4 80736 606107 TNFRSF10D 8793 603614 
LOC285858 285858 NA PDGFRB 5159 173410 RELB 5971 604758 SOX10 6663 602229 TNFSF14 8740 604520 
LOC389641  389641 NA PGF 5228 601121 RP1L1 94137 608581 STK19 8859 604977 TNXA 7146 NA 
LOXL2 4017 606663 PICK1 9463 605926 RPGR 6103 312610 SUSD4 55061 615827 TNXB 7148 600985 
LY96 23643 605243 PLA2G12A 81579 611652 SDC1 6382 186355 SYN3 8224 602705 TOMM40 10452 608061 
MASP1 5648 600521 PLA2G6 8398 603604 SDC2 6383 142460 TFPI 7035 152310 TPI1P3  728402 NA 
MASP2 10747 605102 PLAT 5327 173370 SEC24B 10427 607184 TGFB1 7040 190180 TRIP10 9322 604504 
MBL2 4153 154545 PLAU 5328 191840 SEC61B 10952 609214 TGFBR1 7046 190181 TSPYL4 23270 NA 
MDC1 9656 607593 PLAUR 5329 173391 SERPINA1 5265 107400 THBD 7056 188040 TUBB 203068 191130 
MIF 4282 153620 PLEKHA1 59338 607772 SERPINA5 5104 601841 TIMP3 7078 188826 VARS2 57176 612802 
MIR1236 100302242 NA PLG 5340 173350 SERPINB2 5055 173390 TLR1 7096 601194 VAV1 7409 164875 
MIR3941 100500866 NA PROC 5624 612283 SERPINC1 462 107300 TLR2 7097 603028 VEGFA 7422 192240 
MIR548A2 693126 NA PROCR 10544 600646 SERPIND1 3053 142360 TLR3 7098 603029 VEGFB 7423 601398 
MIR548G 100313938 NA PROM1 8842 604365 SERPINE1 5054 173360 TLR4 7099 603030 VEGFC 7424 601528 
MMACHC 25974 609831 PROS1 5627 176880 SERPINF2 5345 613168 TLR5 7100 603031 VTN 7448 193190 
NEU1 4758 608272 PROZ 8858 176895 SERPING1 710 606860 TLR6 10333 605403 VWF 7450 613160 
NLRC5 84166 613537 PRPH2 5961 179605 SH2D3A 10045 604721 TLR7 51284 300365 ZBTB12 221527 NA 
NT5DC1 221294 NA PVRL2 5819 600798 SKIV2L 6499 600478 TLR8 51311 300366       
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Table S2. 
Whole exome sequencing filtering steps for 289 candidate genes in 14 affected members of six CD families and 12 sporadic CD cases. 
 
Samples # Variants in  Variant reads Variants in NS/I/SS db SNP  
  candidate genes  ≥ 10 ≥ 20%  exons variants MAF (≤ 0.01) 
Families (Figure 1) # Overlapping variants           
Family 1 – two FM 615 496 491 232 108 4 
Family 2 – two FM 439 326 323 160 69 1 
Family 3 – two FM 549 414 413 196 90 3 
Family 4 – four FM 345 307 305 149 71 0 
Family 5 – two FM 517 405 404 188 86 0 
Family 6 – two FM 586 447 445 230 103 1 
Average 508 ± 100 399 ± 71 397 ±  71 192 ± 34 88 ± 16 2 ± 2 
Sporadic (Figure 2)  
 
     
1AB 675 421 419 209 105 5 
2AB 767 533 526 277 132 6 
3AB 864 661 655 343 163 10 
4AB 839 642 638 298 151 12 
5AB 799 551 546 284 130 6 
6AB 770 585 581 253 122 8 
7AB 716 467 461 231 108 8 
8AB 722 517 514 266 136 8 
9AB 754 515 508 272 122 9 
10AB 836 637 629 327 154 9 
11AB 760 555 553 275 132 10 
12AB 856 618 611 307 148 7 
Average 780 ± 60 558 ± 73 553 ± 72 278 ± 37 133 ± 18 8 ± 2 
 
NS, nonsynonymous variants; I, coding indels; SS, splice acceptor and donor site variants; FM, family members; Families 4 & 5, no overlapping variants detected; Variant 
reads, variants were selected when they were present on 10 or more (≥ 10) variant reads, and when they were present in 20 percent or more (≥ 20%) of the variant reads.
126 
 
 
Table S3. Sporadic case 1AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
3 37560750 ITGA9 1142-1 G>A NA NA 0 6.26 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
12 9246177 A2M 2126-6_2126-2 NA rs3832852 0 0.88 
17 48152859 ITGA3 1506T>G S502R  NA 0 0.78 
19 18192977 IL12RB1 222G>C S74R  rs11575925 0.0004 -0.08 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
 
Table S4. Sporadic case 2AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
3 186959295 MASP1 1277C>T G426E  rs28945068 0.008 1.74 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
5 52225518 ITGA1 2758T>G L920V  NA 0 0.12 
6 6251120 F13A1 614T>A Y205F  rs3024477 0.008 1.88 
8 23148940 R3HCC1 358G>T V120L  NA 0 0.02 
9 101804366 COL15A1 2551T>C F851L  rs35901514 0.003 2.87 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
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Table S5. Sporadic case 3AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position 
 
Nucleotide Amino acid 
 
  Phylop (Base level) 
1 196646696 CFH 518C>G A173G  NA 0 0.31 
3 99649861 FILIP1L 4G>T R2S  NA 0 2.86 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
6 30866675 DDR1 2480C>T T827M  rs150642742 0.0002 5.24 
6 80634724 ELOVL4 314C>G G105A  NA 0 2.41 
7 22771038 IL6 485A>T D162V  rs2069860 0.003 0.12 
12 56079053 ITGA7 2924G>A A975V  rs139136931 0.0008 2.31 
12 7242224 C1R 530 C>T R177H NA 0 -0.1 
16 31336059 ITGAM 2248C>T R750W  NA 0 1.85 
19 55525763 GP6 1550A>C M517R  rs200566792 0.0008 -0.89 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
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Table S6. Sporadic case 4AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
1 145530939 ITGA10 671C>T T224M  rs146565671 0.002 3.38 
3 186959295 MASP1 1277C>T G426E  rs28945068 0.008 1.74 
3 186974474 MASP1 722G>A P241L  NA 0 2.91 
4 55127448 PDGFRA 236G>A G79D  rs36035373 0.004 4.95 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
6 116446506 COL10A1 150A>T S50R  rs142411445 0.001 0.12 
6 30680124 MDC1 1595C>T G532E  rs139338660 0.0004 0.37 
8 17726069 FGL1 767C>A W256L  rs2653414 0.009 5.17 
12 53586255 ITGB7 2014G>A H672Y  rs11539433 0.004 0.31 
12 95603246 FGD6 1814G>A S605L  rs200713610 0.0006 4.52 
12 54793659 ITGA5 2716G>C P906A  NA 0 0.3 
13 31729776 HSPH1 181T>G N61H  rs41292149 0.002 3.15 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
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Table S7. Sporadic case 5AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
1 207300070 C4BPA 719G>A R240H  rs45574833 0.003 -0.77 
3 39307832 CX3CR1 265T>C T89A  rs199811198 0.0008 0.22 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
10 124396776 DMBT1 6473C>T P2158L  NA 0 -0.27 
16 56921840 SLC12A3 2179G>A A727T  rs36049418 0.006 -0.37 
17 54939158 DGKE 1291C>G L431V  NA  0 0.99 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
 
Table S8. Sporadic case 6AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
2 173355800 ITGA6 2728G>A D910N  rs61737182 0.002 2.1 
4 187194331 F11 325G>A A109T  NA 0 2.51 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
5 52225518 ITGA1 2758T>G L920V  NA 0 0.12 
8 17726069 FGL1 767C>A W256L  rs2653414 0.009 5.17 
9 136280025 REXO4 332G>A S111L  rs141547732 0.002 1.08 
10 124175436 PLEKHA1 530G>A S177N  rs142473166 0.0006 4.07 
12 43821128 ADAMTS20 4090A>T Y1364N  rs138035327 0.0004 1.57 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
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Table S9. Sporadic case 7AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
2 21230743 APOB 8997G>T H2999Q  NA 0 -0.03 
4 38798294 TLR1 2159T>G H720P  rs113706342 0.004 1.09 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
5 52225518 ITGA1 2758T>G L920V  NA 0 0.12 
5 127668685 FBN2 4141G>T H1381N  rs78727187 0 5.91 
6 30893728 VARS2 3123C>G D1041E  NA 0 -0.06 
6 30680512 MDC1 1207C>T D403N  NA 0 1.77 
16 31434770 ITGAD 2957C>T A986V  rs150163548 0.0004 0.09 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
 
Table S10. Sporadic case 8AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
1 145530980 ITGA10 712C>T R238W  rs140344269 0.0006 0.007 
3 99514829 COL8A1 2084G>A G695D  rs150077356 0.0002 5.83 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
6 116573958 TSPYL4 1214C>T S405N  rs183681428 0.0004 0.12 
8 10465636 RP1L1 5972C>T G1991E  NA 0 0.89 
12 9246177 A2M 2126-6_2126-2 NA rs3832852 0 0.88 
X 154158285 F8 3780G>C D1260E  rs1800291 0  -0.19 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
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Table S11. Sporadic case 9AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position 
 
Nucleotide Amino acid 
 
  Phylop (Base level) 
1 196709816 CFH 2850G>T Q950H  rs149474608 0.002 -0.74 
2 216251580 FN1 4171G>A R1391C rs116558455 0.001 4.21 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
5 127744469 FBN2 976G>A P326S  rs28763954 0.003 2.71 
6 30893728 VARS2 3123C>G D1041E  NA 0 -0.06 
6 42153428 GUCA1B 465C>A E155D  rs139923590 0.003 0.66 
12 6061684 VWF 7988C>A R2663L  NA 0 0.81 
12 6101167 VWF 6616A>G S2206P  NA 0 0.83 
19 14501850 CD97 305G>A G102E  NA 0 0.66 
 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
 
Table S12. Sporadic case 10AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
4 154626317 TLR2 2258G>A R753Q  rs5743708 0.007 4.54 
4 155533035 FGG 323G>C A108G  rs148685782 0.002 1.82 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
6 76640670 IMPG1 2243C>A R748M  NA 0 3.62 
6 30893728 VARS2 3123C>G D1041E  NA 0 -0.06 
10 50680422 ERCC6 2924C>T R975Q  rs145720191 0.001 6.2 
12 7177276 C1S 1388C>T A463V  rs375077429 0 2.63 
12 43886984 ADAMTS20 940G>A H314Y  NA 0 2.05 
14 92403294 FBLN5 376C>T V126M  rs61734479 0.0008 3.99 
 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
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Table S13. Sporadic case 11AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
1 57395228 C8B 1625G>A T542I  rs61737417 0.003 0.66 
2 21238301 APOB 3449A>T M1150K  rs146223051 0 1.91 
3 124483297 ITGB5 2245G>T H749N  NA 0 5.94 
4 187157943 KLKB1 337C>T R113*  rs121964949 0 -0.05 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
6 161128812 PLG 266G>A R89K  rs143079629 0.002 1.89 
8 17731611 FGL1 419T>A Y140F  rs35431851 0.007 4.66 
10 124189183 PLEKHA1 944C>T P315L  NA 0 3.48 
12 6140659 VWF 2771C>T R924Q  rs33978901 0.007 1.4 
19 6759632 SH2D3A 469G>A R157W  rs148876828 0.0004 0.79 
 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
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Table S14. Sporadic case 12AB, Figure 2 
 
Chromosome Gene Change in  SNP id MAF Conservation 
# Position   Nucleotide Amino acid     Phylop (Base level) 
1 230845755 AGT 842T>C Y281C  rs56073403 0.0008 1.96 
2 56145171 EFEMP1 146T>G D49A  rs55849640 0.0004 2.33 
4 177605082 VEGFC 1258TCA> S420  rs5864401 0.003 2 
6 116263644 FRK 1451C>T R484H  rs141525046 0.001 1.85 
8 10464616 RP1L1 6992G>A T2331M  rs147334256 0.0004 -0.96 
8 97620669 SDC2 413G>C S138T  NA 0 3.04 
13 94197611 GPC6 256C>T L86F  rs143872144 0.002 1.61 
 
 
MAF, Minor Allele Frequency; Phylop score (< 0, less conserved; 0, neutral; > 0 conserved; a large score indicates high conservation) 
 
 
Table S15. Rare sequence variants not confirmed by Sanger sequencing in cases with CD subtype of AMD 
 
Gene Change in  # Family # Sporadic cases 
  Nucleotide Protein (Figure 1) (Figure 2) 
ADAMTS20 4742T>G K1581T 2 0 
ITGA1 2758T>G L920V  6 0 
COL15A1 4094A>T K1365I 0 3AB; 5AB 
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General Discussion 
Age-related macular degeneration (AMD) is a progressive neurodegenerative disease in people aged 
over 50 years [1]. Genome-wide association studies (GWASs) identified nineteen susceptibility loci 
for AMD accounting for 15-65% of the heritability, suggesting that the remaining genetic fraction 
contributing to disease risk has yet to be discovered [2]. The missing heritability may be the 
consequence of a large number of common variants with small effects, rare variants (minor allele 
frequency [MAF] ≤1%) that have large effects, structural variants of the genome, gene-gene 
interactions, or a combination of genotypic, environmental, and epigenetic interactions [3,4]. 
Simulation studies suggested that common variants are insufficient to account for a complete 
disease burden in families with AMD [5]. Emerging evidence suggested that rare sequence variants 
could (partially) explain the missing heritability [6,7]. Therefore, the work described in this thesis 
aimed to identify rare sequence variants in patients with AMD or with cuticular drusen (CD), which 
is a subtype of AMD. This thesis evaluated the role of rare sequence variants in genes of the 
complement system (CFH and C3), and of 289 candidate genes which detected rare sequence 
variants in extracellular matrix (ECM) genes (FBLN1, FBLN3/EFEMP1, FBLN5, FBLN6/HMCN1, 
FBN2, and COL15A1) and in a gene presumably involved in coagulation (FGL1). 
 
1. Complement System in AMD Pathogenesis 
Several variants identified in this thesis locate to genes involved in the complement system, which is 
an essential part of the innate immune system that plays a vital role in clearance of pathogens and 
immune complexes [8]. The complement system comprises over 30 proteins present in body fluids 
and on cell and tissue surfaces, which are activated in a cascade-like manner by three major 
pathways: the alternative, lectin, and classical pathways [8,9]. Complement homeostasis is crucial 
for providing selective clearance of pathogens and also for preventing host tissue damage. Improper 
regulation of the complement system results in host tissue damage and complement-mediated 
diseases [10]. The pathological relevance of the complement system is demonstrated in patients with 
AMD. A number of complement components, complement regulators, and complement activators 
are molecular constituents of drusen, the hallmark symptom of AMD [11]. Moreover, genetic 
studies discovered the association of common variants in the complement factor H (CFH), 
complement factor B (CFB), complement component 2 (C2), complement factor I (CFI), and 
complement component 3 (C3) genes in patients with AMD [12-18]. Finally, blood serum studies 
also demonstrated elevated levels of complement activation in patients with AMD [19]. This 
combined evidence supports the involvement of the complement system in AMD pathogenesis. 
 
1.1 Complement Factor H (CFH) 
The CFH protein is a regulator of the alternative complement pathway that inhibits complement 
activation. CFH is composed of 20 sequential complement control protein (CCP) domains [9]. The 
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N-terminal CCP1-4 domains are involved in complement regulatory activity by acting as a cofactor 
for CFI and mediating decay of C3 convertases [20]. The C-terminal CCP18-20 domains mediate 
surface binding and target recognition [21]. CFH is a glycoprotein that is highly expressed in the 
liver, is abundant in plasma (350-600 mg/litre), and is also expressed in the RPE-choroid [22,23]. 
The involvement of CFH is evident in the pathogenesis of AMD. Numerous studies demonstrated 
that a common variant (p.Tyr402His/rs1061170) in CFH is significantly associated with AMD [12-
15]. Subsequent studies detected the presence of additional independent association signals at the 
CFH and C2/CFB loci in AMD [24,25]. Besides common variation, a number of groups described 
the association of rare variants in CFH to be associated with AMD. One study identified a highly 
penetrant functional variant, p.Arg1210Cys in CFH, which is strongly associated with AMD (AMD 
cases 40/2423; controls 1/1122; P=7.0×10-6) [26]. Recently, two additional functional variants 
(p.Arg53Cys and p.Asp90Gly) were identified in CFH in two AMD families. The p.Arg53Cys 
variant affects decay accelerating activity, whereas the p.Asp90Gly variant affects co-factor 
mediated inactivation of CFH [27]. 
Interestingly, the involvement of CFH seems even stronger in the CD subtype of AMD. One study 
demonstrated that a common variant (p.Tyr402His) in the CFH gene showed a higher frequency in 
cases with CD (70%) than in cases with AMD (55%) and in controls (34%) [28]. Additionally, the 
importance of CFH in the CD phenotype was shown in several studies that discovered heterozygous 
mutations which segregated in multiplexed CD families [29,30]. These findings strongly support 
that the CFH gene is involved in the pathogenesis of AMD and CD. 
Chapter 2 demonstrated the presence of rare sequence variants in the CFH gene, which were 
significantly more frequent in CD cases (8.8%) than in the general population (4.3%, P=0.008). Our 
findings also showed that carriers of rare sequence variants in the CFH gene displayed a 
significantly earlier age at onset than non-carriers (P=0.016). Interestingly, the previously reported 
AMD variant p.Arg1210Cys in the CFH gene was identified in two CD cases but was not found in 
813 AMD cases and 1,175 controls of our Dutch-German cohort [26]. The variant was also not 
found in 1,143 AMD cases of an Icelandic cohort and 258 AMD cases of a Han Chinese cohort 
[31,32]. This suggests that the p.Arg1210Cys variant in the CFH gene may be restricted to a subset 
of cases with CD and AMD and is likely to be a population-specific variant. Recently, the group 
that originally described the p.Arg1210Cys variant in the US population published a report in which 
they phenotyped the carriers of this rare variant. They concluded that the typical phenotype of 
carriers of this variant is associated with extensive drusen, which supports our reported findings 
[33]. 
The majority of the identified rare sequence variants are novel and are clustered in the functional 
domains of the CFH protein. Five variants (p.Ala161Ser, p.Ala173Gly, p.Arg175Gln, p.Ser193Leu, 
and p.Ile216Thr) are clustered in the N-terminal CCP3-4 domains of the CFH protein. A previous 
study demonstrated that the first four N-terminal CCP domains of the CFH protein are functionally 
sufficient for both decay-accelerating activity and cofactor activity [34]. Therefore, this suggests 
that these variants may impact the decay-acceleration activity and co-factor activity of the CFH 
protein. Two variants (p.Trp379Arg and p.Gln400Lys) are located in the CCP6 and CCP7 domains, 
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respectively, in close vicinity to a previously reported AMD variant, p.Tyr402His, that causes 
defective-heparin binding, suggesting that these variants may have a similar effect [35]. Three 
variants (p.Gln950His, p.Thr956Met, and p.Arg1210Cys) are clustered in the C-terminal CCP18-20 
domains that mediate surface binding and target recognition. 
 
1.2 Complement Component 3 (C3) 
The C3 protein is an important component of the complement system, and its cleavage into C3a (9 
kDa) and C3b (177 kDa) by C3 convertase is the central step in the three complement activation 
pathways (the alternative, lectin, and classical pathways). Nascent C3b covalently attaches to cells, 
pathogens, or other target surfaces. This results in the formation of convertase complexes and 
ultimately a cytolytic membrane attack complex [36]. Unbound C3b is inactivated by CFI in 
association with the soluble CFH cofactor or membrane-bound cofactors, such as complement 
receptor type 1 (CR1) and membrane cofactor protein (MCP). This suggests that regulation of the 
complement system at the C3 level is critical for host health. A common variant 
(p.Arg102Gly/rs2230199) in the C3 gene is significantly associated with AMD [17]. Functional 
studies demonstrated that the p.Arg102Gly variant in the C3 protein showed a decreased binding to 
cofactor CFH, causing enhanced complement activation [37]. In a meta-analysis study, among other 
loci, the presence of additional independent association signals at the C3 locus was demonstrated 
[2]. These results prompted our search for rare sequence variants in the C3 gene in AMD patients. 
Chapter 3 suggested the role of four rare sequence variants (p.Lys65Gln, p.Arg161Trp, 
p.Arg735Trp, and p.Ser1619Arg) in the C3 gene in patients with AMD. Three variants 
(p.Lys65Gln, p.Arg735Trp, and p.Ser1619Arg) were associated with AMD in our Dutch-German 
AMD cohort, but two variants (p.Arg735Trp and p.Ser1619Arg) were not associated with AMD in 
the Rotterdam Study [38]. These variants (p.Arg735Trp and p.Ser1619Arg) were also not associated 
with AMD in a cohort from Boston [39]. The p.Lys65Gln variant was discovered only in patients 
from the Nijmegen area but was not detected in the Rotterdam and Boston cohorts, suggesting that 
this variant could be a population-specific AMD risk variant. The p.Arg161Trp variant was detected 
in only three AMD cases and in one control, and it was, therefore, not significantly associated with 
AMD in our Dutch-German cohort. These findings do not conclusively support a causal role of 
these rare C3 variants (p.Arg161Trp, p.Arg735Trp, and p.Ser1619Arg) in AMD pathogenesis. 
Functional studies of two C3 variants demonstrated that the p.Lys65Gln variant caused decreased 
binding to CFH, whereas the p.Arg161Trp variant was shown to cause C3 convertase hyperactivity 
due to increased binding of CFB and decreased binding of CFH and MCP [40,41]. This evidence 
suggests that the identified rare sequence variants in the C3 gene are functional and might contribute 
to the pathogenesis of AMD. More extensive genetic studies in larger cohorts are required to further 
clarify the role of these variants in AMD. 
Chapter 4 discovered a high-risk variant (p.Lys155Gln) in the C3 gene in patients with AMD. 
Whole genome sequencing (WGS) was performed in 2,230 Icelandic samples with an average 
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coverage of 10x, and the identified 34.2 million sequence variants were imputed in 95,085 
genotyped samples. The identified variants were tested for an association in patients with AMD, 
which did not identify novel AMD loci [31]. Subsequently, a conditional logistic regression analysis 
was performed to determine the role of additional variants at previously reported AMD risk loci. 
Two independent association signals were detected at the C3 locus with MAFs of 0.55% and 24%, 
respectively. The best associated variant, rs2230203 (MAF 24%), was strongly correlated with two 
previously reported variants (p.Pro314Leu and p.Arg102Gly) at the C3 locus. Three highly 
correlated variants, which included a non-synonymous variant (p.Lys155Gln/rs14785925), an 
intergenic variant (rs181290250), and an intronic variant (Chr.19: 6,649,204, hg36), remained 
significant after conditioning on the best associated variant at the C3 locus. Subsequent analysis 
focused on the p.Lys155Gln variant because it is located in the coding region of the gene. The risk 
allele of the p.Lys155Gln variant was not detected together with the two previously known risk 
alleles (p.Pro314Leu and p.Arg102Gly) at the C3 locus on the same chromosome background, 
suggesting that the p.Lys155Gln variant represents an independent association at the C3 locus. 
Interestingly, the p.Lys155Gln variant (MAF 0.43%) in the C3 gene showed a higher frequency 
than the p.Arg1210Cys variant (MAF 0.04%) in the CFH gene in the Caucasian population, 
although its effect size is smaller (odds ratio [OR] 3.65 for C3 p.Lys155Gln compared to OR 18.8 
for CFH Arg1210Cys). 
The independent association of the p.Lys155Gln variant at the C3 locus to AMD was further 
supported by two consecutive studies. In one study, 681 genes within known AMD loci and related 
pathways were sequenced in 2,493 AMD cases and controls by targeted next-generation sequencing 
[39]. The study identified a higher frequency of rare missense variants in the complement factor I 
(CFI) gene in AMD cases (7.8%) than in controls (2.3%) (OR=3.6, P=2×10-8). The same study also 
discovered two rare sequence variants, p.Lys155Gln in the C3 gene and p.Pro167Ser in the 
complement component 9 (C9) gene, which showed association with AMD [39]. Another study 
sequenced 57 genes at 10 candidate gene loci in 2,335 AMD cases and 789 controls by targeted 
next-generation sequencing [42]. The study identified two highly penetrant variants, p.Arg1210Cys 
(CFH) and p.Lys155Gln (C3), which showed association with AMD. However, the p.Arg1210Cys 
variant in the CFH gene was already previously shown to be highly penetrant in patients with AMD 
[26]. Additionally, functional studies demonstrated that the p.Lys155Gln variant in the C3 protein 
causes reduced binding to CFH, thus causing enhanced complement activation [43]. 
 
2. Extracellular Matrix (ECM) in AMD Pathogenesis 
The ECM provides physical and biochemical support for surrounding cells in all tissues and organs 
and also initiates crucial biochemical signals that are necessary for tissue morphogenesis, 
differentiation, and homeostasis [44]. The ECM primarily consists of large glycoproteins such as 
laminins, fibronectins, and elastins, and smaller glycoproteins such as fibulins [45]. Fibulins are 
characterized by repeated arrays of epidermal growth factor (EGF)-like domains and are associated 
with basement membranes and elastic fibres. Fibulins consist of binding sites for other basement 
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membrane proteins such as fibrillin, fibronectin, proteoglycans, integrins, and tropoelastin [46]. 
Fibulins form intermolecular bridges within the ECM and also mediate cellular processes and 
remodelling [45]. Genetic studies have identified common risk-conferring variants in several ECM 
genes (COL8A1, COL10A1, ADAMTS9, DDR1, TGFBR1, HTRA1, and TIMP3) in patients with 
AMD [2]. In addition, several rare sequence variants in ECM genes (TIMP3, CTRP5, FBN2, 
FBLN3/EFEMP1, FBLN5, and FBLN6/HMCN1) have been discovered in AMD and in inherited 
forms of macular degeneration [46-50]. This suggests that both common and rare sequence variants 
in ECM genes are implicated in AMD. 
Chapter 5 discovered heterozygous rare sequence variants in several ECM genes, including 
FBLN1, FBLN3/EFEMP1, FBLN5, FBLN6/HMCN1, FBN2, and COL15A1, in cases and families 
with the CD subtype of AMD by whole exome sequencing (WES). The study also identified rare 
sequence variants in two genes (CFH and FBLN5), which previously were shown to harbour rare 
sequence variants in cases with CD [28,46]. The present study identified a missense variant 
(p.Val126Met) in the FBLN5 gene, which was previously reported in the Dutch population (AMD 
cases 1/291; controls 5/91), suggesting that the variant is not rare in the Dutch population and is not 
associated with CD [51]. Missense variants in the FBLN5 gene have previously been associated 
with AMD. A study that evaluated the role of various fibulins in patients with AMD and controls, 
detected seven rare sequence variants in the FBLN5 gene in patients with AMD (AMD cases 7/402; 
controls 0/429; P=0.006). Interestingly, all seven AMD patients with rare sequence variants in 
FBLN5 gene displayed peculiar CD clinical characteristics, suggesting that variants in the FBLN5 
gene are risk factors for both AMD and CD [46]. The FBLN5 gene product is essential for the 
polymerization of elastin, which is a major component of Bruch's membrane (BrM). Additionally, 
Fbln5 knockout mice developed elastinopathy with a disorganization of elastin fibres [52]. This 
suggests that variations in the FBLN5 gene may alter the normal functions of the BrM, which might 
result in accumulation of drusen at the BrM in patients with AMD/CD.  
The present study also identified a rare, highly conserved sequence variant (p.Asp49Ala) in the first 
EGF domain of the FBLN3/EFEMP1 gene, which was previously reported to cause Doyne 
honeycomb retinal dystrophy (DHRD; OMIM 126600) [47]. Fbln3 knockout mice displayed no 
macular degeneration, whereas knock-in mice carrying the p.Arg345Trp variant in the Fbln3 gene 
displayed the symptoms of early AMD in both homozygous and heterozygous states [45,53]. This 
suggests that variants in FBLN3 gene may also confer risk for the CD phenotype. 
The present study identified a rare sequence variant (p.Pro705Leu) in the COL15A1 gene in six 
affected members of a CD family, and in one sporadic case with CD (p.Phe851Leu). The COL15A1 
gene encodes collagen, type XV, alpha 1, which is widely expressed in basement membranes and in 
choroidal endothelial cells [54,55]. The choroid plays a vital role in the maintenance of BrM, and 
variants in the COL15A1 gene, therefore, might alter the normal properties of the choroid and/or of 
BrM, resulting in the formation of drusen in patients with CD. 
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3. Other Pathways in AMD Pathogenesis 
Chapter 5 also suggested the involvement of the FGL1 gene, which was found to harbour rare 
sequence variants in three unrelated CD cases. Further analyses of this gene in larger cohorts are 
required to confirm its involvement in CD and/or in AMD. Fibrinogen-like protein 1 (FGL1) and 
fibrinogen belong to the fibrinogen superfamily [56]. A proteomic study demonstrated that FGL1 is 
bound to the fibrin matrix during clot formation, suggesting that FGL1 is involved in the 
coagulation cascade [56,57]. Interestingly, the molecular composition of drusen consists of 
fibrinogen as one of several constituents [58]. This suggests that variants in theFGL1 gene may be 
involved in both CD and AMD.  
GWASs demonstrated that common variants in genes of the lipid metabolism are associated with 
AMD. These genes include the apolipoprotein E (APOE), hepatic lipase (LIPC), cholesterylester 
transfer protein (CETP), lipoprotein lipase (LPL), ATP binding cassette transporter A1 (ABCA1), 
and fatty acid desaturase gene cluster (FADS1-3) genes [59-61]. Furthermore, the human retina 
consists of a high number of lipids which account for 20% of its dry weight, indicating their 
importance in the retina [62]. These studies strongly support the involvement of lipid metabolism in 
AMD pathogenesis. However, no recurrent rare sequence variants were detected in candidate genes 
of lipid metabolism. A large sample size may be required to determine whether rare variants in 
genes of lipid metabolism are implicated in AMD pathogenesis. 
 
4. Allelic Overlap of AMD with Other Diseases 
Several lines of evidence suggest that an allelic overlap exists between AMD and atypical 
haemolytic uremic syndrome (aHUS), a chronic renal disorder. In Chapter 2, four variants 
(p.Gln400Lys, p.Gln950His, p.Thr956Met, and p.Arg1210Cys) identified in the CFH gene were 
reported previously in aHUS [63-65]. In Chapters 3 and 4, four variants (p.Lys65Gln, 
p.Lys155Gln, p.Arg161Trp, and p.Arg735Trp) were identified in the C3 gene in AMD, which had 
also been described previously in patients with aHUS, further supporting the notion of allelic 
overlap between AMD and aHUS [40,41,43,66]. Interestingly, no renal abnormalities were observed 
in AMD patients carrying aHUS mutations. Strikingly, these findings suggest that certain variants in 
genes of the complement system can lead to very different diseases leading to completely different 
clinical outcomes: an age-related eye disease in the elderly (AMD) and a severe renal disorder in 
children (aHUS). 
Studies have already shown that variants in genes of the complement system are associated with a 
broad spectrum of clinical manifestations. Previous studies discovered genetic overlap at genes of 
the alternative pathway (CFH, CFI, CFB, and C3) in AMD with aHUS and membranoproliferative 
glomerulonephritis type II (MPGN II), two severe renal diseases that can both result in end-stage 
renal failure [2,67,68]. CFI is an important regulator of the complement system, and mutations in 
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the CFI gene are also associated with complement factor I deficiency, which is characterized by a 
variable clinical presentation of severe recurrent bacterial infections, glomerulonephritis, 
autoimmune diseases, and leucocytoclastic vasculitis [69]. MCP is a membrane-bound regulator, 
and mutations in the MCP gene are associated with aHUS, glomerulonephritis with C3 deposits, and 
HELLP (haemolysis, elevated liver enzymes, and low platelets) syndrome [70]. In addition, the 
complement system is also implicated in several other diseases, including Alzheimer’s disease, 
Parkinson’s disease, multiple sclerosis, Huntington’s disease, and atherosclerosis [71-74]. This 
implies that variants in genes of the complement system are associated with multiple and very 
diverse diseases, and that the role of the complement system extends far beyond the removal of 
cellular debris and infectious microbes. 
However, the precise nature and extent of allelic overlap between distinct phenotypes remains 
unclear. In some cases, variants in the same gene can even have an opposite effect in different 
diseases. For example, the p.Arg620Trp variant in the PTPN22 gene is a risk factor for type 1 
diabetes (T1D) and rheumatoid arthritis (RA), whereas it is a protective for Crohn’s disease [75-77]. 
However, in most cases it is not clear how variants in the same gene can lead to different 
phenotypes. A study speculated that the surface-bound glycocalyx, a multifunctional thick layer of 
proteoglycans and glycoproteins covering the laminar endothelium [78], may determine different 
clinical manifestations in AMD and aHUS [79]. This study suggested that a different composition of 
the glycocalyx on the microvascular choroidal endothelium in the eye compared to the glomerular 
endothelium in the kidney may alter the binding properties of mutant complement proteins and give 
rise to different clinical outcomes. Some emerging evidence also supports the involvement of the 
glycocalyx in the pathogenesis of AMD and aHUS. Mutations in theCOG7 gene are known to cause 
aHUS, and the protein encoded by this gene is vital for sialyation of proteins in the glycocalyx [80]. 
Common variants in the B3GALTL gene, which encodes a glycosyltransferase, are associated with 
AMD [2]. This supports the involvement of the glycocalyx in the pathogenesis of AMD and aHUS 
and might provide an explanation for the different clinical outcomes of variants in the complement 
system, as the outcome may depend on the integrity of the glycocalyx in the affected organ. This 
hypothesis, however, has not yet been proven at the cellular level. 
Another hypothesis suggests the requirement of additional genetic factors (multiple hits) or 
compounding (genetic and environmental) factors to manifest a particular disease state. For 
example, one study has demonstrated that additional genetics factors can trigger aHUS disease [81]. 
Another study demonstrated that specific combinations of common variants in the C3, CFB, and 
CFH genes alter the alternative pathway activity to 50%, which suggests that a single variant may 
not be sufficient, but that a combination of alleles are required to cause aHUS [37]. In addition, 
several other risk factors have been described that contribute to aHUS, including genetic factors in 
genes of the coagulation system (THBD), autoantibodies (anti-factor H), and environmental triggers 
(infections, childbirth, immunosuppressive drugs, pregnancy, etc.) [82]. It can be postulated that a 
certain combination of risk factors can lead to aHUS, whereas a combination of other risk factors 
can lead to AMD, with variants in the complement system being the common denominator. Along 
similar lines, a different combination of other risk factors may yet lead to other complement-
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mediated diseases, such as HELLP, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, 
Huntington’s disease, and atherosclerosis. 
These findings support and encourage cross-phenotype studies to identify variants that are unique 
and common to clinically distinct phenotypes. These studies will provide a broader understanding of 
human health and diseases [83,84]. 
 
5. Novel Approaches to Solving the Remaining Missing Heritability 
The present thesis identified several rare sequence variants in AMD. It is likely, however, that a 
greater number of rare variants that contribute to AMD are yet to be discovered. More 
comprehensive approaches are required to employ the entire genome, and the following methods 
can be performed to identify rare variants in AMD [85]. 
 
5.1 Exome Array 
WGS and WES are still expensive methods to sequence large number of samples to detect rare 
sequence variants in complex diseases. Therefore, exome arrays offer an alternative approach to test 
a predetermined set of rare and low frequency coding variants in large number of samples at lower 
costs. The first exome chip, the Illumina Infinium HumanExome BeadChip, was designed to test 
247,870 protein-altering variants. These variants were selected from >12,000 exome and genome 
sequenced individuals [86]. The selected protein-altering variants have been identified three or more 
times in at least two studies. The exome array approach successfully identified rare causal variants 
at GWAS loci for insulin processing and secretion traits [86]. The International AMD Genomics 
Consortium has recently analysed >50,000 samples using exome chips, which identified additional 
common and rare variants in AMD (Fritsche et al., manuscript submitted). In addition, an exome 
array approach was recently used to identify new common and rare AMD variants in East Asians 
[87].  
The exome array approach is a powerful tool for analysis of rare coding variants, and also to fine-
map GWAS loci in complex diseases. However, the approach has some limitations. Firstly, they 
have been designed to analyse a fixed set of coding variants, thereby excluding many other coding 
variants, novel variants, and all non-coding variants. Secondly, exome arrays might not capture rare 
variants homogenously, since the majority of genetic variation is rare and private to different human 
populations [88]. In conclusion, the exome array approach alone is not sufficient to solve the 
missing heritability in complex traits. Therefore, sequencing studies using either targeted capture of 
candidate genes, WES or WGS are ultimate requirements for comprehensive analyses of genetic 
variation in complex diseases. 
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5.2 Targeted Capture and Whole Exome Sequencing (WES) 
Targeted capture is a robust, cost-effective strategy that can be used to sequence specific genes or 
genes of a specific pathway or all protein-coding regions (whole-exome sequencing) in the genome 
with high coverage. This strategy enables sequencing of large numbers of samples than are currently 
practical with WGS. Targeted capture allows for the identification of rare variants in a set of 
candidate genes, for example genes at or near the susceptibility loci in AMD. Targeted capture 
successfully identified rare sequence variants in CFI, C3, and C9 genes in patients with AMD 
[39,42]. Although several target capture methods have been developed, the molecular inversion 
probes (MIPs) strategy offers relatively low-cost sequencing of genes in a large number of samples 
[89]. The MIP strategy is a modified genotyping method that allows for sequencing of genes of 
interest [89,90]. This strategy utilizes specific oligonucleotides, which are composed of a common 
linker sequence flanked by target-specific sequences. The specific oligonucleotide probes are 
circularized upon annealing with target-specific sequences. Then, the target-specific sequences are 
amplified using the universal primers which will bind to the linker sequences. Subsequently, the 
amplicons will be either sequenced or hybridized. The MIP strategy offers a high degree of 
specificity and multiplexing capacity and other advantages over other capture methods. Although, 
several developments have been made to improve the MIP strategy, the high variability in the 
coverage is still a major limitation [91].  
So far, the use of WES to identify rare variants in AMD has been limited. Several studies have been 
performed in multiplex AMD families and detected rare variants in CFH, CFI, FBN2, and HMCN1 
genes [27,48,92,93], and one WES study has been performed in an AMD case-control cohort and 
detected an evidence of association with a rare variant in the UBE3D gene [94]. 
 
5.3 Whole Genome Sequencing (WGS) 
Whole genome sequencing is an unbiased sequencing approach that can be used to study the entire 
genome comprehensively for rare variants in complex diseases. It is still an expensive method to 
sequence large number of samples. The costs are primarily associated with coverage, an average 
number of reads mapping to each position in the genome that determines accuracy and completeness 
[95]. 
Two cost-effective strategies can be used in application of WGS, such as low-depth WGS and high-
depth WGS. Low-depth WGS is designed to sequence large number of samples with an average 
coverage of 4-6 fold, which is insufficient to infer rare variants. Hence, this approach can be used to 
call genotypes using imputation on a reference panel, the 1000 Genomes Project [95]. High-depth 
WGS, in contrast, is designed to sequence a subset of homogenous samples with high-depth 
coverage, and it is necessary to maintain an average coverage of 40 fold to identify rare variants 
[85]. As a next step, the identified variants can be imputed in large number of samples that were 
already genotyped for SNPs. Both strategies can minimize the sequence costs associated with WGS. 
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The Iceland-based deCODE genetics company has successfully identified several rare variants for 
AMD (Chapter 5) and other diseases using the high-depth WGS method [31,96-98].  
 
5.4 Statistical Tests for Analysis of Rare Variants 
NGS technologies discover a large number of rare variants that require specific statistical methods 
to determine their association with diseases. Single-variant tests are typically used to detect 
association of common variants with complex diseases but are often underpowered for rare variants 
due to their low frequencies [99]. Therefore, burden tests are commonly used to detect association 
of rare variants with complex diseases. Burden tests aggregate or collapse multiple functional 
variants, which include loss-of-function, missense, and splice-site variants [95]. These tests 
typically compare cumulative effects of rare variants in a gene or genes of a specific pathway or at 
an association signal in cases versus controls. These tests assume that all functional variants are 
causal and influence disease in the same direction, will have limited power if some variants are non-
causal, and will fail if variants influence the disease in the opposite direction [99]. 
The sequence kernel association test (SKAT) is a powerful method that can account for deleterious, 
protective, and non-causal rare variants [100]. The power of SKAT is limited if large numbers of 
rare variants are causal and influence disease in same direction [99]. These limitations have led to 
an improved SKAT version: the SKAT optimal (SKAT-O) test. The SKAT-O test is a flexible test 
that can automatically act either as a burden test or as SKAT and can be applied, therefore, in a wide 
range of scenarios [99]. However, as the allelic architecture of most complex diseases is largely 
unknown, there will not be one optimal test or filtering strategy that can be applied to all diseases. 
Therefore, novel methods need to be developed, which will also take non-coding variants and 
structural variants into account, to detect associations with complex diseases and to solve the 
missing heritability. 
 
6. Precision Medicine 
Precision or personalized medicine can personalize disease susceptibility assessment, health 
monitoring, and preventive medicine [101]. The development of new technologies such as high-
throughput sequencing and mass spectrometry can facilitate the profiling of multiple ‘-omes’, which 
include the genome, epigenome, transcriptome, proteome, metabolome, and microbiome [101,102]. 
These technologies can increase our understanding of human health and disease at the molecular 
level and have the potential to transform medicine from symptom-based diagnosis and treatment of 
diseases towards early diagnosis and prevention of diseases, paving the way for significant advances 
in precision medicine [101].  
GWASs identified risk-associated common variants at nineteen major susceptibility loci in AMD 
[2]. These variants hold great promise for designing precision medicine for AMD. Several studies 
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developed predictive models for advanced AMD using common variants and environmental risk 
factors and achieved a relatively high reliability in terms of an area under the receiver operating 
characteristic curve (AUC) of 0.8-0.9 [103-105]. Although the AUC is much higher than has been 
achieved for other complex diseases, the discriminative value is not yet accurate enough to offer 
predictive testing to individuals. Moreover, the American Academy of Ophthalmology 
recommended that predictive tests are not routinely used for AMD until clinical studies demonstrate 
that patients with specific genotypes benefit from therapy or surveillance [106,107]. More recent 
sequencing studies identified rare sequence variants in the CFH, CFI, C3, and C9 genes in patients 
with AMD. These variants are highly penetrant and can be a great asset for improved AMD 
prediction and development of precision medicine [26,31,39,108]. For example, AMD patients with 
rare variants in the complement system genes (CFH, CFI, C3, and C9) may be more suitable for 
treatment with complement inhibitors than non-carriers. 
Although most of the molecular studies in AMD have focused on genomics, adding other layers of 
information can further deepen our understanding of the disease and can aid the development of 
precision medicine. Epigenome studies analyse DNA methylation patterns that are vital for many 
biological processes[109]. Methylation of cytosine in the DNA is a common epigenetic mark that is 
essential for gene regulation and normal development. DNA methylation is often present in the 
sequence context of CpG or CpHpG (H = A/T/C) and is repressive at gene promotors [110]. DNA 
methylation patterns are unique to each cell type and are established and maintained by DNA 
methyl transferases [111,112]. Methylation patterns are crucial for many biological processes that 
are involved in transcriptional regulation and silencing of genes on the inactive X chromosome, 
imprinted genes, and parasitic DNAs [113]. Aberrant methylation patterns have been associated 
with various human diseases [109]. Hypomethylation of the IL17RC promotor, for example, has 
been associated with AMD and resulted in elevated expression of its protein and messenger RNA in 
peripheral blood, retina, and choroid of AMD patients [114]. However, another study tried to 
validate DNA methylation of the IL17RC promoter but observed no evidence of association in 
peripheral blood [115]. Therefore, the role of the epigenome in the pathogenesis of AMD is 
currently inconclusive, and additional studies are required to establish its use in AMD progression 
and precision medicine. 
Transcriptome entails RNA sequencing analyses of the complete set of transcripts in a cell and their 
quantity. It is a powerful technique to study the functional elements of the genome, and besides 
having great accuracy and sensitivity in comparison to microarray technology, it can also detect 
splicing isoforms [116]. A study that analysed transcriptome profiles of RPE-choroid and neural 
retina tissues in AMD patients and controls identified 50 genes that are globally overexpressed in 
RPE-choroid tissues of AMD patients, suggesting that these genes can be potential biomarkers for 
AMD disease [117]. The proteome is the entire set of proteins that are encoded by protein-coding 
genes in the genome [118]. Mass spectrometry has become a powerful tool in proteomics, able to 
quantify thousands of proteins in a single sample. Mass spectrometry also enables the detection of 
expressed mutations, allele-specific sequences, and editing events in the human proteome [119]. A 
proteomic study analysed the central and peripheral retina, using matrix-assisted laser 
desorption/time of flight (MALDI-TOF) mass spectrometry to identify 26 proteins that displayed 
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changes at disease onset and with progression in AMD [120]. The metabolome reflects the entire set 
of metabolites in a specific sample. A study profiling the metabolomes of 26 neovascular AMD 
patients and 19 controls demonstrated changes in tyrosine and urea metabolism [121]. However, 
more studies in the areas of transcriptome, proteome, and metabolome analyses are required to 
identify novel molecular drivers and pathways that can pave the way for new therapeutic 
interventions for AMD. 
The microbiome represents a large number of microbial communities that present throughout the 
human body and play a key role in health and disease [122]. Several studies investigated the role of 
the microbiome in obesity, cardiovascular disease, cystic fibrosis, inflammatory bowel disease, and 
skin diseases, and the results may enable personalized interventions [102]. No studies have been 
performed to date on the microbiome in patients with AMD. As the immune system has been 
demonstrated to play a crucial role in the disease, an analysis of the microbiome may provide novel 
insights into the disease mechanisms of AMD. 
The integrated profiles of multiple ‘-omes’ are of great value for health monitoring, preventive 
measures, and precision medicine [101]. As an example, one recent study monitored a healthy 
participant by profiling the blood components for 14 months with an integrated personal omics 
profile (iPOP) analysis [119]. The genome of this participant was sequenced with two WGS and 
three WES platforms to achieve high accuracy and identified elevated risks for coronary artery 
disease, basal cell carcinoma, hypertriglyceridemia, and type 2 diabetes. These elevated risks served 
as guidelines to monitor the participant’s health with iPOP analysis. The study monitored molecular 
profile changes by profiling the transcriptome, proteome, and metabolome for 20 time points in 14 
months. Overall, the study enabled a comprehensive picture of detailed molecular events during 
different physiological states, identified the increased risk of type 2 diabetes, and monitored its early 
onset. This study revealed an important application of the integration of omics for disease 
assessment and precision medicine, which might also be the future for AMD diagnostics and 
therapy [101]. 
 
7. Future Perspectives 
The identified rare sequence variants may improve AMD prediction, and patients that harbour rare 
variants may benefit the most in future clinical trials for novel therapeutics for AMD. These 
discoveries, therefore, are of great value for future applications of precision medicine. However, the 
identified rare sequence variants require further validation in larger cohorts, and more studies are 
required to identify additional rare sequence variants in AMD.  
In conclusion, this thesis identified rare sequence variants in genes of the complement system (CFH 
and C3), the ECM (FBLN1, FBLN3/EFEMP1, FBLN5, FBLN6/HMCN1, FBN2, and COL15A1), 
and the coagulation cascade (FGL1) in patients with AMD or with CD. 
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Summary 
Age-related macular degeneration (AMD) is the most common cause of irreversible blindness in 
people aged over 50 years. Genome-wide association studies discovered 19 risk loci for AMD in the 
human genome, which account for 15-65% of the heritability. The remaining genetic factors that 
contribute to the disease remain to be identified. Several lines of evidence suggest that rare sequence 
variants (minor allele frequency [MAF] ≤ 1%) could (partially) explain the missing heritability. The 
present thesis aimed to identify rare variants in patients with AMD or with cuticular drusen (CD), 
which is a clinical subtype of AMD. The identified rare variants are highly penetrant and will pave 
the way for precision medicine. 
Chapter 1 provides an introduction to the anatomy of the human eye, an overview of the clinical 
characteristics of both AMD and CD, and a summary on genetic (familial aggregation, twin, 
linkage, and association) studies in AMD. In addition, it introduces the role of rare variants that may 
(partially) explain the missing heritability and methods that were utilized in the present thesis to 
identify rare variants in AMD. 
Chapter 2 aimed to determine the frequency of rare variants in the complement factor H (CFH) 
gene in 180 unrelated CD cases and detected rare variants that were significantly more frequent in 
CD cases (8.8%) than in the general population (4.3%, P=0.008). The carriers of rare variants in the 
CFH gene displayed a significantly earlier age at onset than non-carriers (P=0.016). Interestingly, a 
variant (p.Arg1210Cys) in the CFH gene, which had previously been reported to be highly 
associated with AMD in a US cohort, was identified in two CD cases but was not found in a Dutch-
German cohort (813 AMD cases and 1,175 controls). The variant was also not detected in an 
Icelandic cohort (1,143 AMD cases) nor in a Han Chinese cohort (258 AMD cases), suggesting that 
p.Arg1210Cys in the CFH gene may be a population-specific variant. Recently, the study that 
reported the p.Arg1210Cys variant in the CFH gene in AMD for the first time revisited the 
phenotypes of cases who carry this variant and documented an extensive drusen phenotype, 
suggesting that the p.Arg1210Cys variant in the CFH gene is associated with CD and AMD with 
extensive drusen. 
Chapter 3 aimed to identify rare sequence variants in the complement component 3 (C3) gene in 84 
unrelated AMD cases and detected four rare variants (p.Lys65Gln, p.Arg161Trp, p.Arg735Trp, and 
p.Ser1619Arg). Subsequently, the identified rare variants were analysed for their association with 
AMD in 1,474 AMD cases and 2,258 controls. The p.Lys65Gln variant was discovered only in 
cases from the Nijmegen area, suggesting that this is a population-specific AMD risk variant. The 
p.Arg161Trp variant was detected only in three AMD cases and in one control and was, therefore, 
not significantly associated with AMD. The two other variants (p.Arg735Trp and p.Ser1619Arg) 
were associated with AMD in our Dutch-German AMD cohort but were not associated with AMD 
in the Rotterdam study nor in a cohort from Boston. Therefore, these findings do not conclusively 
support a causal role of these rare C3 variants (p.Arg161Trp, p.Arg735Trp, and p.Ser1619Arg) in 
AMD pathogenesis. Functional studies previously demonstrated that two C3 variants (p.Lys65Gln 
and p.Arg161Trp) caused decreased cofactor activity and C3 convertase hyperactivity, respectively, 
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suggesting that rare variants in the C3 gene might contribute to AMD. More extensive genetic 
studies in larger cohorts are required to further clarify the role of these variants in AMD. 
Chapter 4 investigated novel genetic variants for AMD in 2,230 Icelandic samples using whole 
genome sequencing (WGS). The identified 34.2 million sequence variants were imputed in 95,085 
genotyped samples and were tested for an association in patients with AMD, but no novel loci for 
AMD were detected. Next, a conditional logistic regression analysis was conducted to determine the 
role of additional risk variants at previously known AMD risk loci and detected one rare coding and 
two rare non-coding variants at the C3 locus. The risk allele of the coding variant p.Lys155Gln in 
the C3 gene was not detected on the same chromosomal background as two previously described 
common risk alleles (p.Pro314Leu and p.Arg102Gly), suggesting that the p.Lys155Gln variant 
represents an independent association at the C3 locus. The p.Lys155Gln variant was replicated in 
our Dutch-German AMD cohort (1,329 AMD cases and 1,689 controls; OR=3.5, P=1.8×10-5) and in 
a cohort from the USA (1,525 AMD cases and 1,288 controls; OR=5.2, P=1.4×10-6) and 
significantly associated with AMD in both cohorts. In addition, the independent association of the 
p.Lys155Gln variant at the C3 locus to AMD was further supported by two consecutive studies.  
Chapter 5 aimed to identify rare sequence variants in fourteen affected members of six families and 
twelve sporadic cases with CD using whole exome sequencing (WES). This study detected rare 
variants in two genes (CFH and FBLN5), which had previously been shown to harbour rare variants 
in patients with CD. Rare variants in several extracellular matrix (ECM) genes (FBLN1, 
FBLN3/EFEMP1, FBLN5, FBLN6/HMCN1, FBN2, and COL15A1) were identified in cases and 
families with CD. Two rare variants were detected in the COL15A1 gene: the p.Pro705Leu variant 
was found to segregate in a family with six affected members with CD, and the p.Phe851Leu variant 
was detected in a sporadic CD case. In addition, two rare variants were identified in the FGL1 gene, 
which is presumably involved in the coagulation pathway, in three unrelated CD cases. These 
findings suggest that alterations in the ECM and in the coagulation pathway may play a role in the 
pathogenesis of CD. 
Chapter 6 provides a broader understanding of the results of all studies that were conducted in the 
present thesis. It discusses the role of the complement system, ECM, and other pathways in AMD 
pathogenesis. In addition, it describes the allelic overlap of AMD with other diseases and postulates 
hypotheses that may explain this allelic overlap. This chapter also provides an overview of novel 
methods that can be used to solve the missing heritability. Finally, it provides a broader view of the 
application of multiple ‘-omes’ to design precision medicine for AMD. 
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Samenvatting 
Leeftijdsgebonden maculadegeneratie (LMD) is de meest voorkomende oorzaak van onomkeerbare 
blindheid bij mensen ouder dan 50 jaar. Door middel van genoombrede associatiestudies werden 19 
risico gebieden voor LMD in het menselijk genoom ontdekt, die verantwoordelijk zijn voor 15-65% 
van de erfelijke component van LMD. De resterende genetische factoren die bijdragen aan de 
aandoening moeten nog worden geïdentificeerd. Verschillende studies suggereren dat zeldzame 
sequentievarianten (allelfrequentie ≤1%) dit (deels) zouden kunnen verklaren. Dit proefschrift had 
als doel om zeldzame varianten te identificeren bij patiënten met LMD of cuticulaire drusen (CD), 
een klinisch subtype van LMD. De geïdentificeerde zeldzame varianten hebben een hoge 
penetrantie en dragers ervan kunnen in de toekomst mogelijk in aanmerking komen voor op maat 
gemaakte therapie. 
Hoofdstuk 1 geeft een inleiding op de anatomie van het menselijk oog, een overzicht van de 
klinische kenmerken van zowel LMD en CD en een samenvatting op genetische (familiaire 
aggregatie, koppelings-, tweeling-, en associatie-) studies bij LMD. Bovendien gaat het in op de rol 
van zeldzame varianten die mogelijk de ontbrekende erfelijkheid (gedeeltelijk) kunnen verklaren, en 
op de methoden die in dit proefschrift werden gebruikt om zeldzame varianten in LMD te 
identificeren. 
In hoofdstuk 2 werd de frequentie van zeldzame varianten in het complement factor H (CFH) gen 
bepaald in 180 niet verwante CD-patiënten. Zeldzame varianten kwamen significant vaker voor in 
CD patiënten (8,8%) dan in de algemene bevolking (4,3% P=0,008). De dragers van zeldzame 
varianten in het CFH gen vertoonden op een veel vroegere leeftijd de eerste symptomen dan niet-
dragers (p = 0,016). Interessant is dat een variant (p.Arg1210Cys) in het CFH gen, waarvan eerder 
werd gerapporteerd dat deze in hoge mate geassocieerd is met LMD in een Amerikaanse cohort, wel 
werd geïdentificeerd in twee CD gevallen, maar verder niet werd gevonden in een Nederlands-Duits 
cohort (813 LMD patiënten en 1175 controles). De variant werd ook niet gevonden in een IJslands 
cohort (1143 LMD patiënten), noch in een Han-Chinees cohort (258 LMD patiënten), wat 
suggereert dat de p.Arg1210Cys variant in het CFH gen mogelijk populatie-specifiek is. Onlangs 
hebben de onderzoekers die de p.Arg1210Cys variant in het CFH gen voor het eerst rapporteerden, 
het klinisch beeld van patiënten die deze variant dragen nauwkeurig onderzocht, en rapporteerden 
een uitgebreid drusen fenotype, wat erop wijst dat de p.Arg1210Cys variant in het CFH gen 
geassocieerd is met CD en LMD met veel drusen. 
Hoofdstuk 3 was gericht op de identificatie van zeldzame sequentievarianten in het complement 
component 3 (C3) gen in 84 ongerelateerde LMD patiënten, en vond vier zeldzame varianten 
(p.Lys65Gln, p.Arg161Trp, p.Arg735Trp en p.Ser1619Arg). Vervolgens werden de geïdentificeerde 
zeldzame varianten geanalyseerd op een associatie met LMD in 1474 LMD patiënten en 2258 
controles. De p.Lys65Gln variant werd alleen in patiënten uit de omgeving van Nijmegen ontdekt, 
wat suggereert dat deze variant een populatie-specifieke LMD risico variant zou kunnen zijn. De 
p.Arg161Trp variant werd ontdekt in slechts drie LMD patiënten en in één controle, en was dus niet 
significant geassocieerd met LMD. Twee andere varianten (p.Arg735Trp en p.Ser1619Arg) konden 
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worden geassocieerd met LMD in ons Nederlands-Duits LMD cohort, maar zijn niet geassocieerd 
met LMD in de Rotterdamse Studie, noch in een cohort uit de omgeving van Boston, Verenigde 
Staten (VS). Deze bevindingen bieden daarom geen sluitend bewijs voor een causale rol van deze 
zeldzame C3 varianten (p.Arg161Trp, p.Arg735Trp en p.Ser1619Arg) in LMD pathogenese. 
Functionele studies toonden eerder aan dat twee C3 varianten (p.Lys65Gln en p.Arg161Trp) 
respectievelijk verminderde cofactor activiteit en C3 convertase hyperactiviteit veroorzaakten, wat 
suggereert dat zeldzame varianten in het C3 gen kunnen bijdragen aan LMD. Uitgebreidere 
genetische studies in grotere cohorten zijn nodig om de rol van deze varianten in LMD op te 
helderen. 
In hoofdstuk 4 werden nieuwe genetische varianten voor LMD onderzocht in 2230 IJslandse 
patiënten met behulp van whole genome sequencing (WGS). De geïdentificeerde 34,2 miljoen 
sequentievarianten werden vervolgens geïmputeerd in 95.085 gegenotypeerde individuen, en 
werden getest op associatie bij patiënten met LMD, maar er werden geen nieuwe loci voor LMD 
gevonden. Vervolgens werd een conditionele logistische regressieanalyse uitgevoerd om de rol van 
additionele risicovarianten op reeds bekende LMD genomische risico gebieden te bepalen. Daarmee 
werden een zeldzame eiwit-coderende en twee zeldzame niet-coderende varianten in het C3 locus 
gevonden. Het risico-allel van de coderende variant p.Lys155Gln in de C3 gen werd niet 
aangetroffen op dezelfde chromosomale achtergrond als twee eerder beschreven veelvoorkomende 
risico-allelen (p.Pro314Leu en p.Arg102Gly), wat suggereert dat de p.Lys155Gln variant een 
onafhankelijke associatie vertegenwoordigt in het C3 locus. De associatie met de p.Lys155Gln 
variant werd gerepliceerd in ons Nederlands-Duits LMD cohort (1329 LMD patiënten en 1689 
controle personen; OR = 3.5, p = 1,8 × 10-5) en in een cohort van de VS (1525 LMD gevallen en 
1288 controle gevallen; OR = 5.2, p = 1,4 × 10-6) en was significant geassocieerd met LMD in beide 
cohorten. Bovendien werd de onafhankelijke associatie van de p.Lys155Gln variant in het C3 locus 
met LMD verder ondersteund door twee andere studies. 
Hoofdstuk 5 richtte zich op de identificatie van zeldzame sequentie varianten in 14 aangedane 
familieleden van zes families en 12 sporadische patiënten met CD met behulp van exoom 
sequencing (WES). Deze studie ontdekte zeldzame varianten in twee genen (CFH en FBLN5), 
waarin eerder ook zeldzame varianten zijn gevonden bij patiënten met CD. Zeldzame varianten in 
verschillende extracellulaire matrix (ECM) genen (FBLN1, FBLN3 / EFEMP1, FBLN5, FBLN6 / 
HMCN1, FBN2 en COL15A1), werden geïdentificeerd in patiënten en families met CD. Twee 
zeldzame varianten werden gevonden in het COL15A1 gen: de p.Pro705Leu variant bleek met CD 
over te erven in een familie met zes aangedane personen, en de p.Phe851Leu variant werd 
gedetecteerd in een sporadische CD patiënt. Daarnaast werden twee zeldzame varianten in het FGL1 
gen gevonden dat vermoedelijk betrokken is bij de stolling, in drie onafhankelijke CD patiënten. 
Deze bevindingen suggereren dat veranderingen in de ECM en de stolling een rol kunnen spelen bij 
de pathogenese van CD. 
Hoofdstuk 6 geeft meer inzicht in de resultaten van de studies die werden uitgevoerd in dit 
proefschrift. De rol van het complementsysteem, ECM en andere processen betrokken bij 
depathogenese van LMD worden besproken. Bovendien wordt de allelische overlap van LMD met 
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andere aandoeningen beschreven, en worden hypothesen die deze overlap kunnen verklaren 
geponeerd. Dit hoofdstuk bevat een overzicht van nieuwe methoden die kunnen worden toegepast 
om de ontbrekende erfelijke factoren op te sporen. Tot slot biedt het een bredere kijk op de 
toepassing van meerdere ‘-omes’ technieken om precisie medicatie te ontwikkelen voor LMD. 
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